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ABSTRACT
Neuronal nicotinic acetylcholine receptors (nAChRs) are members of a large family 
of ligand gated ion channels that mediate inhibitory and excitatory neural transmission in the 
central nervous system (CNS). The nicotinic subfamily has been implicated in a range of 
neurological disorders including autism, Alzheimer’s disease and nicotine addiction; diseases 
that are currently both challenging and costly to treat. Despite the apparent importance of 
nAChRs in these disorders, only a limited number of drugs are currently available for altering 
nicotinic signalling in the CNS. No drug therapies are currently available that specifically 
target autism and only a limited number of drugs are available for the treatment of 
Alzheimer’s disease. This thesis presents a novel class of nAChR ligands based on the 
natural product desformylflustrabromine (dFBr).
Desformylflustrabromine (dFBr), a metabolite of the marine bryozoan Flustra 
Foliacea, was previously identified as an allosteric modulator of the a4p2 subtype of 
nAChRs. In collaboration with Dr. Richard Glennon at the Virginia Commonwealth University, 
College of Pharmacy, we developed a synthetic dFBr and evaluated its interaction with two 
of the most common subtypes of nAChRS, a7 and a4p2 (Chapter 2). We confirmed that 
dFBr is the active component of Flustra Foliacea and identified an additional inhibitory action 
that becomes evident as dFBr concentrations are increased beyond 10pM. This inhibition 
was not previously reported. Synthetic dFBr appears significantly more potent at potentiation 
of a4p2 receptors then reported for the natural extract and shows only inhibitory action on a7 
receptors.
Multiple analogues of dFBr were designed and synthesized to determine the 
structure activity relation (SAR) for dFBr's action on a4p2 receptors (Chapter 3). We 
identified three analogues capable of potentiating responses of acetylcholine. The majority of 
compounds inhibited responses on both a4p2 and a7 receptors. The data presented here 
provide important information for determining a preliminary pharmacophore for dFBr and 
provide direction for the design of additional analogues on the path to development of more 
potent and potentially therapeutically useful analogues.
To better understand the relationship of dFBr to other nAChR modulators, we also 
compared the action of dFBr to that of physostigmine, zinc and 17-P-estradiol (Chapter 4). 
These compounds are thought to act at three different binding sites on nAChRs. All three 
compounds increase responses of a4p2 receptors to acetylcholine. Our data show that dFBr 
is distinct from the clinically used modulator physostigmine but suggests similarities in
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mechanism with zinc and 17-P-estradiol. These data provide important information regarding 
the mechanism of dFBr modulation and provide direction for future site directed mutagenesis 
studies that will identify the dFBr binding site. Identification of the binding site is critical for the 
development of receptor models that will facilitate computer assisted drug design.
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1CHAPTER 1: INTRODUCTION
Maintenance of homeostasis is a vital biological function. Ion channels, pore forming 
proteins embedded in cell membranes, regulate the flow of ions in and out of cells and 
maintain ionic concentrations thus playing a major role in the regulation of water and ion 
homeostasis inside the cell.
Ion channels conduct ions actively and passively in neurons, the specialized cells of 
the nervous system. Any disruption of the function of ion channels can lead to malfunctions 
in the nervous system, which hampers the ability of an organism to sense and react to its 
environment. Ion channels also play a critical role in non-neuronal systems including the 
cardiovascular system, renal physiological and neuro-endocrine systems.
1.1 Historical perspective:
The concept of ion channels emerged in the 1800s when Luigi Galvani published his 
observations that electric current could cause twitching in the legs of a dead frog. Based on 
these and other observations, Julius Bernstein later provided a physical and chemical 
explanation for all of life's processes. Bernstein hypothesized that a semi-permeable 
membrane surrounded nerve and muscle cells and that differences in potassium ion (K+) 
concentrations inside and outside the cell explained the electrophysiological evidence of ion 
conductance and accounted for the phenomenon of membrane potential (i.e. membrane 
voltage). In 1937, electrophysiologists for the first time used the squid neurons to study ion 
currents. These “giant squid” axons were approximately 100 to 1000 times larger in diameter 
than neurons from other organisms and facilitated the study of ion conductance. In 1952, 
Hodgkin, Huxley and Katz used the giant squid axon as an experimental model to show that 
Na+ and K+ ions move across the neuronal membrane to produce currents responsible for 
generating the action potential (Hodgkin et al., 1952).
1.1.1 History of nicotinic acetylcholine receptors:
David Nachmansohn first postulated that Nicotinic acetylcholine receptors (nAChRs) 
were proteins present on the cell membrane (Nachmansohn, 1959). In 1969, Changeux, 
Kasai and Lee characterized acetylcholine receptors from the electric organ of Eloctrophorus 
Electricus using the polypeptide a-Bungarotoxin obtained from the venom of the snake 
Bungarus multicinctus (Changeux et al., 1970). Electric organs from electric eels and rays 
(Torpedo Califomica and Torpedo Marmorata) provided a rich source of nAChRs similar to 
nAChRs found in muscle. The first affinity labelling of nAChRs were done on the electric 
organ of Eloctrophorus Electricus (Silman and Karlin, 1969). The receptors thus obtained 
were named as the a1 subunit of muscle type of nAChRs (Karlin and Cowburn, 1973). Since 
then, electric organ nAChRs have provided the prototypical model for other nAChR subtypes.
1.2 Classification and characteristics of ligand gated ion channels:
Ligand gated ion channels (LGIC) consist of 3 super-families:
a) Cysteine - loop ligand gated ion channel superfamily;
b) lonotropic glutamate receptor superfamily;
c) Adenosine Tri Phosphate (ATP) - gated receptor superfamily.
The three receptor super-families are classified based on their structure, function 
and primary sequence. General similarities between the three LGIC super-families (Le 
Novere and Changeux, 2001) include their location in the cell membrane, and the presence 
of three major domains structural domains. They share a large extracellular domain involved 
in ligand recognition, a transmembrane domain which forms an aqueous pore and allows the 
passage of ions and an intracellular domain responsible for the communication with the 
intracellular signalling proteins (North, 1995). Super-families differ from one another in 
broadly divergent primary sequences as well as significantly different tertiary and quaternary 
structures. These properties are well conserved within each superfamily although ligand
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selectivity and ion selectivity differ widely between individual members. Super-families are 
further subdivided based on the endogenous agonist thought to activate the receptor.
1.3 Classification of Cysteine-loop ligand gated ion channels:
The Cysteine-loop or “Cys-loop” superfamily is characterized by several unique 
structural features (Arneric and Brioni, 1999). A signature 15 amino acid spaced disulphide 
loop between two cysteine residues located in the extracellular domain of the receptor is 
conserved in all members of this superfamily (Arneric and Brioni, 1999). The superfamily is 
also characterized by a tertiary structure consisting of five individual subunits with agonist 
binding sites thought to form at the subunit interfaces (Arneric and Brioni, 1999). An opening 
at the center and a regulated ion channel form the pore of all cys-loop receptors and an 
intracellular “vestibule" is formed by the intracellular domain that regulates the ion 
conductance (North, 1995). Individual members of the cys-loop superfamily respond to four 
different endogenous neurotransmitters thus forming four sub-families. Cys-loop receptors 
respond to the neurotransmitters acetylcholine (ACh), gama-aminobutyric acid (GABA), 
serotonin (5-HT) and glycine (Connolly and Wafford, 2004) although these ligands also 
activate a family of G-protein linked receptors (Arneric and Brioni, 1999). Table 1.1 identifies 
the different Cys-loop LGIC subtypes and subunits. The major classes of Cys-loop LGIC 
receptors are:
a) Muscle and neuronal nAChRs.
b) GABA (A) and (C) receptors.
c) Serotonin type 3 receptors (5HT3R).
d) Glycine receptors
The acetylcholine receptors and the (5HT3R) are non-selective cation conducting (K+, Ca++, 
Na++) receptor channels (North, 1995), while the GABA (A) and (C) receptors and the glycine 
receptors are non-selective anion conducting (e.g. Cl ) receptor channels (North, 1995)
conducting receptors have depolarizing, excitatory effects while anion conducting receptors 
are hyper-polarizing and inhibitory.
GABA receptors are divided into types A, B and C. GABA (B) receptors is a group of 
G-protein coupled receptors while types A and C are ligand gated ion channels (Enna and 
Mohler, 2007). Sixteen different subunits compose pentameric GABA (A) receptors (a1-6, 
(31-3, y1-3, 5, e , t t  and 0 subunits) (Olsen and Sieghart, 2008) and three different subunits 
(p1-3) form pentameric GABA (C) receptors (Bormann, 2000). The Serotonin type 3 
receptors (5HT3R) are composed of 5 different subunits ranging from A to E. 5HT3R (A) 
receptors are homomeric and contain only the A  subunit. 5HT3R A subunits can also 
combine with 5HT3R B subunits to form hetero pentameric receptors, the stoichiometry of 
which is unknown (Davies et al., 1999). While the genes for 5HT3R (C), 5HT3R (D) and 
5HT3R (E) have been described, their functional characteristics have not been identified 
(Niesler et al., 2003). Glycine receptors can be composed of pentameric arrangements of a1- 
4 or a 3 subunit (Betz et al., 1999). Strychnine sensitive glycine receptors express differently 
in human embryos versus adults. Pre-natal glycine receptors are mainly homomers 
consisting of a2 subunit while the adult glycine receptors mainly consist of heteromeric a13 
subunit with a stoichiometry of 3:2 or 4:1 of a1:3 (Webb and Lynch, 2007).
Table1.1: Classification of Cys-loop ligand gated ion channels (North, 1995):
Neurotransmitter Receptor subtypes and subunits
Acetylcholine Muscle: a1, 31, Y. 5  &  £
Neuronal: a2, a3, a4, a5, a6, a7, a8, a9, a10. 32, 33 & 34
Serotonin (5-HT) Subtype: A, B, C, D & E
Gamma amino butyric acid Type A: a1-6, 31-3, y1 -3, 5, £, t t  &  0
(GABA) Type C: p1, p2 & p3
Glycine Subtype: a1, a2, a3, a4 & 3
1.4 Classification of nicotinic receptor subunits and nomenclature:
Nicotinic acetylcholine receptors (nAChR) represent a large and diverse subfamily of 
Cys-loop LGIC receptors. These receptors are characterized as “nicotinic acetylcholine 
receptors” because all members of this group respond to exogenously applied nicotine and 
to the endogenous neurotransmitter ACh (Arneric and Brioni, 1999). The designation 
“nicotinic” reflects the importance of nicotine as an agonist and pathological agent at nAChRs 
and further distinguishes between the nicotine insensitive and acetylcholine sensitive 
metabotropic muscarinic receptor family (Clementi et al., 2000). The muscarinic receptors 
are composed of seven transmembrane domains and are distinct from the nAChR family of 
LGICs (Caulfield and Birdsall, 1998).
As described above, membranes of electric rays (Torpedo marmorata) are a rich 
source of a nAChR that are similar in structure to nAChRs found in muscle. Using photo­
affinity labeling studies, four subunits of torpedo nicotinic receptors were identified and 
classified as a, p, y and 5 in order of increasing molecular weight (Lindstrom et al., 1995). 
These four muscle subtypes of nAChRs were subsequently found to be very similar to the 
nAChRs obtained from membranes of electric rays. Hence, the four muscle subunits were 
also named a, p, y and 5 in order of increasing molecular weight (Lindstrom et al., 1995).
The cloning and purification of different neuronal subunits of nAChRs were pursued 
simultaneously with muscle nAChRs. It determined that the muscle a subunit contained a 
pair of Cysteine residues in position 192 and 193 (Silman and Karlin, 1969). This pair of 
cysteines is different than those that characterize the cys-loop family and are contained only 
in nicotinic subunits that bind nicotinic agonists. Nicotinic subunits later identified as 
containing a homologous pair of Cysteine residues were all named a subunits. Using photo­
affinity labelling, these two adjacent Cysteine residues were shown to be in the vicinity of the 
ACh binding site in the muscle a subunit and have been determined to be a key feature of 
the ACh binding site in all a-subunits (Clementi et al., 2000). Nine other a subunits forming
nAChRs receptors have been discovered. Based on the order in which they were discovered, 
these nine subunits were classified as a2 to a10 with muscle type receptors containing only 
the a1 subunit and neuronal receptors containing different combinations of a2-a10 (Arneric 
and Brioni, 1999).
Homologous neuronal subunits lacking the two Cysteine residues near the ACh 
binding sites were called p subunits (Arneric and Brioni, 1999). p subunits were unable to 
bind to photo-affinity labels suggesting the absence of ACh binding sites on these subunits 
(Arneric and Brioni, 1999).
The nomenclature of nAChR has now been standardized as shown in Figure 1.1. 
The muscle subtype of nAChRs consists of a1, p i, y, 5 and e  subunits. Twelve neuronal 
subtypes of nAChRs have been identified: a-2 through a-10 and p-2, 3 and 4 subunits 
(Lukas et al., 1999).
Figure 1.1: Classification of nicotinic acetylcholine receptors.
1.5 Nicotinic receptor subtypes:
Muscle nAChRs consist of fetal and adult subtypes: The fetal subtype is composed 
of two subunits of a1 and one subunit each of p i , y and 5. The 5-subunit is substituted by the 
e-subunits in the adult subtype. Neuronal nAChRs are composed of pentameric 
arrangements of a wide variety of combinations of a-1 through a-10 and P-2, 3 and 4 
subunits thus the expression of neuronal nAChRs is complex.
a7 subunits appear to express primarily as homo-pentameric receptors in the brain 
(McGehee and Role, 1995) although a7 subunits can also form functional heteromeric 
receptors in combination with the P2 subunit in vitro when expressed in Xenopus oocytes 
(Khiroug et al., 2002).. The a8 and a9 subunits also express as homo-pentameric receptors 
although a7 can form hetero-pentamers with a8 and a9 subunits can combine with a10 
(Arias, 2000) (Gotti and Clementi, 2004). a10 subunits have only been identified to form 
heteromers with a9 subunits and have not been identified as homomers or in heteromeric 
combinations with any other nAChR subunits (Gotti and Clementi, 2004). Receptors 
containing a7 and a8 or a9 and a10 are the only heteromeric neuronal subtypes of nicotinic 
receptor which bind a-bungarotoxin (Clementi et al., 2000).
Neuronal nAChR subunits a2, a3, a4 and a6 can combine with p2 and P4 subunits to 
form receptors that are composed of pentameric arrangements of two different subunits 
(Lukas et al., 1999). Combinations of a2p2, a2p4, a3p2, a3p4, a4p2, a4p4, a6p2 and a6p4 
have been identified 1 (Gotti et al., 1997). The a4p2 receptor has been shown to express in 
two different stoichiometries of (a4)2(P2)3 and (a4)3(P2)2 with the high ACh affinity receptor
1 Note on nicotinic receptor nomenclature: The number following each subunit identifier (non­
subscripted) is part of the subunit name -  ex. a4 refers to the a-subunit classified as 
neuronal a subunit number 4. The subscript identifies the number of specific subunits that 
comprise the pentameric receptor. Hence, a designation of a4p2 simply indicates the 
pentamer is composed of a4 and p2 subunits but the stoichiometry is undefined; usually 
referring to a heterologous mixture of stoichiometries. A designation of (a4)3(P2)2 defines the 
stoichiometry and identifies the receptor as comprised of 3 a4 subunits and 2 p2 subunits. 
The precise arrangement of these subunits relative to one another is ambiguous and 
generally unknown.
predominating in brain (Gotti et al., 2007). (a4)2((32)3 receptors bind ACh with high affinity of 
about 2 pM, while (a4)3((32)2 receptors bind ACh with low affinity of about 70 pM (Zwart and 
Vijverberg, 1998). a5 and (33 do not form binary complexes or homomers but form ternary 
complexes with a2, a3, a4, a6, (32 and P4 in various permutations and combinations (e.g. 
a4p2a5) (Clementi et al., 2000). Additionally a quaternary complex of subunits could be 
formed through combination of a5 and P3 subunits and the a2, a3, a4, a6, p2 and P4 
subunits (e.g. a3p2p4a5) (Vernallis et al., 1993). Complex combinations having more than 
one a subunit and more than one ACh binding site (e.g. a3p2a6p2p4) are also possible 
(Clementi et al., 2000). Different ACh binding sites are formed between the a1y, a15 and a le  
subunits of muscle nicotinic receptors. Gating properties, ligand selectivity and modulation of 
nAChR subtypes are dependant on subunit composition (Clementi et al., 2000). Even though 
a subunit in a receptor may not contribute to the agonist binding site it will contribute to the 
ion pore and conformational stability of the receptor (Clementi et al., 2000).
1.6 Distribution of neuronal nAChRs:
Peripheral Tissues:
The tissue distribution of nAChRs in mouse has been well mapped using techniques 
such as in situ hybridization and immuno-histochemistry (Figure 1.3). The expression of 
muscle nicotinic receptors is found in other locations including the thymus where they are 
thought to modulate immune responses (Bruno et al., 2004). The expression of functional a7 
nAChRs was also found in developing mammalian muscle cells (Fischer et al., 1999), 
although expression decreased in adults. Additionally, mRNA expression of a4, a5, p2 and 
p4 nicotinic subunits have been found in vertebrate muscle cells (Corriveau et al., 1995). The 
role of neuronal receptors in muscle tissue has not been conclusively determined but they 
may control metabolic and trophic functions as well as gene expression by modulating 
calcium influx. Nicotine binding sites have also been identified in B-lymphocytes and in
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circulating T-lymphocytes (Paldi-Haris et al., 1990). Human macrophages express a l  
receptors and the activation of these receptors by nicotine decreases the release of tissue 
necrotic factor -  a (TNF- a) and interleukins 1 and 6 induced by endotoxin polysaccharides 
(Wang et al., 2003). Mice alveolar macrophages express a402 but not a l  receptors 
(Matsunaga et al., 2001). The presence of nAChR a3, a7, a9, (32 and 04 subunits has been 
demonstrated in human epidermal cells (Grando, 2001). Vascular endothelial cells of blood 
vessels also contain many nicotinic receptor subunits including the a3, a5, a7, a10, 02 and 
04 subunits (Macklin et al., 1998). Vascular smooth muscles express the a2, a3, a4, a5, a7 
and a10 subunits (Bruggmann et al., 2003). Endothelial cells of the blood brain barrier 
express a5, a l,  02 and 03 subunits (Abbruscato et al., 2002). Nicotine is known to alter the 
permeability of the blood brain barrier, possibly by reducing the expression of the a l  and 02 
subunits and the tight junctional protein ZO-1 (Abbruscato et al., 2002).
The Central Nervous System:
The mapping of nAChRs in the human brain is much less comprehensive than for rat 
and mouse brains which have been used to study nAChR distribution (Gotti et al., 2006). A 
variety of techniques have been used to study the localization of nAChR in the brain 
including in-situ hybridization, immuno-histochemistry and radioligand binding studies using 
ligands such as nicotinic and a-bungarotoxin, nicotinic receptor gene knockout studies and 
positron emission tomography.
The majority of nAChRs in the brain can be divided in to two general categories: 
receptors that bind ACh with high affinity (nM concentrations) and those that bind with low 
affinity (pM concentration). Low affinity ACh receptors are typically the homomeric a7 
nAChRs which also bind to a-bungarotoxin. High ACh affinity receptors are typically the a402 
receptors which do not bind to a-bungarotoxin. High affinity a402 receptors account for about 
90% of high ACh affinity receptor in the brain (Whiting and Lindstrom, 1986).
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Dopaminergic neurons in the mesocorticolimbic pathway mediate the addictive 
property of nicotine and a4(32 receptors are implicated in this process (Picciotto et al., 1998). 
The nucleus accumbens and prefrontal cortex receive projections of these dopaminergic 
neurons from the ventral tegmental area. Almost all dopaminergic neurons in the ventral 
tegmental area express a4 and (32 receptors (Klink et al., 2001). The Substantia nigra pars 
compacta contains moderate to high levels of a4(32 nAChR mRNA (Wada et al., 1989). 
Immuno-electron microscopy shows the presence of the (32 subunit in the pre-synaptic 
region of dopaminergic axons in the dorsal striatum (Jones et al., 2001). The presence of the 
a4 subunit has also been demonstrated by immuno-precipitation in dopaminergic projections 
of the dorsal striatum (Zoli et al., 2002).
The distribution pattern of a4 and (32 mRNA is well characterized in the primate 
(monkey) brain (Quik et al., 2000). The most intense expression of these two nAChR 
subunits is seen in the dentate gyrus of the hippocampus, cerebellum, locus coeruleus, 
cortex and lateral geniculate nucleus (Rubboli et al., 1994). a4 and (32 mRNA have moderate 
levels of expression in the CA regions of the hippocampus, hypothalamus and thalamus. 
Expression is lowest in regions such as the caudate nucleus and locus coeruleus (Rubboli et 
al., 1994). While there is some evidence that nicotinic receptor signalling can be post- 
synaptic (Roerig et al., 1997), most of the nicotinic receptor signalling seems to be pre- 
synaptic in the brain (Gray et al., 1996). Immuno-histochemistry and direct 
electrophysiological experiments have confirmed the pre-synaptic location of neuronal 
nicotinic receptors. In one experiment, it was demonstrated that nicotine induced inward 
currents in large pre-synaptic calyces that were blocked by a-BTX, suggesting the 
involvement of pre-synaptic a7 nAChR (Coggan et al., 1997). Therefore it is proposed that 
nAChRs in the CNS primarily modulate rather than directly mediate synaptic transmission 
(Gray et al., 1996) The pattern of expression of the a7 receptor subunit is widespread 
and has considerable overlap with the expression of a4 subunit mRNA (Quik et al., 2000).
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The expression of a7 receptors is highest in the dentate gyrus of the hippocampus. The 
beta-amyloid (a-J31-42) peptide binds with high affinity to the a7 receptors expressed pre- 
synaptically in the hippocampal neurons of patients with early stage Alzheimer’s disease 
(Nagele et al., 2002). A strong to moderate expression of a7 is seen in the CA2 and CA3 
regions of the hippocampus, cerebellum, and reticular nucleus of the thalamus (Figure 1.2). 
Moderate to low expression is observed in CA1, the lateral geniculate nucleus, and other 
thalamic nuclei, cortex, subthalamic nucleus, locus coeruleus, and substantia nigra 
(Hellstrom-Lindahl etal., 1999).
1.7 Structure of Cysteine-loop ligand gated ion channels:
1.7.1 General structure of ‘Cys-loop’ ligand gated ion channels:
Cys-loop ligand-gated ion channels play an important role in electrochemical neuro­
transmission throughout the nervous system and other tissues of the body. Embedded in the 
cell membrane, these receptors are composed of five similar (homopentameric) and five 
different (heteropentameric) polypeptides. The representation of single subunit is depicted in 
Figure 1.3. The five subunits are arranged around an axis perpendicular to the cell 
membrane forming a pore that conducts ions from the outside to the inside of the cell. A 
single subunit typically contains anywhere from 400 to 700 amino acids. The amino acid 
sequence of every subunit is largely conserved among all members of the Cys-loop 
superfamily, and is presumed to be structurally similar. Three structurally distinct domains 
are observed in subunit tertiary structure:
The extracellular ligand binding domain: The N-terminal hydrophilic extracellular region forms 
the ligand binding domain in Cys-loop ligand-gated ion channels and contains a 15-amino 
acid spaced disulphide bond between the two Cysteine residues (Arias, 2000). The 
crystalline structure of the torpedo nicotinic receptor has been resolved up to 4 Armstrong
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units (A0) using electron diffraction (Unwin, 2005) and optimized by molecular modelling. The 
resultant structure shows the amino terminal of each subunit with an N-terminal a-helix, two 
short 310 helices and a core of ten P-sheets which forms a “sandwich” and houses the actual 
ligand binding site. The ligand binding site is located between the two adjacent subunits, 
about 35 A0 from the membrane. Figure 1.5 shows the ribbon structure of the refined model 
of the nAChRs obtained by Unwin et. a t Loops 31-P2, Cys-Cys and 38-39 are essential for 
coupling agonist binding to channel gating (Bouzat et al., 2004).
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Figure 1.2: Representative structure of the ligand gated ion channel subunit. NH2 -  N 
terminal of the protein, C1 -  small intracellular loop between M1 and M2 domain M1, M2, 
M3, M4 -  4 transmembrane domains, C2 -  Variable intra cellular loop.
The transmembrane domain: The amino terminal sequence that forms the extracellular 
domain is followed by four highly hydrophobic a-helices M1, M2, M3 and M4 that comprise 
the transmembrane domain. The M2 transmembrane segment lines the pore of the ion 
channel. Five M2 segments, one from each of the five subunits composing the pentameric 
receptor, constitute the channel pore. Each M2 segment is surrounded by three other 
transmembrane segments (M1, M3 and M4). In a pentameric receptor the five central M2 
segments are surrounded by 15 hydrophobic a-helices. A kink in the M2 helix produces a 
constriction near the mid-point of the channel due to interactions with the surrounding 
hydrophobic residues of the neighbouring M1, M3 and M4 domains (Unwin, 1993a). The M1, 
M3 and M4 transmembrane helices are in contact with the surrounding lipids of the cell 
membrane. The interaction of lipids with the transmembrane domains also contributes to the 
kinetics of channel gating in ligand gated ion channels (Spitzmaul et al., 2004). A tight 
hydrophobic narrowing of the channel in the middle of the membrane that creates an 
energetic barrier for ions and the kink at the centre of the M2 domain are thought to serve as 
the channel gate (Miyazawa et al., 1999). Photo-affinity labelling, site directed mutagenesis 
and biophysical methods have been used to deduce the structure of the ion conducting pore. 
Structural studies have identified the presence of conserved Leucine residues in the middle 
of the M2 domain (Miyazawa et al., 2003). This Leucine along with a nearby valine residue 
forms a hydrophobic girdle that makes up the channel gate. At its narrowest point the 
channel opening is approximately 3.5 A0. This is smaller than the size of a K+ or Na+ ion with 
its single hydration shell. The hydrophobic girdles in the channel counter the electrostatic 
stabilization and release the ion from its shell of hydration to permit ion conductance. The 
hydrophobic interactions between the amino acid residues forming the gate are sufficiently 
weak to destabilize upon agonist binding, leading to channel gating and re-stabilization upon 
the loss of agonist from the ligand binding site (Unwin, 1993b).
The intracellular cytoplasmic domain: The intracellular cytoplasmic domain is hydrophilic and 
mostly a-helical in structure. The intracellular loop is located between the M3 and M4 
domains. This is a highly variable region of the protein and its length differs widely between 
subunits. It varies in size from 30 to 200 amino acids in length. Electron microscopy of 
nicotinic receptors has shown that the cytoplasmic loop forms a closed cage with openings 
that presumably allow the passage of ions into the cell from the pore of the channel 
(Miyazawa et al., 1999). It is likely that charged amino acid residues located on the inner 
surface of the cytoplasmic loop of the pore regulate the passage of ions in the cell (Miyazawa 
et al., 1999). In the 5-HT3R a region of the cytoplasmic loop called the HA-stretch has been 
identified as a major determinant of channel conductance (Kelley et al., 2003). The same 
study identified three positively charged Arginine residues in this region which strongly 
influence channel conductance in the 5-HT3R. The region where the three Arginine residues 
are located is predicted to be an amphipathic helix in the intracellular loop (Miyazawa et al.,
1999). Mutation in this amphipathic helix in the £ subunit of the muscle receptor leads to 
congenital myasthenic disease due to changes in gating kinetics of the receptor (Wang et al., 
2000a). Structural determination techniques such as electron diffraction place these residues 
on the outer rim of the opening present at where cytoplasmic regions of adjacent subunits 
meet (Miyazawa et al., 1999).
The intracellular loop also contains multiple phosphorylation sites that could 
potentially modulate ion channel conductance (Swope et al., 1999). The currents induced by 
5HT binding to the 5-HT3R are potentiated in the presence of protein kinase C and casein 
kinase (Hubbard et al., 2000). This action is presumed to occur due to the phosphorylation of 
specific amino acids of the intracellular loop. An increase in conductance at a single channel 
level is also observed due to the phosphorylation of amino acids in the intracellular loop of 
the 5-HT3R (Van Hooft and Vijverberg, 1995). The intracellular domain is also responsible for 
clustering and anchoring these receptors in the cell membrane.
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Figure 1.3: General structure of nicotinic receptor. From Protein Data Bank (PDB) file 2BG9 
(Unwin, 2005). Side view as seen using DeepView Swiss Pdb Viewer version 3.7.
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The C-terminal of the Cys-loop ligand gated ion channels is located extracellular following 
the M4 loop. The C-terminal is short and presumed to contain a binding site for steroids that 
modulate the channel. The C-terminal of the a4 subunit of nAChRs has been identified as 
the binding site responsible for the potentiating action of 17-P-estradiol on a4|32 subtype 
(Paradiso et al., 2001).
1.7.2 Structure of ligand binding site of nAChRs:
Electron diffraction has been utilized to identify the detailed crystalline structure of 
Torpedo nAChRs to a resolution of 4 A0 (Unwin, 2005). The discovery of acetylcholine 
binding protein (AChBP) and its subsequent crystallization (Brejc et al., 2002) has been used 
to optimize the electron diffractions structures of the N-terminal ligand binding domain of 
nAChRs. The currently accepted structure of nAChRs has been developed from a 
combination of techniques including electron diffraction, homology modelling, and models of 
ligand docking (Arias, 1997). Site directed mutagenesis, substituted cysteine accessibility 
studies and radioligand binding have enabled further refinement of these structures (Arias, 
1997).
After it was demonstrated that nicotinic receptors were cell membrane bound 
proteins, it was hypothesized that the acetylcholine interaction site on these receptors would 
be on the extracellular portion of the protein because positively charged acetylcholine 
molecules could not pass through the cell membrane. Based on this hypothesis, it was 
experimentally shown that the acetylcholine binding sites were located near a disulphide 
bond in the nAChR protein which could be readily reduced (Silman and Karlin, 1969). When 
this disulphide bond was reduced, the receptors were found to be in a state of perpetual 
activation when covalently linked to bromo-acetylcholine (Silman and Karlin, 1969).
Site directed affinity labelling studies with a ligand for nAChRs demonstrated that 
every two moles of affinity labeled ligand coincided with one mole of receptor 
stoichiometrically (Weiland et al., 1976). Using the electric tissue of electrophorus, the 
nAChR subunit was identified by affinity labelling acetylcholine binding site (Reiter et al., 
1972). This subunit was similar to the a1 subunit of muscle nAChRs. The a1 subunits in 
muscle nAChRs were then shown to contain the acetylcholine binding site for the muscle 
nicotinic receptor (Reynolds and Karlin, 1978). The muscle nAChR has two a1 subunits, 
hence it has two ACh-binding per receptor each corresponding to a singe a1 subunit. 
Labelling and cross-linking experiments provided evidence that the ACh-binding sites were 
present in the interface between the receptor subunits.
In muscle nAChRs, the a1 subunit forms the principal face of the ligand binding site. 
The subunit adjacent to the principle a-subunit forms the complementary face of the ligand 
binding site (Corringer et al., 2000). It was thought that the ligand binding site on nicotinic 
receptor was made by six distinct loops, named A, B, C, D, E and F. The crystal structure of 
the AChBP later confirmed that six discontinuous loops contribute to the acetylcholine 
binding site; loops A, B and C form the principal face and loops D, E and F form the 
complementary face (Smit et al., 2003). In the muscle nAChR the two adjacent Cysteines, 
Cys192 and Cys193 of the C-loop form a disulphide bond (Kao and Karlin, 1986).These two 
adjacent Cysteines are characteristic of all nicotinic receptor a-subunits. Additionally, four 
widely spaced aromatic residues of the muscle a-subunit Tyr93, Trp149, Tyr190 and Tyr198 
were found to be conserved in all ACh receptor a-subunits (Galzi et al., 1990), except for 
neuronal a5 subunit. These aromatic amino acid residues in the a-subunit are also involved 
in binding ACh. These cysteines and aromatic residues, contributed by the principal face are 
in the Ach binding site, formed by the a-subunit. Figure 1.5 shows the ligand binding site on 
nAChRs.
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The complementary face is formed by the subunits neighbouring the a-subunit in the 
muscle receptor, which also contributes to the ACh binding site. The ligand binding site is 
formed between the muscle a1 subunit and y or 5 subunits, but not with p subunit (Sine and 
Claudio, 1991). Photo-affinity labelling of the muscle nAChRs with d-tubocurarine specifically 
identified amino acids from the y and the 5 subunits involved in forming the ACh binding site. 
These amino acids are y-subunit Trp53, Tyr111, Tyr117 and 5-subunit Trp55, and Arg113 
(Sine, 1993). Another competitive inhibitor, benzoylbenzoylcholine, was photo-labelled to an 
amino acid pair on y-subunit, Leu109 and 5Leu111 (Wang et al., 2000b). The ACh binding 
site is located in a multi-loop structure localized in a pocket formed by aromatic residues. The 
electron cloud of the aromatic ring in aromatic residues present in the ACh binding site 
stabilizes the quaternary ammonium group of ACh by forming a cation-pi interaction (Sine, 
2002). The positive charge on Arg113 forms a hydrogen bond with the oxygen in the 
carbonyl moiety of ACh (Arias, 2000).
The ligand binding site and the interaction of ACh with other nicotinic receptor 
subunits are similar to those in muscle nAChRs. The aromatic amino acid residues that 
characterize the binding site of muscle nAChRs are present in all of the nAChR subtypes, 
including the neuronal a7 and a4p2. These aromatic residues form similar interactions with 
acetylcholine as those found in the muscle receptor.
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Figure 1.4: Ligand binding site on nicotinic receptor at the subunit interface. The marked box 
indicates the acetylcholine binding site on the nicotinic receptor. From Protein Data Bank 
(PDB) file 2BG9 (Unwin, 2005). Visualized using DeepView Swiss Pdb Viewer version 3.7.
1.7.3. Acetylcholine binding protein:
While studying synaptic modulation in snails (Lymnelia stagnalis), Smit et. al 
discovered a protein that binds to acetylcholine (Smit et al., 2001). Purification and 
characterization of this protein revealed that this protein was a soluble homolog of the 
nAChRs. This acetylcholine binding protein (AChBP) derived from glial cells was
subsequently crystallized and its structure determined to 2.7 A0 resolution (Brejc et al.,
2002). The crystalline structure of AChBP indicates a homo-pentameric quaternary structure. 
Each subunit of the Lymnelia AChBP is composed of 210 amino acids with a sequence 
homology of 20-22% with nAChR subunits (Brejc et al., 2002). AChBP has also been found 
in California sea hare, Aplysia californica (Hansen et al., 2004) and Bulinus truncates, both 
invertebrates (Celie et al., 2005). The biological function of AChBP in the cholinergic 
synapses of snails is thought to be modulation of ACh mediated neurotransmission by 
binding of ACh released in the synapse. Sequence homology between the AChBP and other 
ligand gated ion channels suggests that structural elements of the nicotinic receptor including 
the Cys-loop and binding site structure are conserved. In particular, AChBP displays a 
significant structural similarity to the N-terminal ligand binding domain of torpedo nAChRs 
(Sine et al., 2004). Like other ligand gated ion channel receptors the ACh binding site on 
AChBP is also located at the subunit interface. Crystal structures of the AChBP with nicotine 
or carmaylcholine bound at the binding site have been obtained to 2.7 A° resolution (Celie et 
al., 2004).
Since the high resolution crystalline structure (see Figure 1.6) of the AChBP is 
available, it has been used as a template to develop homology models of the extracellular 
ligand binding domains of nicotinic and other LGIC receptors (Karlin, 2004). These homology 
models have proved useful tools for data interpretation obtained from biochemical 
experiments and the formulation of new hypotheses regarding LGIC binding site structure 
and function (Hansen and Taylor, 2007).
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Figure 1.5: Structure of Acetylcholine binding protein. (A) Bottom view; (B) Side view. From 
Protein Data Bank (PDB) file 1I9B (Smit et al., 2003). Visualized using DeepView Swiss Pdb 
Viewer version 3.7.
1.8 Physiological role of nAChRs:
Nicotinic acetylcholine gated ion channels are primarily located at the neuromuscular 
junction and the neuronal synapse. The principle physiological role of nAChRs is to facilitate 
the process of neurotransmission although nicotinic receptors also play a role in gene 
transcription by permitting Ca2+ entry into cells.
Neuronal signalling: Under resting conditions, the membrane potential across the neuronal 
cell membrane is approximately -70 mV. Changes in cell membrane potential result from 
opening and closing of ion channels, altering the permeability of different ions (Kandel et al.,
2000). The membrane potential will shift toward the Nernst potential of the most permeable 
ions. Flence opening of Na+ channels leads to depolarization (increase in potential) and 
opening of Cl" channels leads to hyper-polarization (decrease in potential). Acetylcholine 
release at the synaptic cleft leads to opening of ion channels on either a nearby pre-synaptic
or postsynaptic membranes depolarizing the membrane at that position (Kandel et al., 2000). 
On the pre-synaptic side, both depolarization and calcium entry serve to facilitate 
neurotransmitter release (Kandel et al., 2000). Post-synaptically, depolarization of the 
dendrites of the postsynaptic cell produces local depolarization of the membrane (Kandel et 
al., 2000). This depolarization slowly spreads down the dendrites toward the cell body by a 
process called passive conduction (Kandel et al., 2000). Typically, if only a few receptors are 
activated the level of depolarization is insufficient to significantly alter the potential at the 
neuronal cell body; however, if a larger number of receptors are open simultaneously, the 
cell body becomes depolarized and an action potential or active conductance is initiated at 
the axon hillock region of the cell and a signal is sent down the axon (Kandel et al., 2000). A 
single release of ACh pre-synaptically may alter the membrane potential by only +1 mV 
(millivolt), however a depolarization of about +15mV is typically necessary to initiate an 
action potential (Kandel et al., 2000). This usually involves multiple cellular inputs releasing 
pulses of neurotransmitter (Kandel et al., 2000). To trigger an action potential sufficient 
numbers of receptors must be activated within a narrow time span in a small area to produce 
a depolarization capable of propagating to the cell body (Kandel et al., 2000). Thus neurons 
integrate the incoming signal from multiple activated receptors both temporally and spatially 
(Kandel et al., 2000).
Synaptic potentials can be inhibitory or excitatory in nature. Inhibitory postsynaptic 
potential (IPSP) reduces the chance of generating action potentials by hyperpolarizing the 
postsynaptic membrane (Kandel et al., 2000). Excitatory postsynaptic potentials (EPSP) 
increases the possibility of generating action potentials by depolarizing the postsynaptic cell 
(Burke et al., 2001). Nicotinic receptors conduct positively charged ions, thus generating 
EPSP’s. GABA receptors which conduct Cl' ions hyperpolarize the membrane thus producing 
IPSPs and acting to prevent action potentials (Kandel et al., 2000). Thus, in addition to 
temporal and spatial integration of inputs, the post synaptic cell also integrates the effects of
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inputs from multiple neurotransmitters (Kandel et al., 2000). Alterations in receptor numbers, 
conductance, open channel probabilities and ion conductivities as well as competitive binding 
of ligands may all contribute to changes in the delicate integration and balance of these 
systems. Loss of acetylcholine receptors either pre or post-synaptically will alter the signaling 
profile of systems mediated by nAChRs.
nAChRs in Gene expression: While the process of fast synaptic transmission is thought to be 
the primary neuro-physiological function of nAChRs, activation of these receptors may also 
alter gene expression. One example of nicotinic receptor mediated gene expression is 
mitochondrial biogenesis in skeletal muscle in response to vigorous exercise (see Figure 
1.7). Skeletal muscles contract and relax in response to signals from motor neurons 
innervating the muscle cells. ACh released at the neuromuscular junction binds to the muscle 
nicotinic receptor on the muscle membrane surface. Since muscle nAChRs conduct calcium 
ions, repeated stimulation during vigorous exercise increases the concentration of calcium in 
the muscle cell. Elevated intracellular calcium stimulates additional calcium release from the 
sarcoplasmic reticulum which binds to the protein calmodulin. Calcium binding to calmodulin 
complex activates the Ca/Calmodulin dependent protein kinase (CaM-kinase), which 
translocates to the nucleus of the muscle cell and phosphorylates a transcriptional co­
activator peroxisome proliferator-activated receptor-y coactivator-1 a (PGC-1a) (Ojuka et al.,
2003). PGC-1a has the ability to auto-regulate its own gene expression. Moreover, it induces 
the expression of nuclear respiratory factor-1 (NRF-1) and NRF-2 which are transcription 
factors for numerous nuclear genes encoding mitochondrial proteins (NUGEMPS) (Hood, 
2001). The expression of mitochondrial transcription factor A (Tfam) is also induced by NRF- 
1 (Gordon et al., 2001). Tfam and NUGEMPS are imported into mitochondria by the protein 
import machinery (PIM) (Joseph et al., 2006). Tfam is responsible for regulating the 
expression of the 13 mitochondrial DNA (mtDNA) genes, including cytochrome c oxidase
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subunit 1 (COX 1) (Hood et al., 2006). PGC-1a coordinates the expression of nuclear and 
mitochondrial genomes which ultimately leads to mitochondrial biogenesis in the muscle cell. 
The increase in mitochondrial density satisfies the demand for more Adenosine tri-phosphate 
(ATP) in the muscle cell undergoing vigorous exercise. A similar mediation of cellular 
processes through calcium entry may also play a role in the CNS and likely plays a role in up 
and down regulation of nAChR expression on exposure to nicotine. Recognition of the 
importance of calcium in nicotinic signalling is likely to grow as more detail about distribution 
and interaction of nAChRs with other neurotransmitter systems is elucidated.
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Figure 1.6: Muscle nicotinic receptor signaling causes gene transcription in the cell. CaM- 
Kinase -  Calcium calmodulin dependent kinase, PGC-1a - proliferator-activated receptor-y 
coactivator-1 alpha, NRF-1 & NRF-2 -  Nuclear respiratory factor-1 and Nuclear respiratory 
factor-2, TFAM -  mitochondrial transcription factor-A, NUGEMPS -  Nuclear genes encoded 
mitochondrial proteins, PIM - protein import machinery, Cox-1 - cytochrome c oxidase 
subunit-1.
1.9 Functional characteristics of nAChRs:
1.9.1 The gating mechanism in nAChRs:
Gating is the process by which nAChRs open to conduct ions and close to a non­
conducting or desensitized state. The gating process involves sequential changes to the 
stability of different confirmations or “states” of the channel. The binding of agonist to the 
receptor is the triggering event responsible for inducing gating in nAChRs. The bound 
agonist leads to conformational changes that stabilize the open channel conformation thus 
permitting ions to move through the pore. The ligand binding site of the nAChRs is present at 
the subunit interface in the extracellular domain. The ligand binding site is present in six 
binding loops that form the ligand-binding pocket of LGICs (Corringer et al., 2000).
Structural determinants of the gating process in nicotinic receptors: Nicotinic receptors 
contain a signature loop with a conserved disulphide bond in the extracellular domain. This 
defining structure is thought to play a significant role in the conformational changes leading 
to channel opening (Dougherty and Lester, 2001). In nAChRs the cys-loop is located at the 
bottom of the subunit interface in contact with an emergent TM2-TM2 loop. TM2 lines the 
channel pore and movement of this transmembrane helix is likely critical to channel opening. 
The interaction with the cys-loop and the TM2-TM3 loop is thought to be destabilized as a 
result of binding of agonists producing a rotation of TM2. A second region of the protein 
typically referred to as ‘loop 2’ is also located in a position near the membrane surface. It is 
possible that both the ‘Cys-loop’ and the ‘loop 2’ regions may interact with the 
transmembrane domain of the receptor to activate the ion channel (Brejc et al., 2001).
Electron micrograph structures of the Torpedo nAChR have indicated that a 
conserved Leucine (L251) forms a kink in the middle of the helical TM2 segment of the 
receptor’s pore. (Unwin, 1995). The hydrophobic interactions of the leucine side chain with 
neighbouring amino acid side chains make a tight hydrophobic girdle around the pore
25
(Miyazawa et al., 2003) forming the gate of the channel. It has been proposed that the 
rotation of one or two TM2 segments weakens the hydrophobic interactions at the girdle, 
causing all of the TM2 segments to rotate and open the channel pore, allowing the passage 
of ions. A linear free energy relationship analysis of mutations within the TM2 segment of the 
nAChR 5-subunit indicates there is a conformational change of the upper half of the TM2 
segment which precedes that of the lower half of TM2 (Cymes et al., 2002). This 
conformational change in the upper half of TM2 weakens the hydrophobic interactions, 
allowing the channel pore to open. The TM2-TM3 loop may thus act as a hinge that allows 
the opening of the channel by the rotation of the TM2 domain, since it is located on the 
extracellular side of the ion channel pore (Lynch et al., 1997). As described above, rotation of 
TM2 may be initiated by destabilization of interactions between the TM2-TM3 extracellular 
loop and the ligand binding domain as a result of ligand binding. This hypothesis is 
consistent with earlier electron micrograph structures of the nAChR (Unwin, 1995) and the 
close proximity of the cys-loop and loop2 with the TM2-TM3 loop. Conformational changes 
have been demonstrated in the TM2-TM3 loop during channel activation associated with 
channel gating (Lynch et al., 2001).
The molecular interactions between the extracellular domain and the TM2-TM3 loop 
in the nAChR are hydrophobic in nature. Miyazawa and colleagues proposed a hydrophobic 
‘pin and socket’ interaction between a Valine residue (a1V44) in ‘loop 2’ of the extracellular 
domain and a hydrophobic pocket between residues a1S269 and a1P272 on the TM2-TM3 
loop (Miyazawa et al., 2003). According to this model, binding of the ligand induces a 
clockwise 15° rotation of loop 2 in the a-subunit on an axis perpendicular to the membrane 
plane. This loop pushes the TM2-TM3 loop and rotates the TM2 transmembrane domain. 
This rotation causes destabilization of the hydrophobic girdle forming the channel gate in the 
TM2 transmembrane domain and results in the passage of ions through the channel pore 
(Miyazawa et al., 2003).
Mathematical modeling of channel gating: The gating of an ion channel can be represented 
by mathematical models which assume multiple meta-stable conformational states and 
channel dictating rates at which these confirmations change (Hille, 2001). A key component 
in modeling the gating of nAChR is the determination of the number of conformations and 
intermediate states of the channel (Hille, 2001). It was previously assumed that there were 
only three states of the receptor channel (see Figure 1.8). These were the resting state 
(closed), the active state (open) and the desensitized state. In the absence of an agonist, 
most of the channels in a population are in the resting state (closed). Ligand binding to the 
receptor opens the ion channel because the probability of ion channel opening increases in 
the presence of an agonist (Hille, 2001). During the prolonged presence of the 
neurotransmitter (agonist), the receptor reaches a stable, desensitized state. In the 
desensitized state, the channel remains closed upon application of agonist, because the 
agonist remains bound (Hille, 2001). The receptor recovers from desensitization by two 
routes. An agonist bound receptor can reopen by shifting back to the open conformation or 
the agonist can dissociate returning the receptor to the (closed) resting state.
Active (open)
Figure 1.7: The three presumed conformational states of nicotinic receptor according to the 
Markov model.
The transition probabilities between the three sites are known as the Few States 
Model or Markov Gating Model (see Figure 1.8) This model assumes that the kinetic rate 
constants are independent of the time spent in the 3 states and also independent of the 
previous sequence of the channel state (Colquhoun and Sakmann, 1981).
1.9.2 Channel kinetics and other biophysical characteristics of nAChRs:
The nAChRs are ion channels and as such allow passage of cations into the cell. 
Cloned nAChRs are routinely expressed in cell lines by stable or transient transfections. 
Electrophysiological techniques such as patch clamp are used to study functional 
characteristics of nAChRs expressed in mammalian cell lines. mRNA coding for nAChRs can 
also be synthesized in vivo and injected into Xenopus laevis (frog) oocytes to study receptor 
function (Buckingham et al., 2006).
Macroscopic biophysical characters of nicotinic receptor: Xenopus oocytes are larger in size 
than mammalian cells and express more nicotinic receptors numerically when injected with 
mRNA. Not only do Xenopus oocytes provide an advantage due to their size, but they also 
conduct a large measurable current when nAChRs are expressed in them. The nAChRs in 
oocytes are typically characterized using two electrode voltage clamp (TEVC) (Joshi et al.,
2004). In this technique two electrodes, one corresponding to voltage and other 
corresponding to current, are inserted into a Xenopus oocyte expressing nAChRs (Joshi et 
al., 2004). The oocyte is continuously perfused with a buffer solution (Joshi et al., 2004) and 
clamped at a fixed holding potential (Joshi et al., 2004), following which the agonist is 
applied. Application of agonist opens the expressing nAChR channels (Buckingham et at., 
2006). The current required to maintain the holding potential is recorded as the ions pass into 
the oocyte through the expressing ion channel (Buckingham et al., 2006). The recorded 
current is equivalent to the number of ions that pass through the ion channels and is a
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macroscopic summation of all open nAChR channels in the oocyte. The current displays 
three distinct phases each corresponding to the change in the number of channels open at a 
particular time after exposure to agonist. Current elicited by application of agonist is plotted 
against time. A typical response is shown below in Figure 1.9. Shown in the figure are two 
traces, one obtained by application of ACh to an oocyte expressing human a7 receptors and 
the other from an oocyte expressing a4|32 receptors.
a7 receptor response a4p2 receptor response
Figure 1.8: Response profiles for a7 and a4|32 receptors expressed in Xenopus oocytes. 
Oocytes were held at a membrane potential of -60 mV. Acetylcholine was applied to each 
receptor at a concentration of 100pM.
Desensitization of liaand-qated ion channel receptors: When ACh is applied at a steady state 
to the muscle tissue, the macroscopic end-plate potential falls within seconds via a 
phenomenon known as desensitization (Hatton et al., 2003). All nAChRs desensitize to some 
extent during prolonged exposure to agonist. This desensitization is typified by the decline in 
the responses shown in Figure 1.9 following the response peak. Some nAChRs like the a7 
subtype have faster rates of desensitization, while others, like the a4(32 subtype, desensitize 
with slower rates (Kim et al., 2007). Desensitization is the result of resistance of nAChRs to
re-activation by application of agonist and is thought to be the result of the presence of a 
closed, ligand bound conformation of the receptor (Hille, 2001). There may, in fact, be 
multiple desensitized conformations of nAChRs (Raines and Krishnan, 1998). Desensitized 
states may offer unique drug targets for inhibitory ligands. One example of this is Sazetidine- 
A, a novel nAChR ligand that binds to the desensitized state of the a4(32 nAChRs without 
activating them (Xiao et al., 2006).
1.10 Role of neuronal nAChRs in various diseases and Conditions:
The a7 and the high affinity a4@2 receptors are the two main subtypes of nAChRs 
with wide distribution in the brain. As such they are involved in the patho-physiology of many 
diseases and disorders. Nicotine addiction, Alzheimer’s disease, human epilepsy syndrome, 
Schizophrenia and Autism are some of the neuro-psychiatric conditions where nicotinic 
receptors are thought to be involved.
Nicotine addiction:
Nicotine is an agonist which binds to all subtypes of acetylcholine receptors. 
Obtained from the leaves of the tobacco plant Nicotiana, nicotine is alkaloidal in nature and 
highly addictive in humans. Humans primarily ingest nicotine through smoking cigarettes. 
The public health risk due to cigarettes and subsequent smoke, which contains nicotine, is 
tremendous. The addictive properties of nicotine due to self-administration are well known. 
Understanding the mechanism of nicotine addiction is important due to the extreme health 
risks associated with nicotine abuse (deRuiter and Faulkner, 2006). The effects of nicotine 
are complex and not well understood at the synaptic level, however the activation and 
desensitization by nicotine likely alters the profile of the synaptic response thus altering the 
temporal integration of synaptic signalling (McGehee, 2007). Synapses respond to nicotine 
by altering expression of receptor subtypes. The a4|32 subtype of nicotinic receptor is up-
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regulated after chronic exposure to nicotine (Fenster et al., 1999). The mesolimbic dopamine 
(DA) projection from the ventral tegmental area (VTA) to the nucleus accumbens (NAc) is a 
central pathway for drug addiction and related behaviours in the brain (Picciotto and 
Corrigall, 2002). The a4(32 receptors present pre-synaptically on dopaminergic neurons of 
this pathway causing the release of dopamine and reinforcing the addictive properties of 
nicotine (Picciotto et al., 1998). Thus nicotinic receptors, particularly the a4(32 subtype, 
contribute to nicotine addiction through alterations of pre-synaptic release of dopamine in the 
brain.
Human epilepsy syndrome:
Mutations in genes encoding neuronal nAChRs have been determined to cause a 
form of sleep-related epilepsy called autosomal dominant nocturnal frontal lobe epilepsy 
(ADNFLE). The genes encoding for a4, a2 and 02 (CHRNA4, CHRNA2, and CHRNB2) 
subunits were implicated by ADNFLE (Marini and Guerrini, 2007). The a4 gene contains an 
S248F2 mutation within the ion channel pore (Kuryatov et al., 1997). A change in the 
functional characteristics of the receptor due to gene mutations forms the basis of 
epileptogenesis (Mulley et al., 2003). In-vitro and in- vivo studies have shown that certain 
mutations in nAChRs present in the thalamus cause over activation of the brainstem’s 
ascending cholinergic pathway and enhanced GABAergic neurotransmission in the reticular 
activating system which controls arousal from sleep and plays a central role in seizure 
precipitation in ADNFLE (Hogg et al., 2003).
2 Nomenclature for amino acid location and mutations within the primary sequence: 
Residues are designated by using the single letter amino acid code for the amino acid found 
in the “typical” or “normal” sequence along with its position in the primary sequence. Hence 
S248 refers to a serine at postion 248 numbered from the initiator methionine as position 1 .A 
mutation would be designated as a second amino acid following the postion. For example 
S248F indicates that the serine 248 amino acids downstream from the initator methionine is 
mutated to phenylalanine. The species and subunit may also be included for clarity (ex: 
/7Q4S248F).
Autism:
Autism is a spectral disorder (Geurts et al., 2008) and in some autistic cases 
neuronal a4p2 receptor protein expression and receptor binding density as well as a4 mRNA 
levels in the parietal cortex is decreased (Lee et al., 2002). Reduced gene expression of the 
a4p2 receptors in the cerebral cortex is a major feature of the neuro-chemical pathology of 
Autism (Lee et al., 2002). The a7 receptors expression however remains unchanged (Lee et 
al., 2002) The precise role of nAChR expression changes in the etiology of Autism remains 
unclear; however, they may contribute to changes in “nicotinic tone” in affected brain regions. 
Nicotinic tone refers to the overall level of activation of synapses modulated by nicotine. High 
nicotinic tone would facilitate synaptic transmission in areas regulated by pre-synaptic 
nAChRs while low nicotinic tone would hinder transmission. Therapeutic agents that could 
restore or improve nicotinic transmission to compensate for decreased a4£2 receptor 
expression can play an important role in treatment options for Autism. This would represent 
an important advance in a disorder with no clear pharmacological intervention.
Schizophrenia:
Schizophrenia is a psychiatric disorder characterized by abnormal perceptions or 
expressions of reality manifested as auditory hallucinations, paranoid delusions or 
disorganized speech and thinking (Lake and Hurwitz, 2006). Sensory gating, an involuntary 
process by which selective attention is paid to sensory stimulus is profoundly impaired in 
schizophrenic patients (Leonard et al., 1996). A high level of nicotine addiction has been 
observed in schizophrenics and it is thought that smoking may restore normal sensory gating 
(Mobascher and Winterer, 2008). The temporal lobes of schizophrenics show a reduced a- 
bungarotoxin binding to nAChRs which are predominantly a7 receptors (Freedman et al., 
1993). Sensory gating defects can be induced in mice by a-bungarotoxin administration 
which targets the a7 subtype of nAChRs (Luntz-Leybman et al., 1992). Many nAChRs
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agonists have been shown to restore normal sensory gating in animal models of sensory 
gating deficits (Martin et al., 2004). However, partial agonists are found to function better 
than agonists in this regard; likely through decreased desensitization of a7 receptors 
(Stevens et al., 1998). Novel modulatory compounds targeting a7 receptors may provide new 
treatment options for Schizophrenia.
Alzheimer’s disease (AD):
Characterized by dementia, AD affects 15 million people worldwide and this number is likely 
to grow as life expectancy increases (Palmer, 2002). A clear pathological feature of AD is the 
presence of amyloid plaques which arise from amyloid-3 (A3 1-42) peptides and 
neurofibrillary tangles formed by the aggregates of hyperphosphorylated tau protein. Severe 
functional loss of cholinergic systems in the basal forebrains of patients suffering from AD 
has been observed (Perry, 1986). In advanced cases of AD cholinergic neurons are lost and 
the number of nAChRs reduced in the hippocampus and cortex (Coyle et al., 1983). 
Paradoxically, smokers have a lower prevalence of AD than non-smokers (Newhouse et al., 
1988), presumably because nAChR expression levels are increased in the brains of smokers 
(Perry et al., 1999), possibly providing a neuro-protective mechanism against AD. The 
common treatment prescribed for AD is acetylcholinesterase inhibitors such as galantamine. 
In addition to being an acetylcholinesterase inhibitor galantamine also allosterically 
potentiates nAChRs present in the brain (Maelicke et al., 2001). Such drugs in AD patients 
are thought to restore normal functioning of cholinergic synapses through dual mechanisms 
of acetylcholinesterase inhibition and nAChR potentiation (Maelicke et al., 2001). Nicotinic 
agents like galantamine improve cognitive deficits of AD patients (Maelicke et al., 2001). The 
loss of pre-synaptic nAChRs due to A31-42 toxicity causes improper release of other 
neurotransmitters such as glutamate in the hippocampus and this may also contribute to 
memory loss in AD patients. Loss of nAChRs in AD may cause mis-functioning of various
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neuronal pathway activities and loss of synaptic plasticity. Drugs targeting specific subtypes 
of neuronal nicotinic receptors could be valuable therapeutic agents in AD since such drugs 
would restore cholinergic tone to the diseased brain.
1.11 Principles of Allostery:
Derived from the Greek word alios meaning “other” and stereos meaning “solid” or 
“shapes”, allostery is the property of proteins to adopt a conformation or shape induced by 
the binding of two or more ligands. When two different ligands are involved in the allosteric 
interaction it is called heterotrophic allosterism (Lehninger et al., 2005). The allosteric effect 
is also seen when the same ligand binds to multiple similar sites on a single protein, known 
as homotrophic allosterism. The binding of Oxygen to haemoglobin is the most widely 
studied example of homotrophic allosterism in biochemistry
In multi-subunit proteins which bind two or more ligands at two distinct sites, the 
binding of one ligand generally increases or decreases the rate of binding of the second 
ligand to the protein (Taly et al., 2006). If the rate of binding of the second ligand increases 
due to the presence of the first ligand this effect is known as positive cooperativity; if binding 
decreases, the effect is known as negative cooperativity (Edelstein et al., 1997). The level of 
cooperativity is indicated by the Hill coefficient (Creighton, 1993) which gives a quantitative 
measure of the degree of cooperativity (Creighton, 1993). The Hill coefficient corresponds to 
the hypothetical number of ligand molecules that would have to be bound to the protein in an 
all-or-none fashion to display perfect cooperativity (Creighton, 1993). However the actual 
binding of a ligand to a protein is not totally cooperative, thus the Hill coefficient is seldom a 
perfect integer value. The value of the Hill coefficient can be as large as the number of 
interacting binding sites only if there was complete cooperativity between these sites 
(Creighton, 1993).
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Jefferies Wyman, Jacques Monard, and Jean-Pierre Changeux in 1965 proposed an 
interesting theory to explain allosterism in proteins. This theory is known as the WMC Model 
or the Concerted Model of Allosteric Transition. According to the Concerted Model, proteins 
can exist in multiple inter-convertible conformations (Creighton, 1993). These conformations 
are determined by thermal equilibrium and this influences the conformational state of the 
protein at any given time. Binding of a ligand shifts this thermal equilibrium favourably for one 
conformation versus another (Creighton, 1993).
The Concerted Model assumes that multiple distinct conformations of a multi-subunit 
protein can exist (Creighton, 1993). A  specific conformation has a higher affinity for the 
ligand than any other conformation the protein assumes (Creighton, 1993). While the ligand 
can bind the protein in any conformation, the conformational equilibrium is favoured for that 
conformation which has the highest affinity for the ligand. Thus, the change in concentration 
of the ligand over a small concentration range leads to a huge shift of equilibrium to the 
conformation favoured by the ligand. This explains the sigmoidal nature of the binding curves 
when ligands bind to multiple binding sites in allosteric multi-subunit protein (Hille, 2001).
Heterotrophic allosteric interactions involving other ligands occur because these 
ligands bind preferentially to one of the conformations that the protein assumes. Generally, 
each ligand controls the apparent affinity of the protein for other ligands by shifting the 
equilibrium towards the conformation that it prefers (Creighton, 1993).
1.11.1 Allosteric transition in nicotinic receptors:
Homotrophic allosteric transition in nAChR by acetylcholine binding to the orthosteric site: 
The concept of allosteric transition proposed by Wymann, Monod and Changeux was found 
to effectively explain the properties of nAChR (Karlin, 1967). This concept explains how the 
nAChR protein can exist in multiple distinct conformations. The closed state of the receptor 
(with no ion conductance) and the open state (ion conducting state) are the two
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conformations identified (Del Castillo and Katz, 1957). The protein can exist in either 
conformation based on the thermal equilibrium. If the thermal equilibrium changes, the 
receptor can undergoes spontaneous conformational changes. The nAChR channels open 
with a low probability even in the absence of an agonist (Grosman and Auerbach, 2000). 
ACh, an agonist for the nAChR, binds and changes the conformational equilibrium to the 
open state of the receptor. If one ACh molecule could open the channel of the nAChR, than 
the conductance of a population of receptors with respect to ACh concentration would 
increase in sigmoidal fashion with a curve similar to the classic Michaelis-Menton equation 
for enzyme kinetics and the conductance would saturate at high ACh concentrations (Hille,
2001). The measured dose-response curve, however, showed approximately a four fold 
increase in conductance for every doubling of ACh concentration and a slope of almost two 
on a log plot (Lester et al., 1975). The dependence on the square of the agonist 
concentration implied that two agonist molecules were needed to open the channel. In a log- 
log plot of conductance versus concentration of ACh for the muscle nAChR, the Hill 
coefficient is 1.5-2.2 in most peer-reviewed literature (Hille, 2001). Biochemical studies 
confirmed that chemically purified muscle nACh receptors had two equivalent ACh binding 
sites formed by two a-subunits (Dunn et al., 1983).
Due to thermal fluctuations the nicotinic receptor channel can open spontaneously 
without the presence of an agonist (Colquhoun and Sakmann, 1981). If the channel can open 
spontaneously without an agonist and two ligands are needed to open it, even a single 
agonist bound state could open the channel. While the channel can open in any of the three 
scenarios, the presence of agonist increases the probability of channel gating. In the 
absence of an agonist, the channel opening probability is 1/1000000; with two bound 
agonists the probability increases to 1/33.
As per the concerted model of allosteric transition, the binding of the ligand shifts the 
equilibrium to a new conformation of the protein. Accordingly, the agonist for nAChR shifts
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the equilibrium to the open state. The energy from the ligand binding interaction provides the 
energy required to stabilize this open conformation of the receptor (Lena and Changeux, 
1993). Acetylcholine, an endogenous agonist for the nAChR, binds to a specific site on the 
receptor and stabilizes the open conformation of the channel. The binding site for ACh could 
be defined as the orthosteric site on the nicotinic receptor. The binding of two ACh molecules 
on the nicotinic receptor happens at two distinct identical sites (Hille, 2001) and is 
homotrophic allosteric in nature (Hille, 2001).
Heterotrophic allosteric transition in nicotinic receptor by ligand binding to allosteric site: The 
presence of multiple distinct binding sites on the nicotinic receptor for many ligands is 
possible. These sites would be different from the conventional ACh binding site and would 
form heterotrophic allosteric interactions. Ligands binding to such sites are allosteric 
modulators for the receptor (Bertrand and Gopalakrishnan, 2007). If an allosteric ligand 
further stabilizes the open confirmation of the receptor channel induced by the agonist, it is 
known as a positive allosteric modulators (PAMs) for the receptor (Bertrand and 
Gopalakrishnan, 2007). Positive allosteric modulators further shift the conformational 
equilibrium of the nicotinic receptor to the open state and increase the receptor response 
(Bertrand and Gopalakrishnan, 2007).
PAMs increase the receptor response in the presence of an agonist. However, it 
would be a misnomer to identify a ligand as a positive allosteric modulator if it can activate 
the channel by itself. A ligand can have an allosteric binding site on the receptor and still 
activate the channel on a microscopic or a macroscopic level. Such ligands may be classified 
as allosteric non-competitive agonists or allosteric partial agonists (Storch et al., 1995). A 
true positive allosteric modulator is one which binds to an allosteric site on the receptor, but 
fails to activate the channel by itself on a macroscopic or microscopic level. The presence of 
either a full or partial agonist is necessary for a positive allosteric modulator to open the
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channel. A positive allosteric modulator must also show dose-dependent potentiation and 
inhibition of the receptor. It may increase efficacy, affinity or both when co-applied with an 
agonist or a partial agonist. A positive allosteric modulator can decrease the EC50 of the 
agonist which means increasing the apparent affinity of the agonist for the receptor. There 
are ligands known to act as negative allosteric modulators for nAChRs (Arias, 2000). 
Negative allosteric modulators shift the conformational equilibrium towards the closed state 
without directly competing with the agonist (Arias, 2000). These compounds increase the 
EC50 and move the dose-response curve for the agonist without directly competing for its 
binding site. Such compounds could potentially bind to the same allosteric site as a positive 
allosteric modulator on the receptor and competitively inhibit the actions of the positive 
allosteric modulator (Arias, 2000). For the benzodiazepine binding site on GABA (A) 
receptors, compounds such as Ro15-4513 and (3-carbolines are known to act as negative 
allosteric modulators (Mehta and Ticku, 1999). Ro15-4513 and (3-carbolines are negative 
allosteric modulators for the GABA (A) receptors.
1.12. Allosteric modulators for a7 and a4p2 subtype of nAChRs:
The neuronal nAChRs receptors are known to have multiple conformations where 
binding of a ligand preferentially stabilizing the receptor protein in a specific conformation 
(Edelstein et al., 1997). There are many ligands which are known to bind a7 and a4p2 
subtypes of nAChRs on allosteric sites, separate from the orthosteric site where ACh binds 
(Bertrand and Gopalakrishnan, 2007). Such allosteric ligands for neuronal nAChR can 
produce a positive as well as a negative effect on the receptors’ responses. Since the a7 and 
a4p2 are the two predominant subtypes of nAChR widely distributed in the brain, they are 
involved in the patho-physiology of many diseases and conditions, hence positive allosteric 
modulators for this receptor holds immense therapeutic potential (Gotti et al., 2006).
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1.12.1. Allosteric modulation of a7 nAChRs:
The first compound identified as a positive allosteric modulator of the a7 receptor 
was an anthelminthic agent, ivermectin (Krause et al., 1998). This compound increased 
maximal ACh-evoked currents, reduced its EC50 value and increased the slope of the dose- 
response curve (Hill coefficient). A partial agonist for the a7 receptor, 
dimethylphenylpiperazinium (DMPP) became almost a full agonist when co-exposed with 
ivermectin (Krause et al., 1998). Genistein, a tyrosine kinase inhibitor was found to act as a 
positive allosteric modulator for a7 receptors that predominantly affected the peak current of 
the receptors (Charpantier et al., 2005). Later, several compounds which could increase the 
ACh induced currents at the a7 receptors were reported (Bertrand and Gopalakrishnan, 
2007).
A novel positive allosteric modulator, PNU-120596 (1-(5-chloro-2, 4-dimethoxy- 
phenyl)-3-(5-methyl-isoxazol-3-yl)-urea) potentiates a7 receptors but lacks action on a4(32, 
a3(34 and a9a10 receptors (Hurst et al., 2005). In a high-throughput screen, PNU-120596 
increased agonist-evoked calcium flux mediated by human a l  receptors (Hajos et al., 2005). 
Electrophysiological studies with PNU-120596 on a7 receptors showed an increase in peak 
agonist-evoked currents and pronounced prolongation of the response in the presence of the 
agonist. With single channel studies PNU-120596 increased the channel mean open time of 
a l  receptors with no effect on ion selectivity (Hurst et al., 2005). Later studies identified the 
importance of the transmembrane regions in potentiation of the a7 receptors by PNU-120596 
in presence of an agonist. Five transmembrane amino acid mutations significantly reduced 
potentiation of a l  receptors by this compound (Young et al., 2008). These amino acids are 
located in the a-helical transmembrane domains TM1 (S222 and A225), TM2 (M253) and 
TM4 (F455 and C459). Mutation of A225 or M253 individually showed a reduction in 
potentiation by PNU-120596 compared to wild type a l  receptors. In the homology models of 
the a l  receptor, based on the 4A structure of the Torpedo nAChR, the side chains of these
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five amino acids point toward an intra subunit cavity located between the four a-helical 
transmembrane domains; computer docking models suggest that PNU-120596 may bind 
within this intra-subunit cavity (Young et al., 2008). A number of other allosteric modulators of 
a7 receptors have been identified. 5-hydroxyindole (5-HI) produces a significant increase in 
the ACh-evoked current of a7 receptors (Zwart et al., 2002). SLURP-1, the secreted 
mammalian Ly-6/uPAR related protein (SLURP-1, a peptide secreted by human 
keratinocytes, is also known to be a positive allosteric modulator of human a7 receptors 
(Chimienti et al., 2003). SLURP-1 produces an increase in the ACh-evoked current on 
human a l  receptor, a reduction in the EC50 for ACh and an increase in the slope of the 
concentration response curve (Chimienti et al., 2003).
1.12.2. Non-selective positive allosteric modulators of a4p2 receptors:
Due to their wide distribution, a4(32 receptors are involved in the patho-physiology of 
many neurological conditions. Schizophrenia, Autism, loss of cognitive function and nicotine 
addiction are some of the diseases and conditions where a4p2 receptors are thought to be 
involved (Gotti and Clementi, 2004). Positive allosteric modulators are potentially useful as 
therapeutic agents since they may be capable of restoring or improving nicotinic tone as a 
result of decreased a4p2 receptor expression.
Galantamine and Physostigmine: The acetylcholinesterase inhibitor physostigmine has been 
shown to directly activate muscle type nAChRs in frog muscle fibers and Torpedo nAChR 
(Shaw et al., 1985). This effect of physostigmine is distinct from its inhibitory action on the 
acetylcholinesterase enzyme (Albuquerque et al., 1988). The agonist action of physostigmine 
is inhibited by the nAChR specific monoclonal antibody FK1, but not by nAChR competitive 
ligands (Okonjo et al., 1991). The epitope for this monoclonal antibody is located between 
amino acids 118 and 145 on the a-subunit of the nAChR. Photo-affinity labelling of Torpedo
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nAChR with [3H]-physostigmine has shown that physostigmine binds to the a-subunit of the 
receptor near K125 (Schrattenholz et al., 1993). Photo-affinity labelling and inhibition studies 
with FK1 confirm that physostigmine and the FK1 antibody share overlapping binding sites. 
In a similar study, the binding site for acetylcholine on the a-subunit of the nAChR was found 
to overlap the epitope for the monoclonal antibody WF6. The WF6 epitope is located 
around amino acids 81 to 200 overlapping the ACh orthosteric binding site on a1 (Conti- 
Tronconi et al., 1991). Taken together, these studies show that acetylcholine and 
physostigmine bind at different binding sites on the a1 receptor making physostigmine a 
unique non-competitive allosteric agonist (Pereira et al., 1993). Galantamine, another 
cholinesterase inhibitor and the opiod codeine have also been confirmed to be non­
competitive nAChR allosteric agonists. The binding site for these compounds is thought to be 
similar to that of physostigmine (Storch et al., 1995).
Physostigmine and galantamine (Figure 1.10) show effects on a4p2 receptors that 
are similar to their action on muscle receptors and are thought to activate the receptor via a 
different binding site than ACh (Pereira et al., 1994). Physostigmine activates chicken a4p2 
receptors expressed in M10 cells, through a binding sight that is also insensitive to ACh 
(Pereira et al., 1994), but did not elicit currents on the same receptor when expressed in 
Xenopus oocytes. When physostigmine is co-applied with acetylcholine on a4p2 receptors 
expressed in Xenopus oocytes, it potentiates ionic currents induced by low concentrations of 
acetylcholine with inhibition at higher acetylcholine concentrations (Smulders et al., 2005). 
Physostigmine has been shown to bind to a low affinity ACh binding site present on a4p2 
receptors distinct from the high affinity site that activates the receptor. Physostigmine 
potentiation of a4p2 receptors is only seen in the presence of low concentrations of 
acetylcholine (Smulders et al., 2005).
Galantamine has been used clinically to combat the symptoms in Alzheimer’s 
disease (Scott and Goa, 2000). Its clinical use is based on both its ability to inhibit
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acetylcholinesterase in the synapse and to simultaneously potentiate both a7 and a4p2 
receptors (Maelicke et al., 2000). In HEK293 cells expressing human a4(32 receptors, 
galantamine reduces the apparent EC50 for ACh by half but has no effect on the efficacy as 
measured by the apparent lmax (Samochocki et al., 2003). In addition to a4P2 and a7 
receptors, galantamine also potentiates a3p4 and a6p4 (Maelicke et al., 2000). The 
proposition that galantamine binds to an allosteric site on nAChR is strongly supported by 
experiments and modeling studies which reveal that this compound binds to the Aplysia 
Califomica AChBP in a region different from the ACh binding site (Hansen and Taylor, 2007).
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Figure 1.9: Structure of (A) Galantamine and (B) Physostigmine
Physostigmine and galantamine are both thought to potentiate neuronal nAChRs by 
stabilizing the open state of the receptor channel (Maelicke et al., 2001). Galantamine and 
physostigmine are non-selective in that they are known to potentiate both homomeric a7 
receptors and the heteromeric subtypes of nAChRs. The beneficial action of these two drugs 
in restoring cholinergic tone in the synapse is expected to be enhanced by their dual actions 
as acetylcholinesterase inhibitors and allosteric modulators of nAChRs (Maelicke et al., 
2000).
Steroids: The primary mechanistic action of steroid hormones derived from cholesterol is to 
control gene transcription through activation of intracellular receptors. This is a slow process
since steroid signalling involves uptake of the steroid into the cell via an endocytotic process 
followed by binding to appropriate regulatory sites for gene transcription and translation. 
However, certain neuro-steroids are also capable of modifying neuronal activity through 
mechanisms that are too fast to involve gene expression. Neuro-steroids are synthesized in 
glial and neuronal cells in the brain and act through the steroid hormone nuclear receptors, 
and other mechanisms including modulation of neurotransmitter gated ion channels (Mellon 
et al., 2001). Steroid injections have been shown to improve cognition, memory and learning 
(Frye and Sturgis, 1995). The first evidence of a steroid targeting a4p2 receptors was 
provided by an experiment in which water soluble serum albumin-attached progesterone and 
unbound progesterone effects on a4-containing receptors were compared. This experiment 
showed that albumin-bound and unbound progesterone are equally capable of inhibiting a4- 
containing receptor activity in Xenopus oocytes. Since albumin-bound progesterone can not 
cross the cell membrane, this supported an extracellular site of action for progesterone on 
the a4 subunit of the nAChRs (Valera et al., 1992). Progesterone was tested for its ability to 
potentiate ot4p2 receptors, but it failed to do so. However, 17-P-Estradiol (17-BE) potentiated 
human a4p2 receptors and inhibited rat a4p2 receptors without potentiation (Paradiso et al., 
2000). The difference in action of 17-BE in the two species was used to locate the binding 
site on the a4p2 receptor responsible for potentiation. Using site directed mutagenesis, it 
was determined that the short C-terminal end of the a4 subunit with the amino acid sequence 
WLAGMI was the key determinant for 17-BE potentiation of human a4p2 receptors. The 
tryptophan (W) in this C-terminal sequence has been hypothesized to form a specific t t - t t  
interaction with the ethynyl moiety of 17-BE. The binding site of 17-BE for potentiation was 
shown to be different than the steroid inhibition site because the mutation in the C-terminal 
sequence has no effect on progesterone inhibition (Paradiso et al., 2001). The complex 
modulation of a4p2 receptors by steroids seems to be determined by both the chemical 
structure of the steroid and the amino acid sequence of the nAChR subtypes. There is
growing evidence to suggest a transmembrane location of an inhibitory binding site for 
different steroids in other subtypes of nAChRs (Arias, 1998). Experiments attempting to 
locate such a binding site have not been carried out in a4p2 receptors. Single channel 
studies have confirmed that mechanistically, 17-BE increases the opening probability of a4p2 
receptors (Curtis et al., 2002).
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Figure 1.10: Structure of (A) Progesterone; (B) 17-p-Estradiol
Zinc: Ionic zinc (Zn2+) is a key modulator of neuronal excitability which is present in neurons 
throughout the brain, specially in the cerebral cortex and the hippocampus (Frederickson et 
al., 2000). Zinc plays an important role in modulating synaptic activity (Howell et al., 1984) 
and modulates the function of many LGIC receptors including GABA type A (Krishek et al., 
1998) and glycine receptors (Harvey et al., 1999). Zinc was found to inhibit a7 (Palma et al., 
1998) and a3p2 receptors. When tested for its action on neuronal nAChR, it produced a 
biphasic dose response on a2p2, a2p4, a3p4, a4p2 and a4p4 subtypes (Hsiao et al., 2001). 
ACh generated currents on a2p2, a2p4, a3p4, a4p2 and a4p4 subtypes of nAChRs were 
potentiated by zinc at low pM concentrations and inhibited at a higher mM concentration 
range. For the a4p2 receptor, the half-maximal concentration for potentiation (EC50) was 
about 16 pM and the half-maximal concentration for inhibition (IC50) was about 440 pM 
(Hsiao et al., 2001). ACh responses on a4p2 receptors were potentiated by 260% with zinc.
Application of 50 pM zinc increased the response of a4(B2 receptors at saturating ACh 
concentrations (Hsiao et al., 2001). Zinc potentiation and inhibition are both pH dependent, 
but voltage independent (Moroni et al., 2008). By site directed mutagenesis and the 
substituted cysteine accessibility method (SCAM) certain key residues of the (32+/a4- 
interface of a4p2 receptor have been identified as critical to zinc potentiation (Hsiao et al., 
2006). Of the two different stoichiometries of the a4p2 receptor in the central nervous 
system, zinc potentiates only the low ACh affinity stoichiometry (a4)3(P2)2 receptors while 
inhibiting both high and low affinity stoichiometry of the receptor (Moroni et al., 2008). The 
inhibition of Zinc on the high affinity (a4)2(P2)3 receptor is voltage dependent while it is 
voltage independent on low affinity (a4)3(P2)2 receptors (Moroni et al., 2008). Based on these 
observations and through site directed mutagenesis studies, the p2+/a4' subunit interfaces 
were proposed as the Zn2+ inhibition site on (a4)2(p2)3 and (a4)3(P2)2 receptors and the 
a4+/a4" subunit interface was proposed as the site for the potentiating action of Zn2+ on 
(a4)3(P2)2 receptors (Moroni et al., 2008). Single channel studies suggest Zn2+ potentiates 
a4p4 receptors by increasing the burst frequency of the receptor (Hsiao et al., 2008). Since 
Zn2+ potentiates a4p4 and a4p2 receptors, the mechanism of action of zinc on a4p2 
receptors may be similar to its mechanism of action on a4p4 receptors.
Thiazole(2-amino-5-keto) and Carbamate Analogues: Three novel (2-amino-5-keto) thiazole 
analogues have been reported allosteric modulators of neuronal nAChRs (Broad et al., 
2006). These compounds potentiated a2p4, a4p2, a4p4, a7 but not a3p2 and a3p4 
receptors (Broad et al., 2006). Unlike the previously discussed a4p2 potentiators 
galantamine and physostigmine, none of these compounds are acetylcholinesterase 
inhibitors (Broad et al., 2006). All three compounds enhanced the potency and maximal 
efficacy of different nicotinic agonists on a4p2 receptors, a profile typical of allosteric 
potentiators. At concentrations required for potentiation, the compounds did not displace
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[3H]-epibatidine from the agonist-binding site, and potentiation was observed at all agonist 
concentrations, suggesting a non-competitive allosteric mechanism of action. Interestingly, at 
concentrations higher than that required for potentiation these compounds also showed 
intrinsic agonist activity which was blocked by competitive and non-competitive nAChR 
antagonists (Broad et al., 2006).
Very recently a series of carbamate analogues were reported as a4(32 nAChR 
potentiators. In addition to a4(32 receptors these molecules also bound to a3p2 and a3p4 
receptors and were optimized for CNS penetration (Albrecht et al., 2008). These compounds 
also increased the response of a4p2 receptors to ACh (Springer et al., 2008) without 
competing for binding with the orthosteric ligand cytosine (Albrecht et al., 2008). These 
carbamate analogues represent a new class of compounds with immense therapeutic 
potential, possibly acting by an allosteric site on a4p2 receptors. It has not been reported if 
these carbamate analogues do or do not have agonist activity.
Desformylflustrabromine (dFBr): Many alkaloid compounds from natural sources are known 
to act as agonists or antagonists for nAChRs. Epibatidine found in the skin of a neo-tropical 
poisonous frog, Epipedobates tricolor is a potent agonist of nAChRs (Daly, 2005). Curare 
extracted from Chondrodendron tomentosum, a plant found in South American jungles, 
contains an active component d-tubocurarine, which is an antagonist for nAChRs (Bowman, 
2006). Desformylflustrabromine (dFBr) is a metabolite of the marine bryozoan Flustra 
foliacea which is common in the North Sea (Lysek et al., 2002). The structure of dFBr is 
derived from a brominated indol ring as seen in Figure 1.12.
Some of the tryptophan derived metabolites of Flustra foliacea were first shown to 
have muscle relaxant properties (Sjoblom et al., 1983). Flustramine A, another Flustra 
extract could also block potassium channels (Peters et al., 2002). When the Flustra 
derivatives were tested on a432 and a7 subtypes of the neuronal nAChR using radioligand
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binding assays, it was determined that dFBr had low pM affinities for the nAChRs (Peters et 
al., 2004). dFBr extracted from its natural source was tested functionally on heteromeric 
a4p4, a3(32, a3f34, a4(32 and a7 nAChR expressed in Xenopus oocytes (Sala et al., 2005). 
When co-applied with ACh, dFBr selectively potentiated but did not inhibit a4p2 receptors. At 
the applied concentration, dFBr had no potentiating effect on other heteromeric a4p4 or a3p2 
receptor but showed an inhibitory effect on homomeric a7 receptors. The potentiation 
induced by dFBr on ACh induced currents was reversible and concentration dependent. In 
single channel experiments, no changes in conductance or reversal of potential were seen. 
When the single channel data was subjected to dwell time analysis, it indicated that dFBr 
acts by either increasing the opening rate constant or decreasing the closing rate constant of 
a4p2 receptors (Sala et al., 2005).
Figure 1.11: Structure of desformylflustrabromine (dFBr)
Drugs of the cholinergic system. 5-HT & codeine: Cholinergic drugs like atropine, 
scopolamine, rivastigmine, and tacrine have also been tested for their ability to potentiate 
a4p2 receptors (Smulders et al., 2005). Physostigmine-like compounds such as atropine, 
scopolamine and tacrine combine potentiation of an ion current induced by low 
concentrations of acetylcholine with inhibition of ion currents evoked by high concentrations 
of acetylcholine. Only rivastigmine causes inhibition of ion currents evoked by low 
concentrations of acetylcholine. No potentiation is observed. (Smulders et al., 2005).
N H - C H 3
Codeine, serotonin and the muscle relaxant benzoquinonium have been described 
as non-competitive allosteric agonists for nAChR, but have different actions on a402 
receptors. The endogenous neurotransmitter 5-HT has also been shown to potentiate 
agonist activated currents for nicotinic receptors in PC12 cells (Schrattenholz et al., 1996). 
When expressed in Xenopus oocytes however, a4|32 receptors are inhibited by 5-HT in a 
non-competitive manner by a channel blocking mechanism (Garcia-Colunga and Miledi, 
1995), but no potentiation is observed. Codeine, an opiate, potentiates nicotinic receptors by 
binding to the FK1 antibody site (Storch et al., 1995), though such action has not been 
demonstrated on a4p2 receptors.
Since nAChRs are implicated in the patho-physiology of many diseases and 
conditions, positive allosteric modulators for these receptors could be important therapeutic 
agents in treatment of neuro-pathological conditions where these receptors are implicated. 
The benzodiazepine class of compound, for example, is an amazing success story in the 
related GABA receptor (Mehta and Ticku, 1999). Allosteric modulatory ligands for nAChRs 
will lead to clinically applicable drugs targeting these receptors. Such compounds will provide 
a novel means of treatment for various neurological disorders where these receptors play a 
critical role.
1.13 Research Hypothesis:
1.13.1 Basic premise of studying allosteric modulators for nAChRs:
The principle reasons for studying allosteric modulation in nAChRs are:
1) To identify new mechanism of receptor function. Conventional agonists, antagonists and 
partial agonist act on the nicotinic receptors via interaction with the orthosteric site. Study of 
allosteric modulation may reveal new mechanisms of receptor activation.
2) To identify novel binding sites on neuronal nicotinic receptors for unconventional ligands. 
Neuronal nAChRs may contain multiple distinct sites for the binding of different ligands.
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Using novel ligands as molecular probes, putative allosteric sites on nicotinic receptors can 
be found and studied. Experimental methods like Site directed mutagenesis, chimeric 
constructs and the substituted cysteine accessibility method (SCAM) can be utilized to 
pinpoint the amino acid residues in the allosteric binding site and their involvement in binding 
of allosteric ligands.
3) To discover novel allosteric modulatory ligands for neuronal nAChRs as lead molecules 
and develop them into clinically applicable drugs. One purpose of basic pharmacological 
research is to produce novel drug therapies. The discovery of novel allosteric modulators 
could provide new drug compounds which selectively target nAChR subtypes and lead to 
new treatment options for diseases and conditions where nicotinic receptors are involved. 
Since the large majority of nAChR modulators are non-selective, the development of subtype 
selective ligands will facilitate identification of the role of select subtype in disease processes.
1.13.2 General hypothesis.
Members of the ligand gated ion channel super-family (LGICS) include 5-HT3R, 
nAChRs, GABA (A) and (C) receptors, glycine receptors and the acetylcholine binding 
protein (AChBP). All the members of this family are allosteric proteins (Edelstein et al., 
1997). There are many available drugs such as benzodiazepines and barbiturates that act as 
alosteric modulators for GABA (A). These drugs are prescribed clinically as anti­
depressants, anxiolytics and anaesthetics (Mehta and Ticku, 1999). However, there are no 
clinically available drugs that target neuronal nAChRs with selectivity for a specific subtype of 
nicotinic receptor. Based on preliminary molecular modelling studies and sequence 
comparison between members of the LGIC family, we formed the general hypothesis that 
dFBr is a subtype selective positive a llosteric m odulator o f neuronal nAChRs. As such, 
dFBr will serve as a lead molecule for the development of a novel drug class with applicable 
to enhancing nicotinic synaptic transmission.
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1.13.3 Specific hypotheses:
1) Synthetic dFBr is a selective3 positive allosteric modulator of the a4f32 subtype of 
the neuronal nAChR with no potentiating activity on the a7 subtype of neuronal 
nicotinic receptors.
This hypothesis is based on previous studies that used dFBr from its natural source, 
the marine bryozoan Flustra foliacea and examined its effects on both a4p2 and a7 subtypes 
of nAChRs. We used a synthetic water-soluble HCI salt of dFBr in our studies. The 
experiments evaluating the effects of synthetic dFBr on a4(32 and a7 subtype nAChRs are 
described in Chapter 2 of this thesis. These experiments were designed to determine if the 
synthetic compounds exhibited similar effects to the naturally extracted dFBr.
2) Different functional groups in the chemical structure of dFBr are responsible for the 
potentiation versus inhibition of acetylcholine induced responses on a4f32 receptors.
While structurally similar, the chemical analogues of dFBr presented in this thesis 
contain different functional groups. These differences in structure are responsible for the 
differences in potentiation and inhibition observed on a4p2 receptors. In other words, we 
hypothesize that inhibition and potentiation occur due to binding of dFBr on different binding 
sites present on a4p2 receptors, each with unique structural requirements. Different dFBr 
analogues will produce different effects on potentiation and inhibition of ACh induced 
responses on a4(32 receptors. Structural modification of the parent compound dFBr would be 
expected to produce different effects on the potentiation and inhibition properties observed 
for dFBr. Based on this hypothesis, 16 analogues of dFBr were tested on a4p2 and a7 
receptors. The results of these experiments are discussed in Chapter 3 of this thesis. These
3 The term “selective” within the context of this thesis refers only to a relatively narrow 
definition of selectivity within the acetylcholine receptor family. This does not imply that the 
compound does not bind to other LGIC or non-LGIC receptors. Further testing beyond the 
scope of this thesis is required to validate claims of broad rather then narrow definitions of 
selectivity.
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experiments were not designed to determine broad subtype selectivity of dFBr other than a 
simple comparison of a4(32 to a7 receptors, however, these data form the basis by which 
subtype selectivity can be examined in future studies in the laboratory.
3) The effects of dFBr are due to its binding at a unique binding site that is different 
from the binding site for other a4p2 receptor allosteric modulators.
Since the action of dFBr is selective for the a4p2 receptor subtype while 
physostigmine, Zn2+ and 17-p estradiol non-selectively potentiate other nicotinic receptor 
subtypes, we hypothesize that the binding site for dFBr will only be present on the a4p2 
receptor. Physostigmine, Zn2+ and 17-p estradiol which also potentiate a4p2 receptors would 
not be expected to bind to this presumed dFBr binding site. This hypothesis will be tested 
pharmacologically by first evaluating the effects of all dFBr, physostigmine, Zn2+ and 1 7-p  
estradiol on a common system (a4b2 receptors expressed in Xenopus oocytes) than through 
combination studies in which two potentiators are co-applied. The results of these 
experiments are presented and discussed in Chapter 4 of this thesis.
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CHAPTER 2: ACTION OF SYNTHETIC DESFORMYLFLUSTRABROMINE ON ALPHA7
AND ALPHA4 BETA2 SUBTYPE OF NEURONAL NICOTINIC RECEPTORS1
2.1 Abstract:
Desformylflustrabromine (dFBr; 1) and desformylflustrabromine B (dFBr-B; 2) have been 
previously isolated from natural sources, and the former has been demonstrated to be a 
novel and selective positive allosteric modulator of a4p2 nicotinic acetylcholine receptors 
(nAChR). The present study describes the synthesis of water-soluble salts of 1 and 2, and 
confirms and further investigates the actions 1 and 2 using two-electrode voltage clamp 
recordings. When obtained by extraction from the natural source, dFBr potentiated ACh 
induced responses of a4|32 receptors and appeared selective for the 0402 nAChR subtype 
compared to other common nicotinic receptor subtypes including the a7 receptor. The 
synthetic HCI salts described here showed enhanced solubility and potency compared to the 
naturally obtained compound. In addition, a second inhibitory effect was observed at higher 
dFBr concentrations for a4p2 and a7 receptors. No potentiation of responses was observed 
on a7 receptors. While dFBr is a positive allosteric modulators of a4p2 receptor it lacks such 
an action on a l  receptors. dFBr-B is not a positive allosteric modulator for a4p2 or a7 
nicotinic acetylcholine receptors but is capable of inhibiting both receptor subtypes.
1 This data presented in this chapter has been previously published as a peer-reviewed 
research article: J.-S. Kim, A. Pandya, M. Weltzin, B. W. Edmonds, M. K. Schulte, and R. A. 
Glennon. (2007). "Synthesis of desformylflustrabromine and its evaluation as an alpha4beta2 
and alpha7 nACh receptor modulator." Biooraanic Medicinal Chemistry Letters 17(17): 4855­
60.
The experimental data presented in this chapter is entirely my work, except for a portion of 
the data in Figure 2.3. Two repeats of this experiment were performed by Maegan Weltzin 
and two repeats were performed by me. The compounds tested were synthesized by J.-S. 
Kim and R. A. Glennon at the Virginia Commonwealth University, School of Pharmacy, 
Department of Medicinal Chemistry, Richmond, VA. The synthesis of the compounds is not 
included in this chapter.
2.2 Introduction:
Over the past decade or so, nicotinic acetylcholine receptors (nAChRs) have been 
targeted for the development of agents with potential for the treatment of certain 
cardiovascular and neurological (e.g. Parkinson’s disease, Schizophrenia, Alzheimer’s 
disease) disorders, memory and learning deficits, appetite control problems, and pain (Arias, 
2000; Glennon, 2004). These pentameric ion channel receptors are composed of 
heteromeric or homomeric assemblies and, although numerous subtypes have been 
identified, the most prevalent in the brain are the heteromeric a4(32 and the homomeric al 
nAChRs (Arias, 2000; Glennon, 2004). While some recently developed ligands differentiate 
between the a4(32 and al sub-type of nAChRs, only a few (if any) have been shown to 
selectively target either a4(32 or any other nACh receptor subtypes (Glennon, 2004). A novel 
strategy for modulation of nACh receptors is the identification of allosteric modulators that 
interact with receptors at a site distinct from that of the endogenous ligand. These agents 
modulate the receptor protein via a non-competitive mechanism. Negative allosteric 
modulators of nACh receptors have received some attention (reviewed in (Arias, 1998; Arias, 
2000; Arias et al., 2006). Some compounds, specially the acetylcholinesterase inhibitors are 
known to be positive nAChR allosteric modulators (or non-competitive agonists) 
(Albuquerque et al., 2001; Arias, 2000; Hurst et al., 2005; Pereira et al., 2002). However, it is 
not yet known precisely how they work (Samochocki et al., 2003; Smulders et al., 2005). 
Nevertheless, several distinct binding domains of the latter agents already have been 
proposed from docking studies using models of a3p4, a4p2, and al nACh receptors (Arias, 
2000; lorga et al., 2006)
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Figure 2.1: (A) Structure of desformylflustrabromine (B) Structure of desformylflustrabromine- 
B
Desformylflustrabromine (Figure 2.1.A) was identified as a positive allosteric 
modulator of nACh receptors (Sala et al., 2005). Desformylflustrabromine (dFBr) and 
desformylflustrabromine-B (Figure 2.1.B), and at least a dozen additional indolic alkaloids 
have been isolated and characterized from the marine bryozoan Flustra foliacea (Lysek et 
al., 2002; Peters et al., 2002; Peters et al., 2004). In particular, dFBr and dFBr-B lack 
appreciable affinity for a4|32 receptors, and bind with >3,500-fold lower affinity at this 
receptor subtype than the standard agonist (-)-nicotine (K, <1 nM); dFBr displays even lower 
affinity (K, >50,000 nM) for a7 nACh receptors (Peters et al., 2004). However, it has been 
further demonstrated with several heteromeric (i.e., a3(32, a3(34, a4p2 and a4p4) and the 
homomeric a7 nACh receptors expressed in Xenopus oocytes, that dFBr, but not dFBr-B, 
selectively increases the whole cell current obtained when co-applied with the endogenous 
agonist acetylcholine in a4p2-containing preparations (Sala et al., 2005). Single channel 
studies with dFBr are consistent with the hypothesis that it increases the channel open 
probability, perhaps by increasing the ratio of the rate constants for channel opening and 
closing (Sala et al., 2005). As such, dFBr offers a novel tool for the investigation of nACh 
receptors, and serves as a lead structure for the development of selective agents with
potential therapeutic application. To date, studies with dFBr and dFBr-B have employed 
dimethyl sulfoxide (DMSO) solutions of their water-insoluble free bases as isolated directly 
from the marine organism. The purpose of this study was to confirm the actions of synthetic 
dFBr and dFBr-B as selective allosteric potentiators of a4p2 receptors and the lack of such 
action on al receptors. We evaluated the actions of synthetic dFBr and dFBr-B as their HCI 
salts at concentrations ranging from 1 nM to 100 pM on human al and a4p2 nACh receptors 
expressed in Xenopus oocytes with two-electrode voltage clamp techniques.
2.3 Materials and Methods:
The chimeric DNAs (cDNA) for human al and a4p2 receptors were obtained from 
Dr. Jon Lindstrom’s laboratory (Department of Neuroscience, School of Medicine, University 
of Pennsylvania). Subunit of cDNA was cloned into a pBud-CE4.1 (Invitrogen, CA) vector 
prior to mRNA synthesis. Xenopus laevis frogs and frog food were purchased from Xenopus 
Express (Homosassa, FL). Ovarian lobes were surgically removed from Xenopus laevis frogs 
and washed twice in Ca+2-free Barth’s buffer (82.5 mM NaCI / 2.5 mM KCI / 1mM MgCI2 / 5 
mM HEPES, pH 7.4) then gently shaken with 1.5 mg/ml collagenase (Sigma type II, Sigma- 
Aldrich) for 1 h at 20-25 °C. Stage IV oocytes were selected for microinjection. Synthetic 
cRNA transcripts for human al and a4p2 were prepared using the mMESSAGE 
mMACHINE™ High Yield Capped RNA Transcription Kit (Ambion, TX). Oocytes were 
injected with a total of 50 nL cRNA at a concentration of 0.2 ng/nL in appropriate subunit 
ratios then incubated at 19 °C for 24 to 72 h prior to their use in voltage clamp experiments. 
Recordings were made using an automated two-electrode voltage-clamp system 
incorporating an OC-725C oocyte clamp amplifier (Warner Instruments, CT) coupled to a 
computerized data acquisition (Datapac 2000, RUN technologies) and autoinjection system 
(Gilson). Recording and current electrodes with resistance of 1-4 MD were filled with 3 molar
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KCI. Details of the chambers and methodology employed for electrophysiological recordings 
have been described earlier (Joshi et al., 2004). Oocytes were held in a vertical flow 
chamber of 200-(iL volume and perfused with ND-96 recording buffer (96 mM NaCI / 2 mM 
KCI /1.8 mM CaCI2 / 1 mM MgCI2 / 5 mM HEPES; pH 7.4) at a rate of 20 ml/min. Test 
compounds were dissolved in ND-96 buffer and injected into the chamber at a rate of 20 
ml/min using the Gilson auto-sampler injection system. For dFBr and dFBr-B experiments, 
compounds were co-applied with 100 pM ACh.
2.3.1 Data Analysis:
Concentration-response curves were fit by non-linear curve fitting and Graph Pad 
Prism Software (San Diego, CA) using standard built-in algorithms. For the 
potentiation/inhibition curves obtained for a4p2 modulation by dFBr-HCI the data was fit to a 
bell shaped dose-response equation based on a hormetic model. The hormetic model 
simultaneously fits both the potentiation and inhibition phases of the response to give an 
EC50 for the potentiation component and an IC50 for the inhibitory component. 
Mathematically, this is equivalent to fitting a stimulatory and inhibitory equation 
simultaneously. Data was fit to the following equation:
I = (1 + ((lm -1 ) / (1  +10  «lo9£C50-XrnHp)^ j /  ^  + 1Q ((loglCSO)) 21
Where, I = fractional current obtained at a given ligand concentration, lm = lmax (maximum 
theoretical current obtainable by the potentiator), EC50 = concentration of potentiators 
producing I = 14 lmax, IC50 = concentration of potentiators inhibiting to 14 lmax, nHp = Hill slope 
for potentiation, nHi = Hill slope for inhibition.
The accuracy by which this algorithm separates these two constants is dependant on 
the degree of difference between them. In the case of dFBr-HCI and dFBr-B-HCI, this
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difference is about 33-fold. For IC50 determinations data were fit to a single site competition 
model, equation:
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y  = 1/ [1 + (IC50/[antagonist])nH 2.2
Where, nH is the Hill coefficient.
Statistic analysis: Quantitative data are expressed as mean ± S.E. Associations between the 
variables, where needed, were tested by using paired stunents-f test. All statistical 
differences were deemed significant at the level of P  <0.05.
2.4 Results:
2.4.1 Action of dFBr on a7 receptors
Application of 100 pM ACh produced a near maximal response in a7 receptors 
(Figure. 2.2). Co-application of >0.1 pM dFBr and 100 pM ACh inhibited the response to 
ACh. No potentiation of o l  responses was observed over the range of dFBr concentrations 
tested. A dose response curve obtained from multiple experiments identical to that shown in 
Figure 2.2A is plotted in Figure 2.2B. Peak amplitudes of currents obtained from a7 receptors 
were inhibited by dFBr (IC50 = 44.1 ± 1.25 pM). The low potency for dFBr inhibition is 
consistent with its low affinity for the receptors (Peters et al., 2002). Our data demonstrate an 
inhibitory action of dFBr on a7 receptors. Sala et al (Sala et al., 2005) also observed slight 
inhibition of a7 receptors by dFBr isolated from Flustra foliacea.
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Figure 2.2: Effects of dFBr on a l  nACh receptors dFBr (1 nM to 100 pM) was co-applied 
with 100 pM ACh to Xenopus oocytes expressing human a l  nACh receptors. Responses 
were obtained using two-electrode voltage clamp at a -60 mV holding potential. Drug 
exposure is indicated by the horizontal bar above the traces. Peak amplitudes were 
normalized to the responses obtained using 100 pM ACh in the absence of dFBr (1). A: 
Currents elicited by 100 pM ACh at dFBr 1 concentrations of OpM, 0.1 pM and 1.0pM. B: 
Concentration-response curve for dFBr inhibition of peak currents elicited by 100 pM ACh 
(ICso=44.1 +/-1.25 pM).
2.4.2 Action of dFBr on a4(32 receptors
On a4(32 receptors, co-application of 100 pM ACh and dFBr produced a biphasic 
response over the concentration range tested (Figure 2.3). Responses elicited by 100 pM 
ACh were potentiated by dFBr (0.001 pM to 100 pM), although inhibition of the response was 
observed at concentrations greater than 10 pM dFBr, producing a bell shaped dose- 
response curve. Similar results were obtained when the slope of the rise time of the 
response was plotted rather than peak amplitude (data not shown). The IC50 value estimated 
for the inhibitory component of this curve is 6.01 ± 0.92 pM. This value is about twice than 
that reported by Peters et al (Peters et al., 2002) 3.4 pM for inhibition of 3H-epibatidine 
binding on rat a4p2 receptors. Similar to our data, Sala et al. (Sala et al., 2005) did not report 
inhibition of ACh responses at these concentrations of dFBr but observed potentiation at 3 
pM. While Peters’ data showed displacement of 3H-epibatidine binding it is not clear if this is 
due to competitive or non-competitive effects. If dFBr binding to an allosteric potentiation site 
reduces the affinity of the antagonist epibatidine, than dFBr could appear as an inhibitor in a 
binding assay (Peters et al., 20002) and as a potentiator of acetylcholine responses in a 
functional assay (Sala et al., 2005) Unlike Sala, we did observe inhibition of 100 pM ACh 
responses at high dFBr concentrations (> 10 pM). However, the current traces obtained at 
these concentrations were not typical of those resulting from displacement of agonist. 
Displacement of an agonist typically produces a decrease in overall response amplitude with 
little change in response profiles. In our study, high dFBr concentrations produced currents 
with a greater increase in the apparent rate and extent of desensitization rather than a simple 
decrease in overall response amplitudes (see Figure 2.2A). This is particularly evident when 
comparing equal amplitude responses in the presence of dFBr (Figure 2.3 A c and d); trace c 
(1 pM dFBr -  a sub-inhibiting dFBr concentration) shows a relatively slow apparent rate of 
desensitization while trace d (10 pM -  an inhibiting dFBr concentration) shows a much
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sharper peak with a faster apparent rate of desensitization. If inhibition were due to 
displacement of ACh binding, these two response profiles would be expected to be similar. 
We also typically observed rebound currents on washout of Ach-dFBr (Figure 2.4). These 
currents are commonly observed with open-channel block due to removal of the channel 
blocker prior to dissociation of the agonist from the receptor. The rebound currents are 
particularly evident in the 10 pM responses as shown in Figure 2.4. Our data support the 
hypothesis that open channel block contributes to inhibition of ACh responses by dFBr. 
Similar effects have been observed for other potentiating ligands including physostigmine 
and levamisole (Albuquerque et al., 2001; Levandoski et al., 2003). Thus, the inhibition we 
observe at high dFBr concentrations may not be related to the inhibition of 3H-epibatidine 
binding observed by (Peters et al. 2002) but may occur via other mechanisms. Additional 
studies will be necessary to fully explain inhibition of 3H-epibatidine binding at potentiating 
dFBr concentrations and the inhibition of response amplitudes at higher dFBr concentrations.
The potentiating component of the dose response curve obtained by co-application 
of dFBr and 100 ACh produced a half-maximal potentiation at a concentration of 120 ± 
0.60 nM dFBr although the true potency is likely obscured by the inhibitory component of the 
dose-response curve (Figure 2.3B). A maximum potentiation of 295 ± 67% (n=4) of the 
control trace was observed at approximately 3 pM dFBr. This is similar to the 250% 
potentiation observed by Sala et al (Sala et al., 2005).
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Figure 2.3: Effects of dFBr a4p2 nACh receptors A: Responses were obtained using two- 
electrode voltage clamp on Xenopus oocytes expressing human a4|32 nACh receptors. The 
responses elicited by each concentration of ACh/dFBr are indicated by the letters above the 
current trace. The time of drug exposure is indicated by the horizontal bar above the traces. 
Trace c (1 pM dFBr) produced a maximum potentiation of the peak response. Reduced 
peak amplitudes are seen at concentrations >1 pM dFBr (trace d). Peak amplitudes for each 
trace are: a. 14 pA, b. 24 pA, c. 37 pA, d. 25 pA) B: Dose/response curve for dFBr applied 
in the presence of 100 pM ACh on human a4|32 receptors. Peak amplitudes were 
normalized to peak currents obtained from 100 pM ACh in the absence of dFBr. Identical 
experimental conditions were used Figures 2A and B. The half maximal potentiation 
observed is 120 nM with an IC50 of 6.0 pM. Maximum potentiation was 295 +/- 67 % of the 
control trace (n=4, 13 oocytes).
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Figure 2.4: Rebound currents evident on washout of ACh and dFBr. Current traces were 
elicited by co-application of 100 pM ACh and dFBr (10 pM and 30 pM). Experimental 
conditions are identical to those shown in Figure 2.3. All three responses were obtained from 
a single oocyte. The horizontal black bar above the traces indicates the presence of ACh (a) 
or ACh + dFBr (b). Rebound currents are particularly evident in trace b.
2.4.3 Dose response curve of ACh with and without dFBr on a4p2 receptors:
A comparison of ACh dose response curves in the presence and absence of 1 pM 
dFBr (Figure 2.5) showed a decrease in the apparent EC50 (36.8 ± 8.75 pM to 18.9 ± 3.22 
pM) for ACh and a corresponding increase in the maximal response obtained, suggesting 
that potentiating effects may be due to binding of dFBr to a site distinct from the agonist 
binding site as has been proposed for other ACh potentiating ligands. The apparent efficacy 
of Ach increased from 1.03 +/- 0.08 without 1 pM dFBr to 3.60 +/- 0.23 with 1 pM dFBr. 
There was a significant increase in apparent efficacy with 1 pM dFBr (P=0.0009).
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Figure 2.5: ACh dose/response curves the presence and absence of dFBr. Responses were 
obtained using two-electrode voltage clamp on Xenopus oocytes expressing human a4(32 
receptors. Peak amplitudes were normalized to peak currents obtained in the presence of 
100 pM ACh in the absence of dFBr. A  comparison of EC50 values with and without dFBr 
shows a shift in potency of ACh for a4p2 receptors from 36.8 pM (without dFBr) to 18.9 pM 
(with dFBr). dFBr increased the maximal response by 360 % when compared to the maximal 
peak amplitudes in the absence of dFBr. The data shown reflect at least 4 repeated 
evaluations for each point on a minimum of 6 oocytes (n=4).
2.4.4 Action of dFBr-B on a7 and a4p2 receptors:
dFBr-B was evaluated for its effects on a7 and a4p2 nACh receptors (Figure 2.6). 
Co-application of dFBr-B with 100 pM acetylcholine on a7 receptors produced responses 
that were inhibited when compared to those obtained using 100 pM acetylcholine alone (IC50 
= 14.2 ± 2.77 pM). Inhibited response profiles were similar to those resulting from co­
application of dFBr on a7 receptors; currents were decreased in amplitude with no alteration 
in the rate of desensitization. Co-application of dFBr-B with 100 pli/l ACh s on a4p2 receptors 
also showed inhibition of the responses (IC50 = 209 ±4.12 pM). Inhibiting concentrations of 
dFBr-B produced responses showing increased desensitization rates and decreased peak 
currents similar to that obtained for high concentrations of dFBr on a4p2 receptors (Figure 
2.6B). These data suggest that dFBr and dFBr-B may inhibit a4p2 responses by a similar
mechanism. Since both dFBr and dFBr-B alter desensitization rates on cc4p2 receptors but 
not on al their mechanism of action may be different on each receptor subtype.
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Figure 2.6: dFBr-B effects on A: al and B: a4p2 nACh receptors. Currents elicited by 100 
pM ACh in the presence of dFBr-B using two electrode voltage clamp. dFBr-B was co­
applied at varying concentrations with 100 pM ACh to Xenopus oocytes expressing human 
a4p2 or human al nACh receptors. C: Concentration/Response curve showing the 
normalized response to co-application of dFBr-B (2) and 100 pM ACh on human a l  nACh 
receptors. D: Concentration/Response curve of the normalized response to co-application of 
dFBr-B and 100 pM ACh on human a4p2 nACh receptors. Peak amplitudes were normalized 
to peak currents elicited by 100 pM ACh in the absence of dFBr-B (2). Data reflect at least 4 
repeated evaluations for each point on a minimum of 5 oocytes (n=4).
2.5 Discussion and conclusion:
The synthetic HCI salts of dFBr and dFBr-B evaluated in this study behaved similar 
to the compounds obtained from Flustra foliacea. Two primary differences were observed. 
First, while Sala et al. (Sala et al., 2005) observed only potentiation, we observed both
potentiation and inhibition of peak amplitudes by dFBr on a4(32 receptors and inhibition only 
on a7 receptors. IC50 values for inhibition of acetylcholine responses on a7 receptors agree 
with the K| values determined by Peters et al. (Peters et al., 2002) in competition binding 
experiments. IC50 values obtained on a4(32 receptors were significantly higher than those 
obtained by Peters for inhibition of 3H-epibatidine binding and did not produce the decrease 
in overall responses typical of competitive antagonists. The change in response profiles, 
particularly the apparent loss of the slow desensitizing phase and the presence of rebound 
currents on washout of Ach-dFBr support the hypothesis that the inhibition we observed at 
high dFBr concentrations is due, at least in part, to open-channel block. In addition to the 
inhibitory effects of dFBr, we also observed an increased strength for potentiation and a 
slight increase in the maximal amount of potentiation obtained compared to data obtained by 
Sala et al (Sala et al., 2005). While these differences are not easily explained they could be 
due to a difference in solubility between the synthetic HCI salt used in our study and the 
compound purified from Flustra Foliacea used by Sala et al. (Sala et al., 2005) utilized 
DMSO to solubilize dFBr, due to its low solubility in buffer, while we used a more soluble HCI 
salt that may have permitted better dissolution of the compound. Decreased availability of 
dFBr due to DMSO solubilization or decreased concentrations of dFBr due to solubility 
problems would be reflected in an apparent decrease in strength for potentiation and may 
have prevented observation of inhibition. This conclusion is consistent with the higher 
potency and maximal potentiation we observed. In our preparation, dFBr showed potentiating 
effects at concentrations as low as 30 nM, while Sala et al (Sala et al., 2005) reported no 
potentiation below 3 pM. The rapid perfusion system used in our study may also have 
contributed to these differences. We used a modified Xenopus oocytes recording chamber 
that permits solution changes that are significantly faster than those used by Sala et al. (Sala 
et al., 2005) This system more accurately detects peak amplitudes prior to desensitization
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since the solution exchange takes place within 200 milliseconds. Slower perfusion and 
exchange rates would result in smaller response amplitudes due to receptor desensitization 
and less potentiation would be observed at lower dFBr concentrations.
The water-soluble HCI salt of dFBr examined in this study provides a novel, a4(32 
receptors verses a l  receptors, selective modulator of nACh receptors. We have confirmed 
that dFBr, but not dFBr-B, is capable of significantly increasing responses on a4p2 receptors 
when co-applied with ACh. This modulation is due to an increase in apparent efficacy of ACh 
and not simply a shift in EC50 value. The increase in apparent efficacy in presence of dFBr is 
significant compared to affinity (P=0.0009). dFBr effects are observed at concentrations 
ranging from 30 nM - 100 pM although inhibition of peak amplitudes and alterations in 
desensitization rates are observed at concentrations greater than 3 pM. dFBr-B inhibited 
ACh-induced responses both on a l  and a4p2 nACh receptors.
While significant structural differences are apparent between dFBr and dFBr-B the 
similarity of these compounds, possibly due to the common A/-methyl-6-bromotryptamine 
moiety, may enable them to mediate similar inhibitory effects on a4p2 receptors. The 
potentiating effects of dFBr appear enhanced by structural features not common to both 
compounds. The selectivity of dFBr for a4p2 receptors as against a l  receptors makes it an 
ideal lead molecule for future studies involving modulation of a4p2 nACh receptors and a 
possible candidate for the treatment of diseases such as Autism or Alzheimer’s disease in 
which a4p2 nACh receptors are decreased in some brain regions. Selective, potentiating 
ligands for a specific subtype of nAChRs would produce increased response amplitudes at 
nicotinic synapses without the loss of synaptic control or desensitization that results from the 
use of nicotinic agonists.
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CHAPTER 3: STRUCTURE ACTIVITY RELATIONSHIP STUDY OF
DESFORMYLFLUSTRABROMINE1
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3.1 Abstract:
Desformylflustrabromine (dFBr) is a positive allosteric modulator of the a4p2 subtype 
of neuronal nicotinic acetylcholine receptors. Here we report the results of a structure-activity 
relationship study for a series of dFBr analogues. Test compounds were evaluated using a 
two electrode voltage clamp technique and Xenopus oocytes expressing human a4(32 or a7 
receptors. Out of 15 analogues tested, three potentiated responses elicited by acetylcholine 
on a4p2 receptors. No potentiation of acetylcholine responses was observed for any of the 
compounds on a7 receptors. a4p2 and a7 mediated acetylcholine responses were inhibited 
by the 12 analogs that did not show potentiation on either receptor. These data support our 
hypothesis that potentiation and inhibition are mediated through different binding sites with 
different structural requirements.
3.2 Introduction:
The expression of nicotinic acetylcholine receptors (nAChRs) is widespread, 
particularly in the central nervous system. In the brain, nAChRs are involved in fast synaptic 
transmission, modulation of other neurotransmitter systems and are important contributors to 
neuronal plasticity (Gotti et al., 2007). nAChRs are implicated in a number of neurological 
conditions including nicotine addiction (Mineur and Picciotto, 2008), Alzheimer’s disease 
(Buckingham et al., 2009), Schizophrenia (Woodruff-Pak and Gould, 2002), Parkinson’s 
disease and Autism (Arias, 2006). The most widely expressed nAChRs in the CNS are the
1 The dFBr analogues testing reported in this chapter were designed and synthesized by Dr. 
Richard Glennon and his group at Virginia Commonwealth University. The data present here 
is entire my work except for compound JSK-062, where Maegan Weltzin performed one of 
the four repeats of the experiment testing this compound.
heteromeric a4p2 and the homomeric a 7 receptors (Gotti et al., 2006). Due to their 
importance in regulation of neuronal signalling and their apparent role in neurological 
disorders, a significant amount of effort has been made to develop nAChR ligands, 
particularly those that can act selectively on individual nAChR subtypes (Astles et al., 2002). 
Two broad types of nAChR ligands are being actively pursued. These can be classified as 
orthosteric ligands (ligands that bind at the ACh binding site) and allosteric ligands (ligands 
binding to non-ACh binding sites). Orthosteric ligands have received much attention, 
particularly partial agonists like Varenicline which targets a4p2 subtype of nAChRs and 
provides a treatment option for nicotine addiction (Gonzales et al., 2006). However, most 
partial agonists or agonists cause desensitization of nAChR responses (Buccafusco et al., 
2009). Hence, the use of partial agonists is limited. Subtype selective partial agonists have 
also proved difficult to develop, probably due to the conserved nature of the orthosteric 
binding sites (Springer et al., 2008). Allosteric ligands that enhance the currents elicited by 
ACh provide an alternate approach to treating disorders of decreased nicotinic activity 
(decreased nicotinic tone) (Faghih et al., 2007). Given the variety of allosteric binding sites 
that apparently exist on nAChRs, it may also be easier to develop subtype selective allosteric 
rather than orthosteric ligands (Bertrand and Gopalakrishnan, 2007).
One group of allosteric ligands commonly referred to as positive allosteric 
modulators or “PAMs,” bind to allosteric binding sites and produce an increase in the 
amplitude of responses to agonists (Bertrand and Gopalakrishnan, 2007). Ideally, PAMs 
potentiate responses in the presence of endogenous agonists and do not, by themselves, 
activate the receptor. This can prevent receptor desensitization or inactivation in the 
continued presence of the drug and preserve ACh mediation of synaptic transmission. This is 
in contrast to orthosteric ligands like nicotine which produce receptor up-regulation and/or 
desensitization (Gentry and Lukas, 2002). In pathological conditions where nicotinic 
signalling in the CNS is decreased, positive allosteric modulators could be thus be used to
maintain or restore normal levels of nAChR mediated synaptic transmission while 
maintaining ACh mediated signalling.
dFBr is a positive allosteric modulator for a4p2 receptors that exhibits only inhibitory 
effects on homomeric a l  nAChRs (Kim et al., 2007). Co-application of dFBr and ACh on 
Xenopus oocytes expressing a4p2 receptors produces a bell shaped dose response curve 
characteristic of a hormetic process, with potentiation observed at lower dFBr concentrations 
and inhibition observed at higher concentrations (Mattson, 2008). Our collaborators (Dr. 
Richard Glennon and Colleagues at Virginia Commonwealth University) have synthesized a 
synthetic version of the natural product dFBr and 15 dFBr analogues designed to identify key 
pharmacophoric features of this potentially novel class of a4p2 PAMs (Kim et al., 2007). The 
synthesis and evaluation of synthetic dFBr was discussed in Chapter 2. Of the 15 synthetic 
dFBr analogues synthesized, two analogues (dFBr-B & dFBr-C) are also found in Flustra 
foliacea, the source of naturally occurring dFBr.
We hypothesized that different functional groups in the chemical structure of dFBr 
are responsible for the potentiation versus inhibition of ACh induced responses on a4p2 
receptors and the inhibition of Ach responses on a7 receptors. If this hypothesis is valid, then 
substitutions of different functional groups for those on the dFBr molecule will produce 
analogues displaying different activities for potentiation and inhibition and may produce 
compounds which potentiate but do not inhibit ACh responses. Identification of functional 
groups important for each of the two effects of dFBr begins with the “deconstruction” of the 
dFBr pharmacophore described here. Future studies will utilize this information to 
“reconstruct” the dFBr pharmacophore. Synthetic analogues of dFBr were tested by co­
application with ACh on Xenopus oocytes expressing either human a4p2 or a7 nAChRs. 
Compounds were evaluated for their ability to potentiate and/or inhibit responses to Ach. 
Three analogues displayed potentiating effects similar to dFBr on a4p2 receptors and 12
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produced only inhibition. Using this data we have developed a preliminary structure activity 
relation for the action of the dFBr class of PAMs on a4p2 receptors.
3.3 Material and Methods:
3.3.1 Materials:
Cloned human DNA (cDNA) for human a7 and a4p2 receptors were obtained from 
Dr. Jon Lindstrom’s laboratory (Department of Neuroscience, School of Medicine, University 
of Pennsylvania). Individual cDNA coding for nAChR subunits were cloned into the pBud- 
CE4.1 vector (Invitrogen, CA) prior to mRNA synthesis. Xenopus laevis frogs and frog food 
were purchased from Xenopus Express (Homosassa, FL). Test compounds (dFBr and dFBr 
analogues) were synthesized by Dr. Richard Glennon’s research group at the Virginia 
Commonwealth University School of Pharmacy, Richmond VA. Compounds were provided 
as dry HCI salts.
3.3.2 Xenopus laevis oocytes:
Xenopus laevis frogs were maintained according to approved IACUC protocols 
established by the University of Alaska Fairbanks. Frog surgeries were conducted using the 
standard operating procedure on file at the University of Alaska Fairbanks. Ovarian lobes 
were surgically removed from Xenopus laevis frogs and washed twice in Ca+2-free Barth’s 
buffer (82.5 mM NaCI /2.5 mM KCI / 1mM MgCI2 / 5 mM HEPES, pH 7.4) then gently shaken 
with 1.5 mg/ml collagenase (Sigma type II, Sigma-Aldrich) for 1 h at 20-25 °C. Stage IV 
oocytes were selected for microinjection. Synthetic cRNA transcripts for human a7 and a4p2 
were prepared using the mMESSAGE mMACHINE™ High Yield Capped RNA Transcription 
Kit (Ambion, TX). Oocytes were injected with a total of 50 nL cRNA at a concentration of 0.2 
ng/nL in appropriate subunit ratio and then incubated at 19 °C for 24 to 72 h prior to their use 
in voltage clamp experiments.
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3.3.3 Electrophysiology:
Electrophyiological recordings were made using an automated two-electrode 
voltage-clamp system incorporating an OC-725C oocyte clamp amplifier (Warner 
Instruments, CT) coupled to a computerized data acquisition (Datapac 2000, RUN 
technologies) and auto-injection system (Gilson). Recording and current electrodes with 
resistance of 1-4 MD were filled with 3 M KCI. Details of the chambers and methodology 
employed for electrophysiological recordings have been described previously (Joshi et al., 
2004). Oocytes were held in a vertical flow chamber of 200-pL volume and perfused with 
ND-96 recording buffer (96 mM NaCI / 2 mM KCI /1.8 mM CaCI2 / 1 mM MgCI2 / 5 mM 
HEPES; pH 7.4) at a rate of 20 ml/min. Test compounds were dissolved in ND-96 buffer and 
injected into the chamber at a rate of 20 ml/min using the Gilson auto-sampler injection 
system. Compounds were co-applied with 100 pM ACh on a4p2 receptors and 1000 pM ACh 
on a7 receptors. All test compounds easily dissolved in ND-96 buffer with the exception of 
JSK-068(12) which required ND-96 buffer containing 5% DMSO.
3.3.4 Receptor Expression:
a4p2 receptors can express in two stoichiometries: the high ACh affinity (a4)2((32)3 
containing 2 a4 and 3 32 subunits and the low ACh affinity (a4)3(P2)2 containing 3 a4 and 2 
32 subunits. The ratio of a4 to 32 mRNA can be varied to obtain different stoichiometry 
receptors a4:32 ratio of 9:1 produced low Ach affinity receptors with an EC50 for Ach of 58.8 
pM. a4:32 ratio of 1:9 produced low Ach affinity receptors with an EC50 for Ach of 1.58 pM. A 
1:1 ratio of subunits produced a mixture of low and high affinity receptors with an 
intermediate apparent EC50 of 65.6 pM. We inject Xenopus oocytes with mRNA synthesized 
from cDNA of the pBud-CE4.1 vector containing both a4 and 32 subunits. The a4 and 32 
mRNA is injected in a 1:1 proportion thus giving a mixture of the two stoichiometries of a432
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receptors. For both a402 and a7 receptors, test compounds were co-applied with 100 pM 
ACh in concentrations ranging from 1 nM to 100 pM.
3.3.5 Data Analysis:
Curve fitting o f Concentration/response data:
Concentration/response curves were fit by non-linear curve fitting and GraphPad 
Prism Software (San Diego, CA) using standard built-in algorithms. For IC50 determinations 
the data were fit to a single site competition model using the equation:
y  = 1/[1 + (ICso/[antagonist]) nH 3.1
Where, nH is the Hill coefficient.
For potentiation/inhibition data obtained for a4p2 modulation by different 
compounds, the data was fit to a hormetic model. The hormetic model uses a bell shaped 
dose-response equation and simultaneously fits both the potentiation and inhibitory effects to 
give an EC50 for the potentiation component and an IC50 for the inhibitory component. The 
accuracy by which this algorithm separates these two constants is dependant on the amount 
of difference between them. Mathematically, this is equivalent to fitting the stimulatory and 
inhibitory phases simultaneously. Data are fit to the following equation:
I  =  (1 +  ( ( l m  _ 1)/(1 +  10 « l°9EC 50-X>'nHP ) ) ) )  /  (1 +  10 (doglCSO)) 3 2
Where, I = fractional current obtained at a given ligand concentration, lm = lmax (maximum 
theoretical current obtainable by the potentiator), EC50 = concentration of potentiators 
producing I = V2 lmax, IC50 = concentration of potentiators inhibiting to !4 lmax, nHp = Hill slope 
for potentiation, nHi = Hill slope for inhibition.
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3.3.6 Statistical Analysis:
Quantitative data are expressed as mean ± S.E.M Associations between the 
variables such as EC50 and IC50 values for the different compounds were compared. These 
variables were tested by using paired student’s f-test. P values are reported thoughout the 
text and represent stastical differences. All statistical differences were deemed significant at 
the level of P <0.05. N represents the number of repeat for each data point.
3.4 Results:
3.4.1 Overview:
Fifteen synthetic analogues of dFBr were evaluated for there ability to potentiate and 
inhibit Ach induced responses on human a4|32 and a l  receptors. Three of the 15 synthetic 
analogues were able to potentiate Ach induced responses on a4|32 receptors with EC50s 
ranging from 0.120 pM to 6.7 pM. Compounds which potentiated also inhibited at 
concentrations greater than the peak potentiating concentration although rank potencies for 
potentiation and inhibition were different. Compounds with potentiating and inhibiting 
activities gave a hormetic response profile typified by a bell shaped dose response curve 
similar to that observed for dFBr (Kim et al., 2007). All compounds were capable of inhibiting 
ACh induced responses on a4p2 receptors with IC50 values ranging from 4 pM to 209 pM 
(Table 3.2). All compounds also inhibited Ach responses on a l  receptors although rank 
potencies for inhibition were substantially different for a7 versus a4p2 receptors (Tables 3.2 
and 3.3). Synthetic dFBr-C and dFBr-B (naturally occurring analogues of dFBr) inhibited but 
did not potentiate ACh responses.
3.4.2 Potentiating Analogues of dFBr:
Sixteen compounds were synthesized by Dr. Glennon’s research group including 
dFBr; 13 novel analogues of dFBr and two analogues that occur naturally with dFBr in
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Flustra folicea. Of these sixteen compounds, dFBr and three of the dFBr analogues 
potentiated ACh responses on a4(32 receptors when co-applied with ACh (Table 3.1 and 
Figures 3.1 and 3.2). Test compounds were co-applied with 100 pM ACh in concentrations 
from 1 nM to 100 pM. The responses obtained from individual oocytes expressing a4(32 
receptors were normalized to the current obtained by applying 100 pM ACh alone. All three 
analogues produced hormetic responses typified by a bell shaped dose response curve 
similar to dFBr itself (Figure 3.2). The remaining 12 analogues and the 2 naturally occurring 
analogue of dFBr showed inhibition but did not potentiate ACh induced responses on a4|32 
receptors. Figure 3.1 shows responses obtained for all three potentiating analogues. These 
compounds differ at two positions; the structure of the gem di-methyl group (R2 in Table 3.1) 
and bromination of the aromatic group (R4). Overall response profiles, levels of potentiation, 
rise times and effects on desensitization were similar to those observed for dFBr. All three 
compounds showed “hump currents” on washout of dFBr although this was somewhat more 
pronounced for NG-088 (4) and JSK-062 (2). Hump currents are typically observed on 
washout of agonists if the agonist is involved in open channel block (Liu et al., 2008). This 
effect is due to the dissociation of an agonist from the channel block binding site prior to 
dissociation from the orthosteric binding site.
Figure 3.2 shows the effect of the structural changes for potentiating analogues on 
both the EC50 and IC50 values. Data from these curves is shown in Table 3.1. The EC50 
values for compound 2 (JSK-062) and dFBr were not significantly different (P=0.3094). 
Neither was the EC50 values significantly different for compound 3 (NG-089) compared to 
dFBr (P=0.3503) or compound 4 (NG-088) compared to dFBr (P=0.4511). However, the EC50 
values for compound 2 (JSK-062) and compound 4 (NG-088) are significantly different 
(P=0.0016). As The IC50 values of dFBr and its three potentiating analogues do not vary 
significantly (all values of P>0.05). The maximal potentiation observed with each compound 
including dFBr was in to range of 250 to 300 %.
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A.
Drug Application
B
Drug Application
1.0 pA
a. 10GpM Ach + lOO|iMNG-089
b. IOCjjM Ach + 3CpM NG-089 
C. lOOpMAch
d. lOCjJM Ach + 3|iM NG-28S
e. IOCjjM Ach + ICpM NG-089
5 sec
Drug Application
Figure 3.1: Potentiation of ACh evoked responses by dFBr analogues. Responses were 
elicited by application of 100 pM ACh on Xenopus oocytes expressing a4p2 nicotinic 
receptors. Test compounds 2, 3 and 4 were co-applied with ACh at the concentrations 
indicated in the figure legends. Each series of traces (A-C) were elicited from a single oocyte. 
Concentration/response curves for these compounds are shown in Figure 3.2 A. NG-088 
(4). B. NG-089 (3). C. JSK-062 (2).
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Figure 3.2: Dose/response curves for potentiating dFBr analogues. Test compounds (NG- 
088, NG-089 and JSK-062) were co-applied with 100 pM ACh on human a4|32 receptors. 
Peak amplitudes were normalized to peak currents obtained from 100 pM ACh in the 
absence of NG-088. Curves were fit to a hormetic model as described in the data analysis 
section. Data are presented in Table 3.1 A: Compound 4, NG-088: The half maximal 
potentiation (EC50) is 1.22 +/- 0.66 pM (n = 4) with an IC50 of 4.02 +/- 0.23 pM (n = 4). 
Maximum potentiation was 260% of the control trace. B: Compound 3, NG-089: The half 
maximal potentiation (EC50) is 6.77 +/- 0.35 pM (n = 4) with an IC50 of 17.5 +/-1.75 pM (n = 
4). Maximum potentiation is 250% of the controlled trace (100pM ACh). C: Compound 2, 
JSK-062: The half maximal potentiation (EC50) is 97.2 +/- 40.0 nM (n = 4) with an IC50 of 3.93 
+/- 1.15 pM (n = 4). Maximum potentiation was 290% of the controlled trace (100 pM ACh). 
All dose-response curves, data points are mean +/- S.E.M. Lines correspond to the best fit 
obtained with the hormetic model bell shaped dose-response equation.
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Table 3.1: Structures and activity of potentiating dFBr analogues on a4[32 and a7 receptors. 
Data are shown for compounds which show potentiating activity on a4|32 receptors. EC50 
values for a4P2 receptors reflect the concentrations that give half maximal potentiation. No 
EC50 values are shown for a7 receptors since no potentiation was observed on a7 receptors. 
IC50 values for a4P2 and a7 receptors reflect the concentration required to inhibit Vi of the 
response to 100 pM ACh. dFBr data (1) is reproduced from chapter 2 for comparison. All 
values represents mean +/- S. E. M.
L > -" 2
'* 3
Compound ECS0 IC50 ICso R1 r 2 R3 R4
name a4p2 a4p2 a7
1 dFBr 0.120 +/- 6.00 +/- 44.1 ± NH-CH, c h 3 H Br
0.006 pM 0.20 pM 1.25
pM'
/
/ CH3 2
2 JSK-062 .0972 +/- 3.93 +/- 25.7 +/- SH-CS CHs H Br
0.040 pM 1.15 pM 18.2 Y  c h .
pM C H ,
3 NG-089 6.77 +/- 17.5+/- 7.74 + / - NH-C-j c h 3 H H
0.35 pM 1.75 pM 3.99 - CH-. - CH3 *
pM
4 NG-088 1.22 + / -  
0.66 pM
4.02 + / -  
0.23 pM
20.6 + / -  
8.09
NH-CH,
/  1 ^ —  C i-3 - Y  C H ,
H H
pM / C H ,
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Table 3.2: Structure and Activity of non-potentiating dFBr analogues on a4p2 and a7 
receptors. Ri, R2, R3 and R4 refer to functional groups referenced in the structure shown in 
Table 3.1. dFBr-B data (5) is reproduced from chapter 2 for comparison. All values 
represents mean +/- S. E. M.
Compound
name
dFBr-B
IC50
c*4p2
209 +/- 
4.00 pM
ICso
a7
14.2 ± 
2.77 pM*
R1
IH -CH ,
r 2
H
R3
/
h/ ^ 3
R4
Br
6 dFBr-C 6.68 +/- 
1.10 pM
6.92 +/- 
2.54 pM
NH -C H ,
/
H \
/
Br
7 JSK-039 40.1 +/- 
4.72 pM
30.1 +/- 
2.41 pM
N H -C H ,
/
H H Br
8 JSK-067 71.1 +/- 
13.9 pM
2 1 .6 +/­
2.57 pM
NH -C H , /  1
/
y - m , H Br
9 JSK-073 18.5+/­
4.75 pM
44.2 +/-
19.2 pM
NH -C H ,/  3
/
y - m , H H
10 JSK-095 3.53 +/- 
1.35 pM
29.5 +/- 
15.0 pM
N H -C H , /  1 J i O , H Br
11 JSK-065 45.1 +/- 
19.5 pM
131 +/- 
20.2 pM
n;ch3)2
\
H H Br
12 JSK-068 42.9 +/- 
12.7 pM
20.7 +/- 
1.32 pM
+KCH3h
s
H Br
13 JSK-076 46.6 +/- 
16.1 pM
34.5 +/-
21.5 pM
1+013)2
s
H H H
14 JSK-096 15.7+/­
4.10 pM
13.2+/­
7.23 pM
nh2
s /
H Br
15 JSK-090 91.1 +/- 
33.7 pM
43.7 +/- 
13.6 pM
CH:
C-i-CHj *
H \/ Br
16* JSK-092 57.9 +/-
15.9 pM
155+/­
40.4 pM
CH;
- ' ‘ ‘CH- CH; ’
H / H
5
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3.4.3 Inhibition of ACh induced responses on a4(B2 by dFBr analogues
All 15 analogues, including the two naturally occurring analogues 5 (dFBr-B) and 6 
(dFBr-C) act as inhibitors of a4(32 receptors. Compounds that potentiated (previous section) 
also inhibited Ach induced responses at higher concentrations. IC50 values for individual 
analogues varied over a range from 3.53 pM to 209 pM (Tables 3.1 and 3.2). Dose response 
curves for compounds showing only inhibition of ACh responses on a4p2 receptors are 
shown in Figure 3.3 and data obtained from these curves is presented in Table 3.2.
1.2-i
0)10
o 0 .9 -| a(0 0)
-  0-6Hra c 
o
o 0.3H to
UL
0.0- T
-7 -6 -5 -4 -3
Log [ dFBr analogues] M
• JSK-039
■ JSK-065
▲ JSK-067
▼ JSK-068
♦ JSK-073
D JSK-076
1 JSK-090
JSK-092
— 1 4 JSK-095
-2 , JSK-096
♦ dFBr-C
Figure 3.3: Dose/response curve for all the dFBr analogues (except dFBr-B) that inhibit cc4p2 
receptors without potentiation. All dose-response curves, data points are mean +/- S.E.M of 
at least 4 repeated evaluations (n = 4). Lines correspond to the best fit obtained with the 
single site competition model equation.
3.4.4 Effect dFBr analogues on a7 receptors:
All 16 compounds inhibit responses of a l  receptors to 100 pM ACh over a potency 
range of 6.92 to 131 pM. IC50 values for inhibition of responses to 100 mM ACh on a7 
receptors are shown in column 5 of Table 3.1 and column 4 in Table 3.2, column potencies 
of most compounds were similar on both a7 and a4p2 receptors and changes in IC50
resulting from structural changes on the ligand were equivalent in most cases. No 
potentiation of a l  responses was observed for any of the 16 compounds tested.
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3.5 D iscussion:
R i
NH-CH 3
F t N CH.'3
* 3
B r
H CH.'3
Core Structure dFBr
R! = terminal amine group;
R2= geminal dimethyl group;
R3 = ring nitrogen group;
R4 = 6-Bromo group;
Figure 3.4: Core Structure of desformylflustrabromine
3.5.1 Important functional groups of dFBr responsible for potentiation:
Two functional groups stand out as being important in the potentiation of a4(32 receptors by 
dFBr analogues. These are:
1) Geminal-dimethyl group at R2 position:
All the compounds that are potentiators of a4p2 receptors have a geminal (gem)- 
dimethyl group at position the R2 position (Table 3.1). Any drastic changes in the structure of 
this side group compound 8 (JSK-067) or the loss of it, compound 7 (JSK-039) leads to loss
of potentiation (Table 3.2). The EC50 values for dFBr and compound 2 (JSK-062) are not 
significantly different (P=0.3094). dFBr and compound 2 (JSK-062) differ only in the structure 
of the gem-dimethyl group in which the double bond is removed in compound 2 (JSK-062) 
relative to dFBr. Removal of the double bond would increase rotational freedom of this group. 
Similarly, the IC50 values for compound 2 (JSK-062) was increased slightly but not 
significantly compared to dFBr (P=0.773). Our data from analogue testing generally suggest 
that the gem-dimethyl is essential for the potentiating action of dFBr class of compounds. As 
long as the integrity of the structure of gem-dimethyl group is retained there is no significant 
change in either EC50 or IC50 values of the potentiating analogues.
2) Bromine at R4 position:
Removal of the bromine at the R4 position produced a significant change in EC50 
when compared to compounds identical at all other positions (dFBr compared to compound 3 
(NG-089) and compound 2 (JSK-062) compared to compound 4 (NG-088)). The EC50 value 
for Compound 3 (JSK-089) was increased slightly but significantly compared to dFBr (P= 
0.0002). However, the EC50 values for Compound 2 (JSK-062) was significantly lower 
compared to Compound 4 (NG-088) (P=0.0016). Compound 2 (JSK-062) and compound 4 
(NG-088) are identical except for the lack of the Br at position R4 in compound 4 (NG-088). 
The significant decrease in EC50 resulting from removal of the bromine indicates an 
involvement of this group in interaction with the receptor. This is likely due to a change in the 
electronics of the aromatic group of dFBr. While we have not evaulated any analogues where 
the Br atom is replaced by other halogens it is likely that such changes at 6-position may 
change the potentiating activity of dFBr and its analogues. Such analogs are planned during 
the future “reconstruction” phase of this project.
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3.5.2 Importance of functional groups of dFBr for inhibition of a4(32 and a l  receptors:
The testing of dFBr analogues also aided in defining the structure activity 
relationship for the inhibitory action of dFBr analogues on a l  and a4|32 receptors. For this 
purpose all three side groups, namely the Ri - terminal amine group, R2 - geminal-dimethyl 
group and bromine at R4 position, in the structure of dFBr were found to be important. Each 
of these side groups are discussed below:
1) Ri - terminal amine group:
a) ct4B2 receptors: Conversion of the primary amine at R-, of compound 7 (JSK-039) to a 
secondary amine to make compound 11 (JSK-065) produced no significant change in IC50 
value (7: 40.1 +/- 4.72 pM, 11: 45.1 +/- 19.5 pM, P=0.0726) and a slight, but significant 
decrease in IC50 was observed for conversion of the primary amine in compound 8 (JSK-067) 
to a tertiary amine to make compound 12 (JSK-068) (8: 71.1 +/- 13.9 pM, 12: 42.9 +/- 12.7 
pM, (P=0.0308). Conversion of the primary amine to an amino group in compound 8 (JSK- 
067) to an amino group to make compound 14 (JSK-096) decreased the IC50 to 15.7 +/- 4.10 
pM making a significant decrease in IC50 (P=0.0224). Thus, increasing the organic 
substituents on the amine nitrogen produced an apparent progressive increase in IC50 
values.
b) a7 receptors: Conversion of the primary amine at Ri in compound 7 (JSK-039) to a 
secondary amine in compound 11 (JSK-065) produces a significant change in IC50 for 
inhibition of a7 receptors (7: 30.1 ± 2.41 pM, 11: 131 ± 20.2 pM, P=0.0177). This change of 
4 fold is in contrast to no change in IC50 on the a4[32 receptor. No significant change in IC50 
(P=0.4400) was observed when the secondary amine of compound 8 (JSK-067) is converted 
to a quaternary amine compound 12 (JSK-068).
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2) R2-  Geminal - dimethyl group and R3-  Ring nitrogen group:
a) a4B2 receptors: A comparison of inhibitors differing at position R3 reveals the importance 
of this group for inhibition of a4p2 receptors. Compounds 5 and 6 (dFBr-B and dFBr-C) differ 
only in the presence of propylene rather than a propyl group at R3 in compound 5 (dFBr-B) 
versus compound 6 (dFBr-C). This change produces a significant decrease in IC50 from 209 
+/- 4.0 pM for compound 5 to 6.68 +/- 1.10 pM for compound 6 (dFBr-C) on a4p2 receptors 
(P=0.0060). Removal of this propyl group entirely as in compound 7 (JSK-039) results in an 
IC50 value that is intermediate between that of compound 5 (dFBr-B) and compound 6 (dFBr- 
C) (40.1 +/- 4.72 pM). Removal of the propyl from R3 and addition of a propyl group at R2 to 
make compound 8 (JSK-067) does not alter the IC50 compared to complete removal of the 
group from R3 (IC50 = 3.53 +/- 1.35 pM).Thus, for potent inhibition of a4p2 receptors, a propyl 
group appears necessary for potency at R3 but addition of a similar group to R2 has little 
effect and does not restore the function lost by the removal of the group from R3.
b) a7 receptors: A comparison of IC50 for dFBr and 6 (dFBr-C) shows that the addition of a 
propyl group at position R3 in dFBr results in a decrease in IC50 (dFBr: 44.1 ± 1.25 pM, 6: 
6.92 ±. 2.54 pM, P= 0.0020). This decrease is equivalent to that observed for a4|32 receptors 
with similar potencies for these compounds on both receptors. Addition of the propyl group to 
R2 does not alter the IC50 when compound 7 (JSK-039) is compared to compound 8 (JSK- 
067). These data are similar to that observed for the a4p2 receptor, however the a7 receptor 
appears more resistant to the conversion of the propyl to a propylene group at R4 with no 
significant change in IC5o observed for compound 5 (propylene) versus compound 6 (propyl). 
This is compared to a 31 fold decrease in IC50 on inhibition of a4p2 receptors.3)
1 0 0
3) R4-  6-Bromo group:
a) oc4B2 receptors: Unlike potentiation, inhibition was less affected by removal of the bromine 
group at position R4. Removal of the bromine from dFBr as in compound 3 (NG-089) 
produces only about a three fold increase IC50. Although this change is significant (P= 
0.0372). A comparison of Compound 2 (JSK-062) and compound 4 (JSK-088) which also 
contain a change at R4 shows no significant change in IC50 (P=0.9144). Similar effects are 
seen with other pairs of analogues that have similar changes in the R4 bromine. Compound 8 
(JSK-067) is structurally similar to compound 9 (JSK-073), except for the absence of bromine 
at R4 in compound 9. The presence of bromine significantly increases the IC50 values of 
compound 8 by four fold to 71.1 +/- 13.9 pM from 18.5 +/- 4.75 pM for compound 9 (P= 
0.0387).
b) al receptors: The presence of bromine at the R4 position appears to have little if any 
effect on IC50 values for inhibition of a7 receptors. Compound 3 (NG-089), which is identical 
in structure to dFBr but lacks the R* bromine is about 5.5 fold more potent than dFBr 
(P=0.0374). The change in IC50 on removal of the bromine group from dFBr is similar to that 
observed for a4p2 receptors although in the opposite direction. Removal of the bromine from 
dFBr appears to enhance apparent affinity for al while decreasing apparent apperant for 
a4p2. Compounds 2 (JSK-062) and compound 4 (JSK-088) also differ with respect to the 
presence in compound 2 or absence in compound 4 of a bromine at R4, but their IC50 values 
are identical. Similar effects on IC50 values are seen for other pairs including compound 8 
(JSK-067) and compound 9 (JSK-073) as well as compound 11 (JSK-065) and compound 13 
(JSK-076).
3.7 Conclusion:
Taken together, the data from functional testing of dFBr analogues has lead to the 
development of a general SAR for this class of positive allosteric modulator for a4(32 
receptors. We had originally hypothesized that different functional groups in the chemical 
structure of dFBr are responsible for the potentiation versus inhibition of acetylcholine 
induced responses on a4p2 receptors. We have identified the important groups and their role 
in potentiation and inhibition of a4p2 receptors. The gem-dimethyl group in dFBr and its 
analogues is essential for the potentiating effect. Other functional groups do not seem 
essential for potentiation and have varying effect on inhibition of a4p2 receptors. It is likely 
that inhibition and potentiation occur due to binding of dFBr and its analogues on different 
binding sites present on a4p2 receptors. dFBr and its potentiating analogues represent a 
unique class of positive allosteric modulators for heteromeric a4p2 subtype of neuronal 
nAChRs.
1 0 1
1 0 2
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CHAPTER 4: COMPARATIVE ANALYSIS OF THE EFFECTS OF POSITIVE ALLOSTERIC 
MODULATORS ON HUMAN NICOTINIC ALPHA4 BETA2 RECEPTORS EXPRESSED IN 
XENOPUS OOCYTES.1
4.1 Abstract:
A number of allosteric modulators have been identified that are able to potentiate 
acetylcholine (ACh) responses on neuronal nicotinic acetylcholine receptors (nAChR). These 
compounds can be grouped into broad structural classes typified by ionic zinc (Zn2+), 
physostigmine and 17-(3-Estradiol (17-BE). Each class of modulator appears to bind to 
unique binding sites to produce potentiation (Hsiao et al., 2006; Paradiso et al., 2001; 
Schrattenholz et al., 1993). Recently, desformylflustrabromine (dFBr), a metabolite from 
Flustra folicea was found to potentiate nAChRs and may represent a new structural class of 
allosteric modulators for these receptors. Unlike other known potentiating agents, dFBr 
shows high selectivity within the nAChR family for the a4(32 subtype compared to a7 
receptors (Kim et al., 2007). Our laboratory, in conjunction with Dr. Richard Glennon (Virginia 
Commonwealth University, College of Pharmacy) have synthesized and characterized the 
synthetic form of dFBr (Kim et al., 2007). In this study, we evaluate dFBr's action on a4p2 
receptors along with Zn2+, physostigmine and 17-BE. The goal of this study is to first 
compare all four allosteric modulators independently within the same system and secondly to 
determine the effects of co-application of each modulator with dFBr. Since some data is 
available regarding the site of action of other modulators, a comparison of dFBr with these 
modulators will serve as a guide and starting point to further exploration of dFBr’s 
mechanism and binding site through Site directed mutagenesis.
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1 The dFBr used for this study was synthesized Dr. Richard Glennon and his group at 
Virginia Commonwealth University.
Two electrode voltage clamp experiments were conducted using Xenopus oocyte 
expressing human a4p2 receptors. dFBr potentiated both high and low ACh affinity a4p2 
receptors, similar to Zn2+ by increasing the current elicited by ACh even at saturating 
concentrations of agonist. Unlike dFBr however Zn2+ potentiated only low ACh affinity 
receptors (Moroni et al., 2008).
Physostigmine decreased the lmax values at saturating concentrations of 
agonist along with a decrease in apparent affinity. When co-applied with dFBr, physostigmine 
induced a proportional decrease in lmax value and apparent affinity, the effects of 
dFBr/physostigmine appeared additive. This is consistent with independent mechanisms and 
sites of action for these two compounds. In contrast, neither Zn2+, 17-BE, nor dFBr 
significantly increase the apparent affinity of ACh on a4p2 receptors. When co-applied with 
dFBr, Zn2+ produced no significant additional effect on the changes in apparent efficacy but 
significantly altered apparent affinity compared to dFBr alone. No changes in these 
parameters were observed in these parameters on co-application of 17-BE and dFBr. The 
lack of additive effects of dFBr with 17-BE could indicate similar mechanisms of action and 
possibly similar binding domains for these compounds. These data represent important leads 
for the identification of the dFBr binding domain as they will guide future site directed 
mutagenesis studies.
4.2 Introduction:
Nicotinic acetylcholine receptors (nAChRs) are proteins present on the cell 
membrane that respond to the neurotransmitter ACh. nAChRs along with 5-HT3R, GABA(A), 
GABA(C) and Glycine receptors form a super-family of Cys-loop ligand gated ion channels. 
In the brain, nAChRs are involved in fast synaptic transmission and neuronal plasticity. They 
have been implicated in a number of neurological conditions including nicotine addiction, 
Alzheimer’s disease, Schizophrenia, Parkinson’s disease and autism (Gotti et al., 2006).
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Positive allosteric modulators (PAMs) are rapidly being developed for neuronal nAChRs and 
may represent a promising new approach for treating disorders involving these receptors 
(Gopalakrishnan et al., 2007).
A number of allosteric modulators have been identified that are able to potentiate 
ACh responses on neuronal nAChR. These compounds can be grouped into broad structural 
classes typified by Zn2+, physostigmine (see figure 1.10(B) for structure of physostigmine) 
and 17-p-Estradiol (17-BE) (see figure 4.5 structure of 17-BE). Each class of modulator 
appears to bind to unique binding sites to produce potentiation (Hsiao et al., 2006; Paradiso 
et al., 2001; Schrattenholz et al., 1993).
The acetylcholinesterase inhibitors galantamine and physostigmine were among the 
first compounds demonstrated to have an allosteric modulatory effect on neuronal nAChRs 
(Maelicke et al., 2000). Physostigmine was shown to potentiate a4p2 receptors at an ACh 
concentration of 1 pM (Smulders et al., 2005). Photo-affinity labelling studies in torpedo 
nAChR determined that a region located near K125 of the a-subunit is the likely binding site 
for physostigmine and this binding site is distinct from the ACh orthosteric binding site 
(Schrattenholz et al., 1993).
The steroidal ligand 17-BE modulates a4p2 receptors by binding to the short C- 
terminal tail of the a4 subunit of this receptor (Paradiso et al., 2001). At the single channel 
level, 17-BE potentiation results from an increase in opening probability of the a4p2 receptor 
channel. (Curtis et al., 2002).
Zn2+, another allosteric modulator of nAChRs, potentiates both p2 and P4 containing 
subtypes (Hsiao et al., 2001). Receptors expressed with a stoichiometry of 3 a4 and 2 p2 
subunits, (a4)3(P2)2 receptors, show low affinity for ACh (60 pM) and are potentiated by Zn2+ 
while those expressed with a stoichiometry of 2 a4 and 3 (32 subunits, (a4)3(p2)2 receptors, 
show high affinity for ACh (2 pM) and are not potentiated by Zn2+. The apparent selectivity of 
Zn2+ for low versus the high affinity subtypes led to the suggestion that the a4+/a4- subunit
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uniquely present on the low affinity subtype is responsible for Zn2+ potentiation (Moroni et al., 
2008). Using site directed mutagenesis and the substituted cysteine accessibility method 
(SCAM) key residues within the |32+/a4- interface of the a4p2 receptor have been identified 
as critical for Zn2+ potentiation (Hsiao et al., 2006). Single channel studies have determined 
that Zn2+ potentiates a4P4 receptors by increasing burst frequency of the receptor (Hsiao et 
al., 2008).
Desformylflustrabromine (dFBr) a metabolite isolated from the marine bryozoan 
Flustra foliacea has also been shown to potentiate the a4p2 subtype of nAChR (Sala et al., 
2005). It does not potentiate ACh responses on other nAChR subtypes including a7, a3p4 
and a3p2 (Sala et al., 2005). Our laboratory and our collaborators in Dr. Richard Glennon's 
Laboratory (Virginia Commonwealth University, School of Pharmacy) have developed a 
synthetic HCL salt of dFBr and have confirmed the action of this compound as an allosteric 
potentiator for a4p2 (Kim et al., 2007). This compound is unique in its ability to potentiate 
a4p2 receptors while inhibiting ACh induced responses on homomeric a7 receptors. Co­
application of increasing dFBr concentrations (1 nM to 100 pM) along with a fixed 
concentration of ACh produced a hormetic dose response curve on a4p2 receptors with the 
receptor responses potentiated at low concentrations of dFBr and inhibited at higher 
concentrations of the drug (Kim et al., 2007). A standard sigmoidal inhibition curve is 
observed under these conditions for a7 receptors.
We have hypothesized that the effects of dFBr are due to its binding at a unique 
binding site that is different from the binding site for other a4p2 receptor allosteric 
modulators. In this study we evaluated the modulatory actions of the three classes of positive 
allosteric modulators (PAMs) on human a4p2 receptors expressed in Xenopus oocytes. We 
compare the characteristics of modulation by physostigmine, 17-BE and Zn2+ to the effects 
produced by dFBr on both a4(32 and a7 receptors. Although another class of recently
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identified PAMs, represented by (2-amino-5-keto) thiazole, are also active on a4p2 receptors 
(Broad et al., 2006) these compounds are not commercially available, and thus could not be 
included in this study.
In our study, dFBr potentiated both high and low ACh affinity a4p2 receptors. This is 
in contrast to the effects of Zn2+ which potentiates only the low affinity subtype. When co­
applied with dFBr, Zn2+ did not produce any increase in potentiation compared to dFBr alone. 
This may suggest similar mechanisms but perhaps different binding site locations for dFBr 
and Zn2+. Similar to Zn2\  17BE did not produce and additional potentiation when applied with 
dFBr; again suggesting either similar mechanism and/or binding sites. In contrast to dFBr, 
physostigmine decreased the lmax values at saturating concentrations of agonist along with a 
decrease in apparent affinity. When co-applied with dFBr, physostigmine produced a 
decrease in lmax similar to the decrease observed in the absence of dFBr. The apparent 
affinity also decreased a similar amount whether or not dFBr was present. These data 
indicate additive actions of dFBr and physostigmine mediated by different mechanisms and 
sites of action. Thus, possible binding sites for dFBr are at the plus face of the 32 subunit 
that would overlap with the Zn2+ binding site or on the c-terminal region overlapping the 17- 
BE site.
4.3 Materials and Methods:
4.3.1 nAChR subunit cDNA:
The cDNA for human a4p2 receptors were obtained from Dr. Jon Lindstrom’s 
laboratory. Individual subunit cDNA was cloned into the pBud-CE4.1 (Invitrogen, Carlsbad, 
CA) vector prior to mRNA synthesis. The cDNA for a4 and 32 subunits were cloned 
individually in to the pcDNA3.1/Zeocin and pcDNA3.1/Hygromicin (Invitrogen, Carlsbad, CA) 
vectors respectively. For obtaining 1:1 expression both a4 and 32 subunits, cDNA from
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vector pBud-CE4.1 was injected. To obtain expression in different stoichiometries mRNA of 
a4 and (32 subunits in the pcDNA3.1/Zeocin and pcDNA3.1/Hygromicin vectors respectively 
was used.
4.3.2 Test Compounds:
Acetylcholine (ACh), physostigmine, 17-Beta estradiol (17-BE) and Zn2+ in form of 
ZnCI2was obtained from (Sigma Aldrich, St. Louis, MO). Desformylflustrabromine (dFBr) was 
synthesized by Dr. Richard Glennon's laboratory as the HCL salt according to protocols 
described elsewhere (Kim et al., 2007).
4.3.3 Synthesis of mRNA and Injection into Xenopus oocytes:
Expression vectors containing the appropriate cDNA were linearized using the 
restriction endonuclease FSP-1 for all three vectors. Synthetic cRNA transcripts for human 
a4(32 receptor were prepared using the mMESSAGE mMACHINE™ High Yield Capped RNA 
Transcription Kit (Ambion, TX). For production of high and low affinity a4(32 receptors we 
used the method of Zwart et. al. in which neuronal nAChR a4 and (32 receptor coding 
mRNAs are injected into Xenopus laevis oocytes at different ratios of a4 to (32 (9:1, 1:1, and 
1:9) (Zwart and Vijverberg, 1998). The EC50 values they obtained from the a4:(32 ratios 9:1, 
1:1, and 1:9 were 58.8 pM, 65.6 pM and 1.84 pM respectively (Zwart and Vijverberg, 1998).
Xenopus laevis frogs and frog food were purchased from Xenopus Express 
(Homosassa, FL). Ovarian lobes were surgically removed from Xenopus laevis frogs, 
washed twice in Ca+2-free Barth’s buffer (82.5 mM NaCI / 2.5 mM KCI /1  mM MgCI2 / 5 mM 
HEPES, pH 7.4) then gently shaken with 1.5 mg/ml collagenase (Sigma type II, Sigma- 
Aldrich) for 1 h at 20-25 °C. Stage IV oocytes were selected for microinjection. Oocytes were 
injected with a total of 50 nL cRNA at a concentration of 0.2 ng/nL in appropriate subunit 
ratios then incubated at 19 °C for 24 to 72 h prior to their use in voltage clamp experiments.
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4.3.4 Electrophysiological Recording:
Recordings were made using an automated two-electrode voltage-clamp system 
incorporating an OC-725C oocyte clamp amplifier (Warner Instruments, CT) coupled to a 
computerized data acquisition (Datapac 2000, RUN technologies) and auto injection system 
(Gilson). Recording and current electrodes with resistance of 1-4 MQ were filled with 3 molar 
KCI. Details of the chambers and methodology employed for electrophysiological recordings 
have been described earlier (Joshi et al., 2004). Briefly, oocytes are held in a vertical flow 
chamber of 200 pL volume and perfused with ND-96 recording buffer (96 mM NaCI / 2 mM 
KCI /1.8 mM CaCI2 / 1 mM MgCI2 / 5 mM HEPES; pH 7.4) at a rate of 20 ml/min. All test 
compounds were dissolved in ND-96 buffer. Dissolution of 17-BE required the use of 0.15% 
DMSO in ND-96 buffer. Test compounds were injected into the chamber at a rate of 20 
ml/min using the Gilson auto-sampler injection system. For experiments involving application 
of both modulators ACh and the appropriate modulator were mixed prior to injection.
4.3.5 Data and statistical Analysis:
Concentration-response curves were fit by non-linear curve fitting and GraphPad 
Prism Software (San Diego, CA) using standard built-in algorithms. For EC50 determinations 
data obtained from electrophysiological experiments were fit to the Hill equation:
l = lmax/(1 + E C 50/ [ A ] n) 4.1
Where, I is the current at a given agonist concentration, /max is the maximal current obtained 
at saturating agonist (ACh) concentration, EC50 is the agonist concentration that elicits a half- 
maximal current, and n is the Hill coefficient.
Quantitative data are expressed as mean ± S.E M. Paired student’s-f test and one 
way Analysis of Variation (ANOVA) with post-hoc Dunnett's multiple comparison tests were 
used to compare data from electrophysiological experiments. Variables such as the EC50, Hill
1 1 0
coefficient and lmax values were compared. P values are reported throughout the text and 
significance was set as P<0.05. N represents the number of repeats for each experimental 
data point and unless otherwise stated n was four or more for each data point.
4.4 Results:
4.4.1. Zinc and dFBr:
Figure 4.1A below shows responses obtained from a4p2 expressing oocytes on co­
application ACh with 100 pM Zn2+ or 1 pM dFBr. Zn2+ and dFBr concentrations were chosen 
based on the concentration producing a peak potentiation of the hormetic response curve 
(Hsiao et al., 2001). Both Zn2+ and dFBr potentiated ACh responses on a4p2 receptors 
although the maximum change in lmax for Zn2+ was only 147% compared to 355% with dFBr 
(Table 4.1). Despite the change in response amplitudes both Zn2+and dFBr produces similar 
effects on the overall response kinetics; increasing the peak with little apparent change in 
desensitization rates. Zn2+did not produced a significant change in the ACh EC50 (P= 0.1770) 
and dFBr produced only a slight change in ACh EC50 which was not significant (P= 0.0970). 
Co-application of Zn2+ and dFBr produced no additional change in potentiation compared to 
the strongest potentiator dFBr alone (Table 4.1) but did produce significant changes in both 
EC50 (P=0.05) and Hill Coefficient (P=0.05). This may be a cumulative effect of slight but 
statistically significant changes for both dFBr and Zn2+ together.
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Figure 4.1: The effect of Zn2+ and dFBr on a4(32 receptors.
Responses shown in A and B were obtained using Xenopus oocytes and two-electrode 
voltage clamp. Membrane potentials were clamped at -60 mV. Peak current amplitudes for 
each point were normalized to peak currents obtained in the presence of 1 mM ACh without 
dFBr or Zn2+ present. Data are tabulated in Table 4.2. A: Responses obtained from Xenopus 
oocytes expressing a4p2. Membrane potential was clamped at -60 mV. Traces a, b, c and d 
were obtained from different oocytes and were normalized to the trace obtained from 
application of 1 mM Ach. B. ACh concentration/response curve with dFBr, Zinc and dFBr with 
Zinc on human a4p2 receptors. All dose-response curves, data points are mean +/- S.E M. 
Each data point on all the four curves were evaluated at least 4 times on a minimum of 2 
oocytes for each curve (n=4). Lines correspond to the best fit obtained with the Hill equation.
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Table 4.1: EC50 for ACh activation, lmax and Hill slopes for responses obtained by zinc, dFBr 
and by co-application of zinc with dFBr on mixed stoichiometry a4p2 receptors. The lmax was 
normalized to that obtained for 1 mM ACh on the same oocyte. All values are mean +/- 
S.E.M.
EC50(pM) Normalized Hill slopes
lmax
ACh 36.8 +/- 8.75pM 1.03+/-0.04 1.07+/-0.17
1 pM dFBr 18.9+/-3.22 pM 3.57 +/- 0.23 0.60 +/- 0.01
100 pM Zinc 22.4 +/- 3.47 pM 1.47+/-0.05 0.99 +/-0.14
1 pM dFBr + 100 pM zinc 10.1 +/- 5.2 pM 3.55 +/- 0.21 0.43 +/- 0.05
The effects of dFBr and Zn2+ on EC50 and Hill slope when co-applied may indicate an 
additive effect of the two compounds although this additive effect was not evident in their 
effects on potentiation. To explore the binding site interactions more fully, we evaluated the 
action of dFBr on different stoichiometries of the a4(32 receptor. Previous studies have 
shown that Zn2+ potentiates the low affinity a4p2 subtype but it is unable to potentiate the 
high affinity subtype (Moroni et al., 2008). Figure 4.2 shows the effects of dFBr on the two 
different stoichiometries of a4p2 receptors. The potentiated responses are the same for both 
high and low affinity receptors although the high affinity potentiated response appears 
sharper, possibly due to increased rate of desensitization. The increase in lmax produced by 
co-application of dFBr is significantly more for the high affinity receptor compared to the low 
affinity receptor (Table 4.2 - 504% vs. 274%) (P= 0.0007). It is evident from these data that 
dFBr is capable of potentiating both high and low affinity a4p2 receptors in contrast to Zn2+ 
which appears to potentiate only the low affinity receptor (Moroni et al., 2008).
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Figure 4.2: The effect of dFBr on (a4)2((32)3 and (a4)3(|B2)2 receptors.
(a4)2((32)3 and (a4)3(P2)2 receptors have high and low affinities for ACh respectively. 
Responses shown in A and B were obtained using Xenopus oocytes and two-electrode 
voltage clamp. Membrane potentials were clamped at -60 mV. Peak current amplitudes for 
each point were normalized to peak currents obtained in the presence of lmax for ACh without 
dFBr present. Data plotted in C were obtained from at least 4 different experiments on 
multiple oocytes. Data are tabulated in Table 4.2. A: (a4)2(p2)3 receptors: Traces a and b 
were obtained from same oocytes and represent traces obtained at 1 mM Ach. B: (a4)3(P2)2 
receptors: Traces a and b were obtained from same oocytes and represent traces obtained 
at 100pM Ach C: EC50 values obtained from ACh responses obtained in the absence and 
presence of 1 pM dFBr. All dose-response curves, data points are mean +/- S.E.M. Each 
data point on all the four curves were reflects at least 4 repeated evaluations for each point 
on multiple oocytes for all the curves (n=4). Lines correspond to the best fit obtained with the 
Hill equation.
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Table 4.2: EC50 for ACh activation, lmax and Hill slopes for responses obtained by ACh and by 
co-application of ACh with dFBr on High and Low affinity receptors. All values are mean +/- 
S.E.M.
High affinity Low affinity
(a4)2(p2)3 (a4)3(p2)2
ECS0 (pM)
ACh Only
EC50(mM)
ACh + 1 pM dFBr
Change in lmax resulting from 
co-application with 1 pM dFBr.
Hill slope
ACh only
Hill Slope
ACh + 1 pM dFBr
2.00 +/- 0.33pM 69.5 + /-1 0.3pM
4 .8 3 + /-0.48pM 37.7 +/- 7.14pM
5.04 +/- 0.07
0.85+/-0.17
1.25 +/-0.15
2.72 +/-0.18
0.87 +/- 0.02
0.97 +/-0.16
4.4.2. Physostigmine and dFBr:
Physostigmine is an acetylcholinesterase enzyme inhibitor which allosterically 
potentiates nAChRs (Maelicke et al., 2000). We compared dFBr and Physostigmine for their 
action as PAMs for a4p2 receptors.
Figure 4.3 shows the effect of physostigmine on a432 receptors expressed in 
Xenopus oocytes and stimulated with 1 mM ACh. Oocytes were injected with a 1:1 ratio of 
a4 and p2 subunits thus producing a mixture of high and low affinity receptors. A 
concentration of 10 pM physostigmine has been shown to be the concentration that provides 
maximum potentiation of a4p2 receptors expressed in Xenopus oocytes when co-applied 
with low concentration of ACh (1 pM) (Smulders et al., 2005). However when applied with 
higher ACh concentration, 10 pM Physostigmine appears to inhibit the response but does not
change the response kinetics (Figure 4.3A). When applied in combination with 1 pM dFBr, 
the dFBr potentiated response is also inhibited by the presence of physostigmine. To 
quantify this data, concentration response curves for ACh were determined in the presence 
of 1 pM dFBr, 10 pM physostigmine and a combination of both 1 pM dFBr and 10 pM 
physostigmine (Figure 4.3B) (n=4). Co-application of 10 pM physostigmine appears to shift 
the concentration response curve to the right, thus decreasing the EC50 from 36.8 +/- 8.75pM 
(ACh only) to 117 +/- 21.8 pM (ACh + 10 pM physostigmine). This represents a significant 
change in apparent affinity (P=0.0425). Hill slopes did not change significantly (P=0.9347).
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10 pM physostigmine
10 pM physostigmine
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Figure 4.3: The effects of physostigmine and dFBr on a4p2 receptors.
Responses shown in A and B were obtained using Xenopus oocytes and two-electrode 
voltage clamp. Membrane potentials were clamped at -60 mV. Peak current amplitudes for 
each point were normalized to peak currents obtained in the presence of 1 mM ACh without 
dFBr or physostigmine present. Data are tabulated in Table 4.3. A: Responses obtained 
from Xenopus oocytes expressing a4p2. Membrane potential was clamped at -60 mV. 
Traces a, b, c and d were obtained from different oocytes and were normalized to trace 
obtained with 1 mM Ach. B. ACh concentration/response curve in the presence dFBr, 
Physostigmine and dFBr with physostigmine on human a4p2 receptors. All dose-response 
curves, data points are mean +/- S.E.M. Each data point on all the four curves were reflects 
at least 4 repeated evaluations for each point on multiple oocytes for all the curves (n=4). 
Lines correspond to the best fit obtained with the Hill equation.
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Table 4.3: EC50 for ACh activation, lmax and Hill slopes for responses obtained by 
physostigmine, dFBr and by co-application of physostigmine with dFBr on mixed 
stoichiometry a4(32 receptors. The lmax was normalized to that obtained for 1 mM ACh on the 
same oocyte. All values are mean +/- S.E.M.
EC50 In Hill Slopes
ACh 36.8 +/- 8.75pM 1.03+/- 0.04 1.07+/-0.17
ACh + 1 pM dFBr 
ACh
+ 10 pM Physostigmine 
ACh + 1 pM dFBr 
+ 10 pM Physostigmine
18.9+/-3.22pM 
117+/-21.8 pM 
59.8 +/- 7.89 pM
3.57 +/- 0.23 0.60 +/- 0.01
0.78+/-0.11 1.11+/-0.21
2.73 +/- 0.22 0.96 +/- 0.06
4.4.3. 17- p Estradiol and dFBr
17-BE is the first and only steroid molecule reported as a positive allosteric 
modulators of nAChRs. It was determined that the short extracellular c-terminal amino acid 
sequence (WLAGMI) of human a4(32 receptors is critical for potentiation by 17-BE (Paradiso 
et al., 2001). In this study, we compare the functional effects of dFBr and 17-BE on a4p2 
receptors expressed in Xenopus oocytes.
Figure 4.4 shows the effects of co-application of ACh with dFBr, 17-BE and a 
combination of 1 pM dFBr and 15 pM 17-BE on human a4p2 receptors expressed in 
Xenopus oocytes (n=4). A concentration of 15pM 17-BE elicited maximum potentiation of 
human a4p2 receptors (Curtis et al., 2002). Oocytes were injected with a 1:1 ration of a4 
and p2 subunits thus producing a mixture of high and low affinity receptors. Responses to 1 
mM ACh appear slightly potentiated by 15 pM 17-BE, although much less then that by dFBr 
(Figure 4.4A). Response kinetics appears similar to un-potentiated responses although faster
rise times to peak are apparent. Combining both dFBr and 17-BE did not produce additive or 
synergistic effects but produced similar peaks amplitudes to dFBr alone. Quantification of this 
data in terms of changes in ACh concentration response kinetics yielded Figure 4.4B. 17-BE 
produced a slight change in EC50 similar to that observed for dFBr (Table 4.4). The changes 
in EC50 were not significant for either 17-BE or dFBr (P>0.05). Similarly to the effect of dFBr 
on Hill slopes, no significant change in Hill slopes is observed upon application of 17-BE 
(P=0.2873). The change in lmax produced by 17-BE was much smaller then dFBr but a 
significant 128% increase was observed (P=0.0186). This is in contrast to the 347% increase 
observed for dFBr (P=0.0009). Co-application of dFBr with 17-BE produced a significant 
decrease in Hill slopes to about 1/2 the un-potentiated response (P< 0.0439), however the 
change in EC50 was not significantly (P= 0.3393). The change in Hill slope may suggest a 
decrease in cooperativity between the ACh orthosteric sites as a result of the combined 
application of dFBr and 17-BE.
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Figure 4.4: The effects of 17-BE and dFBr on a4p2 receptors.
Responses shown in A and B were obtained using Xenopus oocytes and two-electrode 
voltage clamp. Membrane potentials were clamped at -60 mV. Peak current amplitudes for 
each point were normalized to peak currents obtained in the presence of 1 mM ACh without 
dFBr or 17-BE present. Data are tabulated in Table 4.3. A: Responses obtained from 
Xenopus oocytes expressing a4|32. Membrane potential was clamped at -60 mV. Traces a, 
b, c and d were obtained from different oocytes and were normalized to the trace obtained 
from 1 mM Ach. B. ACh concentration/response curve in the presence 1 pM dFBr, 15 pM 17- 
BE and dFBr with 17-BE on human a4p2 receptors. All dose-response curves, data points 
are mean +/- S.E.M. Each data point on all the four curves were reflects at least 4 repeated 
evaluations for each point on multiple oocytes for all the curves (n=4). Lines correspond to 
the best fit obtained with the Hill equation.
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Table 4.4: EC50 for ACh activation, lmax and Hill slopes for responses obtained by application 
of dFBr and 17-BE and by co-application of dFBr with 17-BE on a4|32 receptors. The lmax was 
normalized to that obtained for 1 mM ACh on the same oocyte. All values are mean +/- 
S.E.M.
EC50 lmax Hill Slopes
ACh 36.8 +/- 8.75 pM 1.03+/-0.04 1.07+/-0.17
ACh + 1 pM dFBr 18.9 +/- 3.22 pM 3.57 +/- 0.23 0.60 +/- 0.01
ACh + 15 pM 17-BE 19.7+/-4.20 pM 1.32+/-0.09 0.78+/-0.08
ACh
+1 pM dFBr + 15 pM 17-BE 25.2 +/- 6.69 pM 3.62 +/- 0.47 0.46 +/- 0.08
4.5 D iscussion:
The discovery of dFBr and its establishment as an allosteric modulator of a4p2 
receptors raises the question of whether dFBr truly represents a new class of modulator for 
this receptor with a unique mechanism or site of action or whether it is acting similar to 
another class of modulator (Kim et al., 2007). The modulators described here, 
physostigmine, Zn2+ and 17-BE, represent the key groups of allosteric modulators and have 
previously been shown to bind at distinct sites with specific mechanisms of action. We have 
examined the effects of all three modulators along with dFBr both independently and on co­
application within the same assay system. The results of this study suggest that dFBr my be 
acting similar to either Zn2+ or 17-BE although differences in selectivity of high versus low 
affinity nicotinic receptors for dFBr and Zn2+ along with an observed additive effect of these 
agents on EC50 when co-applied would suggest that dFBr and Zn2+ may act via different 
mechanisms. The similarity of dFBr and 17-BE and the lack of any additive effect of these 
two compounds when co-applied strengthens the argument that dFBr and 17-BE may be
acting via similar mechanisms. This conclusion is useful in developing strategies to identify 
the dFBr binding site. Targeting of the putative 17-BE with mutagenesis and a determination 
of the effect of these mutations on dFBr potentiation will ultimately help determine if 17-BE 
and dFBr share a common binding site.
Zinc and dFBr: There is a clear indication that zinc and dFBr are working with each other to 
increase the apparent affinity of ACh for mixed (1:1) ratio expression of a4(32 receptors. As 
shown in Table 4.2. dFBr and zinc together significantly (P=0.05) increased the apparent 
affinity of ACh for a4p2 receptor more than that brought about by either Zinc or dFBr 
individually. The Hill coefficientalso decreases significantly (P=0.05) in presence of both dFBr 
and Zinc. This value of Hill coefficientis less than that obtained by application of dFBr or Zinc 
alone. The mechanism of zinc and dFBr maybe overlapping since zinc does not exert any 
significant effect on apparent efficacy in the presence of dFBr. The decrease in hill slope 
indicates increased cooperativity between the zinc and dFBr binding sites to stabilize the 
open receptor conformation induced by ACh. The cooperativity between dFBr and zinc 
indicate that each has a different binding site on a4p2 receptors.
Zinc and dFBr may share a similar mechanism of action but clearly have a different 
binding site, although this binding site may overlap with each other. The zinc potentiation site 
has been proposed to be present at the a4+/ a4- site of a4p2 receptors (Moroni et al., 2008), 
while other researchers have shown that the zinc-binding residues are be present at the 
P4+/a4- cleft of the a4p4 receptors (Hsiao et al., 2006). The putative dFBr binding site could 
also be present at p2+/a4- or the P2+/P2- cleft of the a4p2 receptors. Data obtained from this 
study would help target these clefts in a4p2 receptors for future site directed mutagenesis 
studies. Critical residues like D218 of P2 subunit and H195 of the a4 are important in binding 
zinc (Moroni et al., 2008). Such mutations will help identify the differences in the binding site 
of dFBr and zinc.
1 2 2
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Physostigmine and dFBr: Physostigmine is the only one of the three PAMs which reduced 
the apparent apperant and apparent efficacy of ACh in presence and absence of dFBr in 
a4p2 receptors. As seen in table 4.3, Physostigmine reduced the apparent affinity of ACh 
and efficacy on a4p2 receptors. 10 pM physostigmine increases the apparent ACh EC50 from 
36.8 pM to 117 pM. This amounts to about a 3.17 fold decrease in apparent affinity of ACh 
for a4p2 receptors in presence of physostigmine. The apparent ACh EC50 for a4p2 receptors 
in presence of 1 pM dFBr is 18.9 pM, which increased to 59.8 pM when 10 pM 
physostigmine is present. This indicates that there is a 3.16 fold decrease in apparent affinity 
of ACh in the presence of 10 pM physostigmine with the presence of 1 pM dFBr. The 
reduction in EC50 and hill coefficients by physostigmine indicates an inhibition of the action of 
ACh on the a4p2 receptors, irrespective of the presence of dFBr. The data from ACh EC50 
experiments (Figure 4.3) supports the observation that physostigmine is directly inhibiting the 
actions of acetylcholine itself since the amount of decrease in apparent affinity of ACh for 
ci4|32 receptors both in the presence and absence of dFBr is similar (3.17 to 3.16 fold without 
and with dFBr respectively). Therefore, physostigmine may be reducing the apparent ACh 
affinity on a4p2 receptors by a mechanism unhampered by the presence of dFBr. Thus, the 
effects of dFBr and physostigmine appear independent. These data support a model in which 
physostigmine and dFBr exert effects mediated by independent mechanisms and this 
mechanism supports the hypothesis that there are different binding sites for physostigmine 
and dFBr. Physostigmine is a partial agonist for a4p2 receptors and it is thought to bind 
the receptor at an ACh equivalent agonist recognition sites (Smulders et al., 2005). The 
inhibition of a4p2 receptor by physostigmine is non-competitive via ion channel block. 
(Smulders et al., 2005). Additionally, on the torpedo nAChRs physostigmine binds to the FK- 
1 antibody site around Lys-125, which is also the an low affinity ACh binding site on the
torpedo nAChRs (Schroder et al., 1994). Physostigmine and dFBr have a different binding 
site on a4p2 receptors and independence of action.
17-P-Estradiol and dFBr: 17-BE which potentiates a4p2 receptors is closely related 
structurally to Progesterone which is a non competitive inhibitor of a4p2 receptors (Arias et 
al., 2006). Progesterone does not bind to the 17-BE potentiation site (Paradiso et al., 2001). 
The chemical structure of dFBr and 17-BE are very different. dFBr is an indolic alkaloid 
derivative (Peters et al., 2004) whereas the structure of 17-BE is cholesterol based (Figure 
4.5);
Data from the ACh EC50 experiments (Figure 4.4) shows that the apparent affinity of 
ACh was similar when 1 pM dFBr and 15 pM 17-BE were applied individually or together on 
a4p2 receptors. The efficacy value for dFBr + 17-BE on a4p2 receptors is the same as the 
efficacy value of dFBr by itself. There is no significant (P > 0.05) enhancement or decrease 
in either apperant affinity or apperant efficacy for dFBr with 17-BE compared to dFBr alone. 
There is no interdependence in the action of dFBr and 17-BE on each other. 17-BE exerts a 
smaller effect of potentiation on a402 receptors which was masked when dFBr is present. 
dFBr exerted a larger potentiating effect on a4(32 receptors compared to 17-BE. There is no 
synergy between 17-BE and dFBr hence the mechanism of potentiation by dFBr and 17-BE 
may be overlapping as seen for zinc. However the differences in the chemical structural of 
dFBr and 17-BE makes it unlike that these two ligands would bind to the same site. However 
the binding site for dFBr and 17-BE may also possibly have some overlap. The data with 
dFBr and 17-BE gives a clear direction to future site directed mutagenesis studies that would 
target the four residues (AGMI) in the C-terminal of the a4 subunit C-terminal which are know 
to bind 17-BE (Paradiso et al., 2001).
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Figure 4.5: Structure of: Desformylflustrabromine (A); 17-Beta-Estradiol (B).
4.6 Conclusion:
The experimental evidence indicates that the action of dFBr is independent of the 
presence of Physostigmine, zinc and 17-BE. The data obtained indicate that Physostigmine, 
zinc and 17-BE applied with dFBr failed to enhance apparent efficacy compared to that 
produced by dFBr alone. Only physostigmine reduced apparent apperant and apparent 
efficacy of ACh on a4(32 receptors in presence and absence of dFBr. Interestingly the 
proportion of reduction of apparent efficacy and apparent apperant by Physostigmine was 
not influenced by the presence or absence of dFBr. The presence of physostigmine reduced 
the effective ACh concentration which was uninterrupted by dFBr. Zinc and 17-BE did not 
induce any additional potentiation with dFBr on a4p2 receptors. Zinc, 17-BE and dFBr may 
share a similar mechanism of potentiation action on these receptors. A synergistic decrease 
in the Hill coefficient for dFBr/Zinc co-application might suggest some overlap in the binding 
domains between dFBr and zinc. 17-BE produced no additive effects on apparent affinity or 
efficacy indicating overlapping or similar mechanisms. The structural dissimilarity between 
17- BE might suggest they act by similar mechanisms but via different binding sites but that 
is not discernable from our data.
Identification of a binding region for a new drug such as dFBr can be challenging and 
must rely on clues from experiments such as those described here. The data in this chapter
supports further study of the putative binding domains for zinc and 17-BE and narrows the 
initial scope of mutagenesis studies to these areas. Zinc is thought to bind at the subunit 
interfaces that do not contain acetylcholine binding sites therfore this region of the receptor 
would be an excellent starting point for mutagenesis. Since 17-BE also shows similarities to 
dFBr the C-terminal end of the a4 subunit should also be explored. A particularly interesting 
result would be identification of overlap between zinc and dFBr. Zinc is not a particularly 
good lead for drug development but identification of an alternate ligand for the zinc 
potentiation site would be an exciting development as it would provide a starting point for 
further exploring this site for drug development. Mechanistic experiments in the future will 
help determine the extent of similarity on mechanisms between these ligands.
The data obtain supports our hypothesis that the effects of dFBr are due to its 
binding at a unique binding site that is different from the binding site for other a4p2 receptor 
allosteric modulators, i.e., physostigmine, zinc or 17-BE. These results show that dFBr is a 
new class of positive allosteric modulator for a4P2 subtype of neuronal nicotinic receptors.
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CHAPTER 5: CONCLUSION AND FUTURE DIRECTION
5.1 An overview
Nicotinic acetylcholine receptors (nAChRs) are widely distributed in the peripheral 
and central nervous system, and play a major role in mediating various physiological 
processes. It is imperative that novel ligands be developed which selectively target these 
receptors. Selective ligands could be useful clinically in diseases and pathological conditions 
where nicotinic tone in the CNS is altered. While many ligands have been developed which 
target a4p2 receptors, these ligands typically act on the receptors via the orthosteric site, 
which is the ACh and nicotine binding site. The orthosteric site is well conserved across all 
subtypes of nicotinic receptors and hence subtype selective ligands have been elusive. 
Orthosteric agonists and partial agonists tend to desensitize and/or produce up regulation of 
a4p2 receptors expression (Gentry and Lukas, 2002). The development of allosteric ligands 
may help overcome some of these obstacles. Since allosteric sites are likely to be less 
conserved across nicotinic subtypes, these ligands may display greater subtype selectivity. 
Additionally, since allosteric ligands do not activate receptors but instead modulate the 
responses to endogenous ligands, control over activation remains under the control of pre- 
synaptic transmitter release. This may also make allosteric ligands less prone to producing 
changes in receptor expression.
This thesis focuses on a novel type of positive allosteric modulator targeted at the a4p2 
nicotinic receptor subtype. While this work has not specifically focused on receptor 
selectivity, this is an important long term goal of the research. Before that goal can be 
accomplished detailed information regarding optimization of the dFBr pharmacophore and its 
interaction with the receptor is required. Chapter 2 of this thesis evaluated the effects of a 
synthetic dFBr to confirm that this compound was capable of producing the effects reported 
for the natural product. Chapter 3 expanded on this work to identify key structural features of
dFBr that contribute to its potentiating effects on a4(32 receptors as well as its inhibitory 
effects on a4(32 and a7 receptors. Chapter 4 addressed the issue of mechanism of action, 
possible binding site location and similarity to other PAMs. Taken as a whole, these data set 
the stage for a second phase of research that will explore in greater detail the receptor 
regions responsible for the binding site involved in dFBr potentiation and optimize the dFBr 
drug class as a selective a4|32 PAM. While it is expected that dFBr will form the basis of a 
new, therapeutically useful agent, understanding the effects and interaction of this compound 
will also contribute towards an improved understanding of the nicotinic receptor family and, 
by extension, ligand gated ion channels in general. Among the contributions expected from 
this work are:
1) Identification of receptor mechanisms: Conventional agonists, antagonists and partial 
agonist act on the nicotinic receptors via interaction with the orthosteric site. Study of 
allosteric modulation may reveal new features of the mechanisms underlying 
receptor activation.
2) Identification of novel allosteric binding sites on neuronal nicotinic: Neuronal nicotinic 
receptors may contain multiple allosteric binding sites in addition to the orthosteric, 
acetylcholine site. Using novel ligands as molecular probes, putative allosteric sites 
on nicotinic receptors can be found and studied. Experimental methods like site 
directed mutagenesis, chimeric constructs and the substituted cysteine accessibility 
method (SCAM) can be utilized to pinpoint the amino acid residues in the allosteric 
binding site and their involvement in binding of allosteric ligands.
3) Discovery of novel allosteric modulatory ligands for neuronal nAChRs: One purpose 
of basic pharmacological research is to produce new lead molecules that can be 
developed into novel drug therapies. The discovery of novel allosteric modulators is 
the first step in developing therapeutic ligands that selectively target nAChR 
subtypes. Since the large majority of nAChR modulators currently available are non-
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selective, the development of subtype selective ligands will facilitate identification of
the role of select subtypes in disease processes.
5.2 Conclusions:
1) Synthetic desformylflustrabromine is a unique positive allosteric modulator of 
a4f32 subtype of neuronal nicotinic receptors.
The ligand-gated ion channel super-family (LGICS) includes a wide variety of ion 
channel receptors including multiple nAChRs, 5-HT3Rs, GABA (A) and (C) receptors and 
glycine receptors. All of these proteins, including a closely related acetylcholine binding 
protein (AChBP) are allosteric proteins. It is thus not surprising that multiple ligands acting at 
distinct binding sites can produce alterations in receptor function. For example, the GABA (A) 
receptor is modulated by a number of compounds that bind to allosteric sites on the receptor. 
These modulators include valuable therapeutic drug classes including Benzodiazepines 
(BDZ) and Barbiturates. These allosteric modulators of the GABA (A) receptor are commonly 
prescribed clinically as anti-depressants, anxiolytics and anaesthetics (Whiting, 2003). Given 
the structural similarity of all members of the LGIC family it is likely that all members contain 
allosteric modulatory binding sites. For the nicotinic receptors the only clinically used 
modulator is galantamine although this compounds primary site of action in the CNS appears 
to be inhibition of acetylcholinesterase while its direct modulatory effects on nAChRs are 
likely secondary. No modulatory agent similar to BDZ or Barbiturates has been developed for 
clinical use in modulating nicotinic receptor activation. dFBr represents a unique positive 
allosteric modulator of nAChRs and our goal is to develop it into a therapeutically useful 
drug. To get to this endpoint, a clear understanding of its interaction with the nAChR and its 
mechanism of action is necessary.
Our original hypothesis for explaining the mechanism of action of dFBr was based on 
comparisons with the action of BDZs on the GABA (A) receptor. Chlordiazepoxide, a BDZ
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drug, allosterically modulates the activation of GABA (A) receptor by GABA (Choh et al., 
1977) by increasing the apparent affinity of the neurotransmitter (GABA) for the receptor 
(Choi et al., 1981). Using the action of BDZ on GABA (A) receptor as a model, we proposed 
that dFBr might allosterically modulate the a4p2 subtype of neuronal nAChRs by increasing 
the apparent affinity of acetylcholine for the receptor. Since early studies of dFBr used 
compound obtained from a natural source, our first step was to confirm that the proposed 
active component was indeed dFBr (Sala et al., 2005). Synthetic dFBr does not contain any 
potential contaminating analogues or metabolites and we demonstrated in Chapter 2 that this 
compound was capable of potentiating ACh induced responses at a4p2 receptors. However, 
the EC50 for synthetic dFBr was over 10X greater then that obtained from natural sources. 
We also discovered a previously unidentified inhibitory effect of dFBr evident at 
concentrations greater then 10pM. This effect was likely observed only in the synthetic 
compound due to improved solubility of the synthetic HCI salt of dFBr compared to the less 
soluble natural product as well as increased purity of the product. Similar to the natural form 
of dFBr, the synthetic compound was selective for heteromeric a4p2 receptors versus 
homomeric a l  receptors (Sala et al., 2005). For a7 receptors we observed inhibition but no 
potentiation. The primary outcomes of the data presented on synthetic dFBr in Chapter 2 
were confirmation of the potentiating nature of dFBr, the discovery that dFBr was also 
capable of inhibiting the a4P2 and a7 receptors at concentrations greater then 10DM and the 
ability to synthesize sufficient quantities of dFBr for further studies. This enabled us to move 
on to the work of identifying the key structural components of dFBr responsible for these 
actions that is presented in Chapter 3.
2) Different functional groups in the chemical structure of desformylflustrabromine 
are responsible for the potentiation versus inhibition of acetylcholine induced 
responses on a4(32 receptors.
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We evaluated 16 synthetic analogues of dFBr, two of which occur naturally. As 
described in Chapter 3. four of the 16 synthetic analogues tested potentiated ACh induced 
responses on a4p2 receptors. Similar to dFBr, these analogues potentiated responses at 
low concentrations and inhibited at higher concentrations. The remaining 12 analogues, 
including two compounds that occur naturally with dFBr, inhibited ACh induced responses of 
a4{32 receptors but did not potentiate. On a7 receptors, all of the 16 analogues, including 
dFBr itself, inhibited ACh induced responses.
Different functional groups in the chemical structure of dFBr and its analogues were 
identified as responsible for their potentiating and inhibitory actions. For potentiation, two 
key groups appear important: The geminal dimethyl group and the bromine attached to the 
indole. Removal of the gem dimethyl eliminates potentiation and removal of the bromine 
significantly reduces the EC50 for potentiation. Modification of other functional groups had 
little effect on potentiation but had larger effects on inhibition of oc4p2 receptors. The different 
structure/activity relationships for potentiation and inhibition support the hypothesis that 
inhibition and potentiation represent two distinct mechanisms and sites of action of dFBr on 
the receptor. This is an important determination since it suggests that dFBr can be optimized 
to obtain a compound that will display potentiation but no inhibition. This would likely result 
in a new compound similar to dFBr but with substantially enhanced efficacy. In future 
studies, further detailed exploration of the precise requirements of these functional groups 
will be accomplished through addition of a variety of modified groups at these positions. This 
“reconstruction” phase will produce not only enhanced efficacy but also increased selectivity. 
While this thesis does not specifically address the broad issue of receptor selectivity, the 
data discussed in Chapter 3 can be used in future studies to identify and optimize the 
selectivity of dFBr for specific receptor subtypes. Identification of the specific binding domain 
for dFBr on a402 receptors and the key pharmacophoric features of dFBr are critical to this
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next step. In Chapter 4, we began to address the binding site location by determining if it is 
likely to be similar or different then other PAMs.
3) Comparison of dFBr and other nicotinic PAMS reveals similarities in potentiating 
mechanisms and possible locations of the potentiating binding site for dFBr.
Along with dFBr, physostigmine, Zn2+ and 17-BE are also known to potentiate a4p2 
receptors. We therefore performed experiments comparing the pharmacology and induced 
effects of dFBr and other positive allosteric modulators of the a4p2 receptor. The initial 
studies presented in Chapter 4 explored the effects of these compounds on ACh induced 
responses on a4p2 receptors using our assay system. Physostigmine is an 
acetylcholinesterase inhibitor which potentiates a4p2 receptors in the presence of low 
concentrations of ACh. Zn2+ is a divalent cation with potentiates only the low ACh affinity 
stoichiometry (a4)3(p2)2 receptor (Moroni et al., 2008). 17-BE potentiates a4p2 receptors by 
binding to the short extracellular C-terminus of a4 subunit in a4p2 receptors (Paradiso et al., 
2001). All four compounds were evaluated independently and in combination with dFBr.
Physostigmine reduced affinity of a4[32 receptors for ACh and increased the 
response to ACh concentrations less then 10 mM but inhibited responses when co-applied 
with ACh at higher concentrations. Thus, unlike the remaining three compounds tested, 
physostigmine did not alter the apparent efficacy of ACh. This is in contrast to dFBr which 
alters ACh affinity only slightly but greatly alters apparent efficacy. When co-applied, dFBr 
and physostigmine produce a result that appears to be the sum of the changes they induce 
independently. The additive nature of this interaction suggests that the two compounds 
produce two different effects through different basic mechanisms.
Zn2+ has been shown to potentiate low affinity a4p2 receptors but not high affinity 
receptors. This is in constrast to dFBr which shows a slight preference for potentiation of 
high affinity receptors. This difference in subunit selectivity suggests at least differences in
134
binding site characteristics for the two compounds. Both compounds produce slight 
decreases in the ACh EC50 and increase the apparent efficacy. When co-applied with dFBr, 
Zn2+ does not produce any increase in the apparent efficacy compared to dFBr alone. This 
lack of additional change in apparent efficacy might suggest that dFBr and Zn2+ act by similar 
mechanisms, but the decrease in EC50 suggests independent mechanisms. These data 
could be consistent with a hypothesis that dFBr and Zn2+ produce similar effects but through 
possibly different binding sites. One explanation would be binding of Zn2+ and dFBr to 
different subunit interfaces such as a7p_ versus p+/a \ This would also explain the differences 
in selectivity for subtypes with different subunit stoichiometries.
17-BE produced similar, although much smaller changes in EC50 and apparent 
efficacy when compared to dFBr, however, unlike physostigmine and Zn2+ no additional 
changes in either parameter were observed when the two compounds were co-applied. 
While this lack of any cumulative effect is not definitive, it does suggests similar mechanisms 
or sites of action for 17-BE and dFBr. This hypothesis can be tested by utilizing single 
channel techniques to determine if dFBr shows stabilization of open state conformation (as 
seen for Zn2+) or produces bursting (as seen for 17-BE). Site directed mutagenesis of the C- 
terminal region would be helpful in confirming if the C-terminal binding site for 17-BE is 
shared, or overlaps, the dFBr site
5.3 Future direction:
dFBr is a lead molecule of natural origin which has been validated as a positive 
allosteric modulator for the a4p2 subtype of neuronal nAChRs (Kim et al., 2007). Here we 
have reported the results from experiments testing the action of synthetic dFBr, a phase 1 
SAR study and identification of a putative binding region on a4b2 receptors. Additional 
studies will be necessary to further develop the dFBr pharmacophore, confirm the dFBr 
binding site and model the interaction of dFBr with the receptor. Ultimately, the goal is to
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establish dFBr analogues as clinically useful drug candidates. These studies will also
contribute to understanding a4p2 receptor mechanisms. Recommended future studies are:
1) Synthesis and evaluation of additional analogues of dFBr. This will be necessary to 
optimize the dFBr pharmacophore and further develop the structure-activity relationship.
2) Confirm the location of the dFBr binding site. Two possible locations have been 
proposed for the dFBr binding site location based on the data obtained in Chapter 4; the 
P+/P" cleft and the C-terminal 17-BE site. Exploration of both regions using site directed 
mutagenesis will confirm or refute these hypotheses. For this purpose, alanine scanning 
mutagenesis (ASM) can be used where each amino acid in a chosen region of the 
protein is mutated sequentially to alanine (Cunningham et al., 1989). An alanine 
substitution of an amino acid residue involved in dFBr binding to the protein will lead to a 
significant change in receptor function. Potentially important residues identified by 
alanine scanning can later be mutated to more similar amino acids to determine specifics 
of the interactions at these positions; i.e., a Phy (F) to a Typ (W). Another commonly 
used technique for identification of the binding site on receptor proteins is the substituted 
cysteine accessibility method (SCAM). In this technique residues within the binding 
domain are mutated to cysteine (Cys) residues then subject to modification by sulfhydryl 
reagents (Wiltfong and Jansen, 2009). Cys residues that are resistant to modification in 
the presence of ligand but modified in the absence of ligand are presumed to be 
protected by the ligand because they are located in the binding site. This technique 
provides important information about location of the binding site but does not provide 
details about specific amino acid/ligand interactions. These interactions are probed with 
traditional site directed mutagenesis approaches.
3) Mechanism of action: Determination of mechanism of action will require single channel 
studies. Single channel recording is the most direct method available for obtaining 
detailed and precise information about the kinetic behaviour of ion channels. The goal of
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these studies will be to determine the precise nature of the dFBr effect compared to 
other modulators. By recording single channel openings and closings over time, it is 
possible to identify changes in stability of open versus closed states, changes in singe 
channel conductance and changes in the latency of channel opening after application of 
dFBr.
4) Animal models. The effect of dFBr in animal models for specific diseases can also be 
studied. Genetically-engineered mice have been developed that exhibit both behavioural 
characteristics of Alzheimer's dementia and protein-derived plaques like those which 
appear in the brains of patients with Alzheimer's disease (Hsiao, 1998). A genetically 
engineered mouse showing excessive grooming and other anxiety-like traits have also 
been developed (Korff and Harvey, 2006). Such mice are a good model for obsessive 
compulsive disorder. Mouse models with cognitive deficits have also been developed 
(Fisch, 2007). dFBr can be directly administered to such animals. Mouse models for 
fragile X syndrome, Rett syndrome and other disorders associated with autistic-like 
behaviour have been developed (Moy and Nadler, 2008). If dFBr could relieve symptoms 
in mice this might indicate a potential therapeutic value of dFBr for neurological 
disorders.
Pre-clinical Studies:
From this point onwards the research involving dFBr will follow the path which is
taken by all drugs are made to be market ready (Remington, 1995).
1) Toxicity studies: Toxicology studies are needed to evaluate the safety of the drug. It is 
likely that a drug candidate targeting a specific receptor or enzyme on a certain cell type 
may have a beneficial outcome in providing treatment for certain disease or condition. 
However, such a drug may also interact with other proteins on different cell types in other 
organs and cause unintended harm due to these interactions. A clear example of this is
137
the drug thalidomide. Thalidomide was developed during the late 1950s and early 1960s 
as a sedative-hypnotic (Diggle, 2001). It was prescribed to women during pregnancy for 
morning sickness and as a sleep aid. However, the safety of the drug was not evaluated 
properly before being release to patients for its use. This resulted in women having 
children with severe malformities like phocomelia. Nearly 10,000 cases of such birth 
were reported the world over because expectant mother were prescribed thalidomide 
during pregnancy (Diggle, 2001). The racemic mixture of Thalidomide contains both the 
left (s) and right (r) handed isomers in equal amounts. While the right handed enantiomer 
of thalidomide is effective against morning sickness, the left handed enantiomer is a 
potent teratogen which causes birth defects (Eriksson et al., 2001). The two enantiomers 
of thalidomide interconvert in vivo, hence when pure r-thalidomide or s-thalidomide is 
given to humans both isomers can be found in the serum (Eriksson et al., 2001). The 
mechanism of action of thalidomide is thought to be by its ability to intercalate into DNA 
in G-C rich regions (Stephens et al., 2000). Since then, thalidomide has been approved 
by FDA in 1999 as an agent for the treatment of multiple myeloma because of its anti- 
angiogenesis action (Barlogie et al., 2001).
2) Formulation development: After the characterization of physical and chemical properties 
of a lead molecule such as dFBr, a suitable formulation has to be developed for its 
administration. A formulation is designed based on properties, such as dissociation 
constant (pKa), melting point, solubility, morphologic structure (crystalline / amorphous) 
and partition coefficient among many others (Remington, 1995). An ideal molecule will 
lend itself to be developed in multiple dosage forms (Remington, 1995). Orally 
administered drugs (Tablet, capsule, powder) are suitable for most patients (Miller et al., 
2007) except in cases where the patent is non-responsive (e.g., unconscious). A liquid 
dosage form (monophasic - syrup or biphasic -  suspension and emulsion) is most 
conducive for administration to young patients: children and infants (Breitkreutz and
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Boos, 2007). Even though injections represent a different route of administration, physio- 
chemically it is liquid or in some cases a powder (Remington, 1995). A drug in powder 
form can be developed in to creams and ointments for tropical or systemic use by using 
an appropriate base (Remington, 1995). Finally a drug can also be developed into 
aerosols and suppositories (Remington, 1995). A suitable dosage form has to be 
developed for a drug in order for it to be available for actual patients for use (Remington, 
1995).
3) Pharmacokinetic parameter analysis, after a drug is developed in a suitable dosage form 
it has to be evaluated for its pharmacokinetic parameters. The pharmacokinetics 
parameters of a drug are largely influenced by its bio-chemical properties and its dosage 
form design (Remington, 1995). Four important criteria essentially make up the 
pharmacokinetics of a drug are:
i) Absorption -  the route of administration may determine absorption of a drug. The 
bioavailability of the drug is based on the rate of absorption. When a new drug is 
being developed, it needs to be determined if the drug undergoes first pass 
metabolism. If it does then is the metabolite active? If the metabolite is active 
then the drug is said to be a pro-drug (Hosokawa, 2008).
ii) Distribution -  The entry of the drug in the general circulation is called distribution 
(Katzung, 2004). It depends on factors such as plasma binding, lipid solubility of 
the drug and if it can cross various selectivity membrane of the body such as the 
blood-brain barrier or the placental membrane in pregnant women.
iii) Biotransformation / metabolism -  most drugs are metabolized in the liver, 
metabolically the most complex organ of the body (Goodman et al., 2008). The 
purpose of drug metabolism is to convert the drug into a form such that it can be 
easily excreted form the body (Goodman et al., 2008). Usually drugs undergo 
oxidation in the live by the cytochrome P450 enzyme system (Xu et al., 2005). In
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cases where the drug is hydrophobic it undergoes processes such as, 
hydroxylation, gluconuride conjugation, sulfation, phosphorylation or methylation 
to produce water soluble metabolite (Xu et al., 2005).
Elimination -  Renal excretion is the most common way of drug elimination 
followed by sweat glands and stools (Goodman et al., 2008). In some cases 
drugs can also be eliminated orally through saliva or through maternal lactation 
process (Goodman et al., 2008).
Clinical trials: The steps in the process of drug development from here on are known 
as clinical trials. The preclinical trials both in vivo and in vitro help set the parameters 
for clinical trials for the drug (Goodman et al., 2008). The preclinical tests help decide 
if it is safe to give the drug to humans and what the toxic dose is. For accurate 
assessment of the result from the clinical studies a double blind study with and 
without placebo are carried out. In phase-1 clinical trials small group of healthy 
volunteers are chosen. Once the safety of the drug is established in this group, small 
group phase-2 trials can be conducted. In phase-2 trials a small number of patients 
in which the drug is supposed to be effective are chosen. The effectiveness and 
safety of the drug is established at the end of phase-2 trials (Goodman et al., 2008). 
In phase-3 clinical trials, large group of patients are included using both placebo and 
comparison standards. A large amount of safety and efficacy data is obtained 
analyzed and presented to the authorities for approval of the drug for general 
marketing. Once the drug is released into the market, the performance of the drug is 
continued to be evaluated for its efficacy and safety in vary large numbers of 
patients. This monitoring is often referred as phase-4 clinical trials. Additionally, 
clinical trials monitoring the drug in small focused group of individual such as 
geriatric patients, patients of certain racial make-up is carried out in order the access 
the safety and effectiveness of the drug in such groups.
141
Reference:
Barlogie B, Zangari M, Spencer T, Fassas A, Anaissie E, Badros A, Cromer J, Tricot G 
(2001) Thalidomide in the management of multiple myeloma. Semin Hematol 
38:250-259.
Breitkreutz J, Boos J (2007) Paediatric and geriatric drug delivery. Expert Opin Drug Deliv 
4:37-45.
Choh DW, Farb DH, Fischbach GD (1977) Chlordiazepoxide selectively augments GABA 
action in spinal cord cell cultures. Nature 269:342-344.
Choi DW, Farb DH, Fischbach GD (1981) Chlordiazepoxide selectively potentiates GABA 
conductance of spinal cord and sensory neurons in cell culture. J Neurophysiol 
45:621-631.
Cunningham BC, Jhurani P, Ng P, Wells JA (1989) Receptor and antibody epitopes in 
human growth hormone identified by homolog-scanning mutagenesis. Science 
243:1330-1336.
Diggle GE (2001) Thalidomide: 40 years on. Int J Clin Pract 55:627-631.
Eriksson T, Bjorkman S, Hoglund P (2001) Clinical pharmacology of thalidomide. Eur J Clin 
Pharmacol 57:365-376.
Fisch GS (2007) Animal models and human neuropsychiatric disorders. Behav Genet 37:1­
10.
Gentry CL, Lukas RJ (2002) Regulation of nicotinic acetylcholine receptor numbers and 
function by chronic nicotine exposure. Curr Drug Targets CNS Neurol Disord 1:359­
385.
Goodman LS, Gilman A, Brunton LL (2008) Goodman & Gilman's manual of pharmacology 
and therapeutics. New York: McGraw-Hill Medical.
Hosokawa M (2008) Structure and catalytic properties of carboxylesterase isozymes involved 
in metabolic activation of prodrugs. Molecules 13:412-431.
Hsiao K (1998) Transgenic mice expressing Alzheimer amyloid precursor proteins. Exp 
Gerontol 33:883-889.
Katzung BG (2004) Basic & clinical pharmacology, 9th Edition. New York: Lange Medical 
Books/McGraw Hill.
Kim JS, Padnya A, Weltzin M, Edmonds BW, Schulte MK, Glennon RA (2007) Synthesis of 
desformylflustrabromine and its evaluation as an alpha4beta2 and alpha7 nACh 
receptor modulator. Bioorg Med Chem Lett 17:4855-4860.
Korff S, Harvey BH (2006) Animal models of obsessive-compulsive disorder: rationale to 
understanding psychobiology and pharmacology. Psychiatr Clin North Am 29:371­
390.
142
Miller LA, Carrier RL, Ahmed I (2007) Practical considerations in development of solid 
dosage forms that contain cyclodextrin. J Pharm Sci 96:1691-1707.
Moroni M, Vijayan R, Carbone A, Zwart R, Biggin PC, Bermudez I (2008) Non-agonist- 
binding subunit interfaces confer distinct functional signatures to the alternate 
stoichiometries of the alpha4beta2 nicotinic receptor: an alpha4-alpha4 interface is 
required for Zn2+ potentiation. J Neurosci 28:6884-6894.
Moy SS, Nadler JJ (2008) Advances in behavioral genetics: mouse models of autism. Mol 
Psychiatry 13:4-26.
Paradiso K, Zhang J, Steinbach JH (2001) The C terminus of the human nicotinic 
alpha4beta2 receptor forms a binding site required for potentiation by an estrogenic 
steroid. J Neurosci 21:6561-6568.
Remington JP (1995) Remington, the science and practice of pharmacy. In, p v. Easton, Pa.: 
Mack Pub. Co.
Sala F, Mulet J, Reddy KP, Bernal JA, Wikman P, Valor LM, Peters L, Konig GM, Criado M, 
Sala S (2005) Potentiation of human alpha4beta2 neuronal nicotinic receptors by a 
Flustra foliacea metabolite. Neurosci Lett 373:144-149.
Sine SM (2002) The nicotinic receptor ligand binding domain. J Neurobiol 53:431-446.
Stephens TD, Bunde CJ, Fillmore BJ (2000) Mechanism of action in thalidomide 
teratogenesis. Biochem Pharmacol 59:1489-1499.
Whiting PJ (2003) GABA-A receptor subtypes in the brain: a paradigm for CNS drug 
discovery? Drug Discov Today 8:445-450.
Wiltfong RE, Jansen M (2009) Probing protein packing surrounding the residues in and 
flanking the nicotinic acetylcholine receptor M2M3 loop. J Neurosci 29:1626-1635.
Xu C, Li CY, Kong AN (2005) Induction of phase I, II and III drug metabolism/transport by 
xenobiotics. Arch Pharm Res 28:249-268.
